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ABSTRACT
we tested the hypothesis that inhibiting stroke development in Kyoto Wistar
__ ,ats (SHRsp) _ captopril lrealJ1lllnl (50 mgIkg) was, in pan,
mediated by reduced plasma akSosterone I~s, independent of an
antihypertensive effect.
Plasma aldosterone levels were measured before and after stroke
devetopr1'Ien in Lrltrealed and captopil treated SHRsp. Plasma aldosterone levels
suppressed by _ were .....levated by aldosten:lne infu~on (16IJll1day) into
captopril treated SHRsp. The resulting blood pressure (BP) and stroke
development was evaluated. we also examined the BP and antistroke effects of
a vasodilatmg agent, hydralazine (<<),,100 mgIl), and aldostarone antagonism by
spironolactone (20 mgIkg).
Untreated SHRsp developed hypertension and 1()()% mortality associated
with intracarabral hemorTI1age by 14 -. of age. Ca_ treatmenI from 6
weeks of age did not lower BP but increased survival past 35 weeks of age.
Hydralazine _ BP butonlymildly'-_dovaIopmont~with
captopril treated rats. Plasma aldosterone levels increased with age in prestroke
SHRsp (0.25 to 3.9 M1OIII) _ .... 1ur1her falowing _ (11.4 rwnoIIl). Captopril
treated SHRsp showed suppressed aldosterone values (0.5 rvnoVI). Restoring
~ in _ traaled SHRsp .-a<Icaptopril's ability to rotanl
stroke devefopment. Spj~one treatment ret\lced BP with little effect on
"""'a developmenl
Adclitionel studies .....sed the hypothesis Ihet co_, treetment helped
preserve contractile fu1ction (refated to bfood flow autoregulation) of isolated
middle cerebral arteries (MCA) from SHRsp. This was accomplished by examining
Iunen c:ianeter changes in response to pteSSUr8, protein kinase C activation and
polessiI.m _ depolerizetion ;" the MeA from untreeted and coptopril treated,
pre end post strol<a SHRsp.
Stroke development was assodated with a defect to the ability of the MCA
to constrict to e1eva1ed transmural pressure (pressure dependent consUiction) and
phorbol dibutyrate induced protein kinase C activation. Caplopril treatrMnt
I"-.ed these func:lions.
We concluded that elevated plasma aldosterone levels promoted stroke
development within captopril treated SHRsp through mechanisms not involving
mineralocorticoid receptor stimulation or the exacerbation of hypertension. The
ristroke eIfecl d captopri may be psrtially medieted through pIasme aldosterone
_. we lu1hor suggest that the ability of eeplopril trsetment to preserve
MCA Pf8SSU'8 dependanI oonstriction may also contribute to the antistn:lke effects
of _opril treetment in SHRsp
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THE EFFECTS OF CAPTOPRIL TREATMENT ON HEMORRHAGIC
STROKE DEVELOPMENT IN SHRsp
CHAPTER 1: THE INVOLVEMENT OF HYPERTENSION AND THE
RENIN ANGIOTENSIN SYSTEM IN HEMORRHAGIC STROKE
DEVELOPMENT
UTERATURE REVIEW
1.1 THE RELATIONSHP OF HEMORRHAGIC STROKE-llEVELOPMENT TO
HYPERTENSION IN HUIlANS
Stroke ~ defined as ... _ onset of Ioc8I or global neurological symptoms
caused by ischemia or hemorrhage in the brain resutting from diseases of the
_ blood-. (Saca> _ Mayer,I994). Consequently, stroI<e is gene<ally
desCribed as being either ischemic or hemorrtIagic in origin.
Ischemic stroke is produced by the regional blockage of blood flow to the
brain resulting tn tissue death. The latter oc:c:uT8l'lC8 of stroke typtcally involves the
development of arteriosderotic or atheroscktrotic lesions in the cerebral arteries
emanating from the circle of Willis, the V8ftebral-basilar arterial system and or
'Nithin the carotid arteries. These lesions result in the production of arterial kJmen
oc:x:Iusion. The areas cortalning these lesions are predisposed to the entrapment
of circulating clots as well as the local development of dot fonnation. When the
process evolves to the point 'Nhere blood flow is interrupted focal or regional brain
ischemia 0CClS, subsequentty resulting in neural deaIh. The definition of ischemic
stroke has also~ the development fA brain ischemia secondary to the
ervapment d large dais into oerebraI vascular 8l"eas without anerial disease. This
0lXU'S when large dots formed in the WI: ventricle (particularty in the valve region)
distodge, and make there Wf1'/ to the brain.
Hemoohagic _ .....Its!rom blMOOg directly into the brain (;mrac:et8bral
hemorrhage) or along the Sl.riace of the brain within lhe sub8r8chnoid space
(Sl..Caracilnoid hernontlage). Cerebni bkleding can produce injury via an increase
in inlracranial pressure leading to a reduclion in cerebral perfusion pr8SSlX8 with
~regiooal_(Oavis_~,1991)0l'~c:ancause damage
by CYlting dfoomecting _ ~ and~ngaanial nerves (~n,
1993). Biochemical substa'lc8s released dLl'ing and after hemorrhage may
adversely affect nearby vaSOJlar or brain tissue (Capl., 1993). Fluid enlering the
~ can include gIutImlU, seroIonin, tally acids, products of the kallikrein-
kininogen system, free radicals and lysosomal enzymes (Davis and Robertson,
1991). The poosibla.-.-__ by lhesa agants includes changes in blood
brain barrier permeability, cell swelling and damage to cell anergy metabolism
(-..am et aI., 1980).
Intraca<ebral hamoITt1aga generally ocx:urs loss IraquantIy than isc:hemic
stroke. Results from a multicentre American study of 1805 patients admitted for
acute stroke revealed intracerebral hemorrhage accounted for 13% of all 80Jte
hospiIaJizaIions, Tho diagnosis .... _ on Clll'l'lll-.ad tor11ogaphy (en scan,
clinical symptoms, angiogram or SlI'gical and/or autopsy results (Foulkes et 81.,
1988). According to Sacco and Mayer (1994) this trwlSIates into approximately
65000 new cases of intracerebral hernon1lage per year in Ihe U.S. Thls rate
however C'8l be considerably higher depending on the population investigated. CT
scans of 2168 Japanese stroke patients revealed a 30% incidence of intracerebral
""""'""- (SuZlAd et aI., 1987).
There is evidence thai the prqJlOSis for patients suffering from hemorrhagic
stroke is worse than those suffering from ischemic stroke. The Framinghlm study
followed 5184 sub;ects for 26 years with initial strokes OCCUlTing in 394 patients.
The 30 day case fatality rate for~ hemorrhage was 82% (14117)
compared to 15% (331222) to< ischemic _0 (Secco e/ 8/.. 1982). Given the
incidence of hemorrhagic stroke and the poor prognosis associated with this
condition, scientific investigation into the mechanisms promoting this disorder is
justified.
Hypertension has been reported to be the most common modifiabfe risk
fadcr__intraee<ellral hernon1lage (Caplen. 1993; Wiltenlirl<, 1994).
Exposure to high pressure can result in vessel wall thickening and reduction in
lumen diameter which may protect capillary beds from the elevated pressure.
fitMtever, with continued exposure to hypertension, lipid and hyaline material can
be deposited in the walls of arterioles compromising their structural integrity
(lipohyaIinosis). The resulting weakening of the vessel wall leads to the formation
of Chacot-Bouc:hard Aneurysms. These are small fusiform anelI"ylmS typicalty
located at the tn.nk of a vessel and are predisposed to ruph.re a'ld hernorThage
(Rubin and Farber. 1995).
The i1ll><>rtanc:o of hypllftension in the development of hemorT!1agic'-'
is supported by human epidemiologK:aJ studies which suggest that a reduction in
the incidence of intracerebral hemorrhage seen in the USA between 1970-1980
may be the result of improved antihypertensive treatment. A study ccnduded by
Furtan at aI. (1979) in Rochester, Minnesota, observed that a decline in the
incidence of intrae:erebral hernorThage was associated with increased use of
antihypertensive agents and a decline in the incidence of hypertension from
15.7/100 000 between 1945 and 195210 7.31100000 between 1969 to 1976. This
study folnd that between 1950 lWld 1954, hypertenston was present in nearty all
patients with intracerebral hemorrhage. More than hatf the pattents had mean
arterial bk>od pressure (BP) of greater than 15OmmHg. Twenty..five years later,
only 48% of patients with intracerebfat hemorrhage were hypertensive and none
had .,...,artorial blood pnllIlU9~than 130mmHg (ONlY etal., 1984). This
_Ihal.. hypllftension beCame bettor managed, the nor>I1ypoftensi risk
f8cttn for hemorT!1agic stroke bec:ame more prominent. In Finland, a decreese in
the..,""" _ of inlnIl:eRlbrlIJ~from 26.21100 (J()() to 15.41100 (J()() was
nlpOrt8d _ 1970 and 1979. This study concluded Ihal aIlhclugh the improved
care of f"rtpertension produced 8 decline in the incidence of cerebral hernort'h8ge,
_hemonllagodidOlX>Sinlhe-.coal~(I(otila, 1984). Thono
... ohlrnlpOrtsrl ...........~oocuringinthe-.coaldYonic
___ Brollatol. (19ll6)loundthal_(8711504)al~inCincimoli
hospitals ""'" had __ .. inlTaaInlbnoI~ had no ..,-.,. al
hyportension by '"-Y -.I .. -.ce al eIodIOC8ldiogl",*,;C (ECG) d1angos
(loti _ '-""PhY) consi...... with the -' pnIMl1CO al hyper\enIi<In.
n-........ Pf"OIlOSOd lhot hyper1ension be v_ u one of _ "-'"'"
risk factors for the oc::currenc:e of~. inlracerebral hemotTh8ge.
ConsisIenl: with this possibility, there are estIIbtilhed non-hyper1ensive C8UI8S of
inracereIlraI~ Including hllmaIoIogic aIlnonnlIIities -.I vascular
maIlormaIions. Aooonling to del Zopo and _ (1992), hllmaIoIogic causes al
hemorrhagic stroke include Pfi"*Y causes such .. deficiencies in c:oagut8tion
facias and.....-y causes sucIlulllrombocytopenill(~Iow_
""""' often reUling!rom~ dis<lrdln). Variousv_maJIamotions -.I
congonilallll>nonnolities ... 8lso _ with the _ al_
~. Arteriovenouo malloonaIions ... chanI<:terized by many enllrgod,
engorged _ al _ diamet.... The _ althe wall is irTeg_,
composed mostty of fibrous tissue with oc:casionIIl smooth musde fibers .-let cen
be associated with saccul.. a"IelXySfTlS. Cavernous hem8ngiomBs.e a10Iher type
al.-_",*",is_with-.nog;c-,which_
as~ cIust1Qd, Ihid< fibrous walled_.
6Based on the above evidence one can conclude that afthough there is an
association between intracerebral hemorrhagic stoke development and the
00Cl.IJ9l'1C8 of hypertension other as yet undiscovered factors independent of the
presence of hypertension li~y also contribute to the initiation of hemorrhagic
_.
1.2 ANIMAL MODELS DF HEMORRHAGIC STROKE
U.1llow1clp..- ofK,-_..-. Prone~ Rata
In 1963 Okamoto and Aoki developed the Kyoto Wi_~y
hypertensive rat (SHR) by the seMJdive inbreeding of Wistar rats with above
average blood pr8SSU"eS. These animals had a genetic form of hypertension that
was tJwlsmitIed to their offspring and was considered to be analogous to essential
hypenension in humans. By 13 weeks fA age, the male SHR developed systolic
blood pressures (BP) of 18OmmHg. In comparison, the normotensive Wistar rats
usodtodoveloptheSHR_in(~namedKyotoW__ (WKY)haG
BP'a 01 approximlllely 13SmmHg. Despite the presence 01 hypertension, SHR only
nnIy dewIoped_. In 1974, Okamoto .. 01. developed • _in 01 the SHR
by aaloctivaty breeding SHR progeny from the few paron.. who auI>aaquorOly
developed stroke. These animals were termed Kyoto Wistar spontaneously
hypertensive stroke-prone rats (SHRsp) to differentiate them from their stroke
resistant parent breed. SHRsp attained BP's greater than2~ during
__hypertension. S-' development in SHRap was abongIy atlacted by
diet. While maintained on reglJlar rat chow (Nihon CIea), the lifespan of SHRsp
was _ 33 and 41 _.01 ago (Okamoto et aI., 1974). Va_ et aI. (1984)
fOl.nd thai by 36__ 01 ago, 88% 01 SHRsp fad a Japanaaa made FunaIlllSrn-SP
diet developed cerebrovascular lesions compared 10 less than 30% of SHRsp fed
a Ralston P!Xina National Institute of Heatth open formula diet. The authors
reported that the only remarkable difference between the 2 diets was that the
American diet had a 22% protein content compared with 15% present in the
J__ The dewlIopnw< 01_ in SHRsp incraasad to 83% at 24 __
of age by adding a 4% NaCl supplement to a North American Japanese-style diet
produead by Zaiglar Bros in tha USA (Tobian, 1986). More _y, selective
coklnies d SHRsp were developed where the incidence d stroke associated wtth
intrac8r8bra1 hernon1"Iage was 100% by 16 "N88ks of age when the animals were fed
the same version of the 4% NBC! Japanese style diet (Smeda, 1989). This
resulted in a raptcI and well defined period of stroke onset beginning at 12 weeks
of age. BP values in these animals increase with age with typical V'MUBS ranging
fraTl141 10233 nmHg belween6Md 16 weeks of age. A predictable time course
d stroke deveq)menI in SHRsp was a prerequisite necessary for studying events
which preceded the development of stroke in this animal model.
1,2.2 SHRop ... _ of Human Homorrhaglc_.
The extent to which hemorrhagic stroke in SHRsp is an aauate model of
human homonhagic _ was _ by Vamori at aI. (1976). These
~ roportod _ tho.- common site for hemorrhagic""" in SHRsp
.... in tho _ region (69.8%). In conlroot, """*' _ ~
_ .... 13.1%0/........-~._.acommonsitefor
stroke ., SHRsp a1d in tunans is the basal glnQlia 'tIltlIich represents 24.5% of
hemorrhagic strokes in ,.. .-.d 66.5 " in t'u'nanI. The anterior rid posterior
..-_which _tobo__for tho rnajotityo/eatical "'""'""
in the rats possessed pelterm of reamtnt branching. The lenticulostriete erteries
from the middle c::ereIJr'a'.-tefy Mlic:h are responsible for stroke in the basal ganglia
in both SHRsp.-.d in I'uT8'-. aIIo bnrd1 rec:urertIy. Reamn arterial branching
ocan whan tho~~ IeaYing a parant arterial brand1 .... angled
in 8"...... where the diredion of flow in the secondary bf81ch is ang6ecI greeter
than 90' to tho parant branch. _ ...~ for _ lesions ...
folrd to have f_ nlCUT8l1I brard1ings.
1,UCBnWII PaIhoIogIcaI -.tlagic_
InSHRap
The paIhoIogical~ in __ organs 0/ SHRsp ... dosctibod by
Ogata et aI. (1982). Using microscopic axamination 0/ tho brains 0/ 38 SHRsp
showing signs of stroke such as roughened flx and ernaci8tion (of which 31 were
absequently observed to have cerebral hemorrhage) arteriolar fibrinoid necrosis
was identified in the neocortex of 29138 ..mall. Artllriaf fibrinoid I'l8O"OSis in the
brain -.:I kidneys is __ with _ ir1UrY~ to malignant
9hypertension (Benditt and Schwar1z. 1994). The disordef is cl1aracterized by
smooth musde cell necrosis, loss of endotheUel cell integrity and increased
vascular penneability. This _ to tho deposition of fibrin and tho entIy of '"""'
plasma proteins into the vessel wall. There ttl subsequent smooth muscle cell
proliferation and an increase in the number of concentric layers of smooth muscle
within the arterial media resutting in an onion skin appearanc:e. Using serial
sections of brains from five SHRsp with neurological deficits, Ogata et aI. (1981)
reported that arterioles with insudation of fibrinoid material showed stenosis and
thrombotic ocdusion. The 0CClIT80C8 of microaneurysms was rare. Massive
inIrac:erebraI hemorrtlages were identified in 3 animals wtlere8s mutlipIe petechial
hemorrhages were seen in 22J38 brains. Multiple ofd hemorrhages, consisting of
smaN collections of hemosiderin laden mac:rophages W'8I"8 seen in 13138 animals.
MiO'O infarcts were seen in 3 .,imals while large infarcts were not encountered.
Regions of ra'efadion of the nIU'opil were allo identified in 31138 animals. Wakita
et aI. (1995), explained that chronic hypoperfusion (possibty due to the disruption
of downstream bleed _ following cerebral hemorrhage) acliYatod phagocytic
mia'oglia in the white matter resulting in rarefacbon in the region.
1.2.4__ Symptomo of Hetnanhaglc _In SHRop
Smeda(1989)desaibedthebehavtoral signs of stroke in SHRsp. An initial
conmon sign was convulsive rhythmic movements of the head and one for8Iimb
whicI1 persisted no Iongor than 2-3 days and -.. periodiaIIly suffICiently violent
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as 10 knock !he raI OW( on its side. NoxI, mild IeIhargy oc:o.mod and !he rats began
10 _ poorly groomed. 1ho IeIhargy w<noned wiIhin • f_ days and !he ability
d the animals to right itseff from a side lying position became compromised. The
rats also adopted an unusual postU'8 charac:terized by having the re.. legs
extended and maintained underneath the body such Ih8I: the toes extended past the
animats head. Subsequently, the animals became quite immobile .-'Id 50% died
within 1.5 weeks of exhibiting the first behavioral signs of stroke.
1.3 THE RENIN-ANGIOTENSIN SYSTEM
1.3.1 _ OvervIew 0111Io RenIn AngI_ System
The renin a"lgiotensin system (RAS) is a mbced enzymatic-honnonal system
controlling Na+ and water balanoe. bbxI vollm8 and arterial blood pressure
(Guyton, 1991). The biochemical pathway which comprises the RAS is
ehar8Ctenzed by the secretion of the enzyme renin from the preglomeruler
artericMes of the kidney. Renin then catalyzes the rate limiting conversion of the
plasma protein angiotensinogen to angiotensin I (AI). AI is then converted to
angiotensin II (All) v~ a'lgKJtensin converting enzyme (ACE). ACE is Ioeated
primIriIy in the endotheItaI lining of capillaries in rTNWlY vescutar beds. In addition
10 ClllaIyzirg!he lonnaIion of All. ACE is also__lor the degradatioo of Ihe
vasodilator bradykinin (VoUalen, 1987).
1ho release of_ is~ primlriyby!he~r.opparatus
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(JGA) whose function it is to translate changes in tubular salt loads (..tlic:h result
from changes in sa" intake) mto changes in gtornerutar filtration rate and renin
seaotion. The JGA is the ........ fonned by the distal tubule passing _ the
afferenI.-ld the etrerert arteriotes d the nephron. The epithetiat cells of the tubule
which contact: the arterioles we known _ the macula dense while the renin
containing j.JxtagIomen.Aa 0( gwlJlar cells .-e modified smooth muscle cells of the
afferent arterio6e (HackenthaJ and Nobiling, 1994). Low Na" and C1 toad
(concentration times flow within the tubule) past the macula dense mediates the
release of renin from the 8'I'ferent pregkJmerul8f artetiotes.
Renin release from the atrerent arteriofes is regulated by several other
factors i~uding beta receptor adrenergic stimulation via sympathetic innervation
of the arterioles (Reid etat. , 1978;Vallotton 1987). TI1ofeisovidonce_ing
that dopaminergic innervation may also stimulate renin secretion (Sowers, 1984)
and that non-JGA mechanisms may play a role to controlling renin release in
response to salt loads. This latter hypothesis is based on the observalion that
.....moIs _ hyd'onophrotic kidnoya (no lundionol tubular stnJcturo and lhoroforo
no macula dense) are ab'e to adapt to ctvonic c:hBnges in salt ingestion. For
example, renal renin release a-ld renin mRNA transcription .. stirrkJlated to a
similar oxtont" the__and _ noonol kidney of No' dopIetod
mice (Munter and Hackenthal, 1989). There is 81$0 evidence tor an intrarenal
ba'oreceptor as 8 regulator of renin ntfease and an inverse relationship exists
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-.""",I petfusion PfOSS'R _ AIf1in _ (_at /1/.• 1964; Eido at
01.. 1973).~ '-bid< inhibition from All is also~ III inIluonce tho
_atrenin(G<iendlinglnl__.I994).
1.3.2Tho~_d~.
The dautc All effect, diNc:ribed above .. rnedi8Ied via the AT1 receptor
wI1id1 is_bl'!heAlIr..-nagon;so-<T-. 1999). This
receptor has been further Sl.bdivided into the AT,,, end AT,. subtypes. However,
!hel\roctional signitiameat_isnoh.__ (GuY1ing at .... 1996). AnAT,
r..- haS .Iso been _ad (ZI>.lo at .1.. 1998).• haS..."." high IpOCificity
for !he All~ fnIgment AIV (i.... All - [~J) lnllow 'l"'dfidty for All and
I~. Raiiot8beIted AN binding studies in the brain reY88Ied ., assoc:iation
with c:hofinergic 1"IeU'Or'lIi, as '11'811 _ motor and sensory ru:::tei. The aIthorI
sa.--. in corOral_lnl_ 8diYiIios _ memory (Zhuo
at .... 1998). An AT, in .--""'-omo oetis _ high aI!inity for All. low
alInty for AlA lnl no alInty lor _ haS also boon roportad (DiM" 81.. 20(1).
StmJ8tion d the ATI receptor in the adr8nIlI cortex ItirT'UaIes the release
at__ into tho blood (Reid. 1985). _ il. _ hormone thot
facilitates the uptake of H.· n 'MUr from the oone in the distal tubu6es of the
kidney. The physiology, pharmacology and mechanisms of aldosterone aetton will
be discussed in detail i1 the lit......, review section d Chapter 2 in this thesis. AI
this point in tho diIaJaion Ais __III _ thet -.one ptOI11OIes fluid and
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Na· retentkHl wtlich has a tendency to expa1d blood and extravascular fluid
volumes, an alteration that can potentially elevate BP (Reid 1985). The AT2
receptor has been noted to adivate cellular protein phosphatases, nitric oxide-
cGMP and phospholipase A2 signaling pathways in cell systems (Nouet and
Nahmias, 2000), however its overall physiological ef'feds are lXlC8f1ain. The
abundance of the AT2 in fetal and neonatal rat tissue suggests a possi~
developmental role for the receptor (Griendling end A1e_. 1994).
Cira.dalilg plasma levels of All are typically in the pice to fVlOfTlOIa' range
(Morishita et aI.• 1995). At these levels of All, the stimulation of AT, receptors on
vascular smooth musc:te cells can facilit8te constric:tion mediated (via stimulation
01 alpha 1 and 2 racaptOl>j by nor&Pinepmne (the predominant neurotransmilte<
present in the~ n8fVOUS system) (Kawasaki et aI., 1988). Stimulation of
AT, receptors on the presynaptic nerve terminals of the sympathettc nervous
system f\.J1her enhrces the release d the vasooonstrictor norepinephrine from the
nerves (Kawaaaki et aI., 1982). The central administration of All into the cerebral
spinel fluid results in 8 massive adivation of the sympathetic nervous system, an
effect that is also mediated by AT, receptors in the central nervous system (Ms et
8/. 1999). "has been suggested that bfOOd circ:ulaling All may gain access to the
cenInIl nervous system thrOugh normal or pathologically produced discontinuities
in the blood tran barier and thus pot8flti8t1y promote~ic nerve activation.
At high levels l7Uterthen 10 nM, All stimulation ofvascu* smooth rnJsde AT,
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rocepIorspraTKHs~<XlflStridion(Smedaetal., 19888). Although such high
levels of All are not typically seen in the circutation, arguments have been
presented that the local tissue production of All via nonrenal sites of renin
production (d_ later) may lead to the llOCUIIW.llation of All higher than that
seen in the draJIation and possi)fy hiIjl~ to promote direct vasoe:onstridion.
At1 important v8SQIlar effect of All is its ability to markedty c:onstrict the
efferen: MerioIe (Merle and Mum, 1992). This has the effect of decreasing urine
output due to a reduclion of bklod now though the glomerulous. The reduced
b1cxxt flow in the parilubul.- capiUaries augment the b..tluI« reabsorption of fluid.
AU can also ad directly on the proximal tubute by decreasing Na· and water
reabsorption via an enhanced Na+, W exchanger (Guyton 2000; Mene and Dunn,
1992).
In SUTlrTI8l')', elevations in cirWating All via the activation d the sympathetic
nervous system, the presynaptic enhancement of norepinephrine release from the
sympathetic nerves and the facmtation of norepinephrine consttic:tion would
.ma vasa..lI. c:onstridion rd raise vascul. resistance to blood flow while the
All mediated release of aldosterone would facilitate bk)od volume expansion. 81'1
alteration that can increase cardiac bloOd flow output. Since BP is a product of
cardiac output times vascular resistance to blood flow (discussed in detail in
Chapt.... 3), elevations in All production can produce hypertension. Hence. many
anlihypertensWe agents (ACE inhil>itors or AT, rec:optor antagonists) exert there
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adion by either preventing the formation of All or inhibiting its action on tissues.
AIlIlouI;I All has. proIa.nd elIact on blood pr8SSI.<8, the primary role 01 All
in the body is to control salt and water balance (M....row, 1999). This goal is often
_ by modifying the~ blood prassur1l. For~,sevara blood loss
can produce a condition termed shock in which blood pressure can decrease to a
point, belowwllicl1 normel glomerular fibion C81 occur. This promotas. decreasa
in primSIY urine production and a deaease in salt load being presented at the
macula densa of the kidney. Renin secretion will inaease, All formation will be
enhanced whiCh in tu'n will facilitate the eleYation in blood pressure which will
attempt to restore normal glomerular filtration and hence salt and water bal&lce
(Reid, 1985). In this insIanceAlI_ aldosterone _will occur. However,
if WJI'f litUe prirnwy lri1e is being produced the ability of aldosterone to extr8d Ne·
Of water at the distal tubules will be limited. Hence, in this instance, its contribution
to the maintenance of homeostasis would also be limited. In other situations,
pathological vascuJar alterations in the kidney can activate RAS. in SHRsp an
important pathofogtcal feature observed in the kidney is the oocurrence of
fib<onec:tosis in the all......rt pragiomenJlar arterioles (Ogalo at 8/., 1982). This
wWd produce a dlllcrease in glomeru. filtration under normal BP conditions and
by the mechanisms desaibed above promote RAS activation. The effed of All
famed Ulder the iatler oonditions would be to raise the BP above nonnallevels to
promole ...... normal fitlnltion and the aldosterone formed would facilitate Na· and
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fluid retention fu1her oonbibuting to the elevation in BP. The net effect would be
that the etevat8d BP woutd be essential to the maintenance of normal glomerular
filtration and salt and __ balance.
A second potentially important effect of All in the maintenance of
hypertension is in the ability of All to remodel the structure of arteries (HajcaJ et aI.•
1991; Chillon and Baumbach, 1999). SHR typically have normal plasma All levels
(Morishita ..BI., 1995) but do exl1ibit 0 hypen:ontradile reactivity to All (Smeda et
8/., 19888). The treatment c:I these ..mall with ACE inhibitor or AT1 receptor
'"""lPlist awl ncnnelize BP. Long lenn d SHR produces 0 nonnal_
of BP even when treament is withc:t'awn (Gm.. and Lee, 1996; Gillies et ai., 1997).
Structural analysis of the vasaAattn (such as the cerebral and mesenteric
vasculatln) of these animals indicates that the inhibition of All action causes the
vascular walls to thin and the vascular lumen to enlarge when the arteries are
studied under dilated conditions (Ha;du et aI., 1991; Gillies and lee, 1996; Gillies
at aI., 1997; Chillon and Baumbach, 1999). All these afterations would contribute
to promoting a decrease in v8ICU* resist.lce to blood flow and are thought to
contribuIe to the maintenance of ...... normal blood pntSSU"8 even after treatment
is-. These eIIects 018 likely not l1Je to !he ardiI1ypef1ensive eIIects of ACE
inhibitors or All anlagoniSl$ since other equally effective antihypertensive agents
that promote their effects through vasodilation can not aher vascular structure in
SHR(_, 19l1l1b;_andLee, 1991).In_dthi.~h8sbeensuggested
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that All can exert a trophic inftuence on vascular growth which through the
promotion of increased Y8SOJlar smooth muscle cetl multiptication of individual cell
grtJWIh may """'"""'" to tho pnxi.Jction of _ smooth rrucIe cell hyperplasia
and hypertrophy commonly seen in the arteries of SHR and other hypertensive
.-Is. Walilhid<ening produced by _ hyperplasia is thought to facilitate tho
mainterwlc8 rI hypertension. This hypothesis is oonsistent with observation made
in o.itu'ed V8S0J'- smooth muscle cells that il"'ldic8le that All can accelerate growth
in culture (Stouffer and Owens, 1992; loukoIovaetaJ., 1998).
1.3.3N........ P__ofAr1gl-.m._
All can ba__ via a~ ",",-". H..".., halot chymasa which
has high IIi:lstrate specific:iIy for AI and cannot degrade bradykinin is the major All
lormingenzymainthotunanhalot (Uralaetal., 1990). ComponenlSoftho-.a
system have been localized in extrwenaI tissues including the t:wajn, adrena' gland
and the V8SOJIar wall (Samani, 1994). These extrarenal or tissue RAS have been
implicated in hypertension. For e>eampla, Sctoelling at aI. (1982) found that during
the developing phase of hypertension, renin activity of brain homogenates from
bilaterally nephrectomized SHRsp was e+ev8ted retmive to age matched WK:f.
Renin activity and All was also found to be elevated in the adrenal g*ld of
nephrectomized SHRsp relative to 'NKY at 18 weeks of age (Kim et 81., 1992).
Further, ACE activity in the aorta of SHR was fOU1d to be elevated ocmpared to
'Ntf:'( and this elevation cxmtIated well with the developing phase of hypertension.
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Although the signiflC8l1C8 of tissue RAS's and the non-ACE All pathway remains
uncIea', there exists a possitliWty that this system coutd contribute to hypertension.
1.3.• The R_~n~"SHRop
Studies involving SHRsp have shown that both plasma renin ~s and
..Mty .........with _ (Volpe et 81., 1990; Camargo 81 81., 1991; Ga/1nom eI 81.,
1994; Glubner et aI., 1995) and that plasma renin activity and All levels we
eIevaled in St-Rsp with established hypertension when compared to normotensive
K)'CIlOW_conInll .... (Slier 8181., 1991; Kimel8l., 1992; HIblofetal., 1995).
The renin angiotensin system responds to dtetary HaCI in a unique manner in
SHRsp. _ -.mons in dietary sodUTl....,.,.... renin activity in normal _
(Stioretal., 1991),rennCMty(Stierelal., 1991; Shibolael8l.,1979), .....lIas
_ deYelopnw1I, (Nagaoka et aI., 1976) is erhanced in SHRsp. The mechanism
lJ'ldertyYlg the inability cia high salt to suppress renin secretion in SHRsp has not
..... lIdeqlaely studied, _ high d....ry satt has ..... shown to acceterate
renal __ in SHRsp and specifically enhance the formation of pregl",""",,'"
arteriolar flbriniod necrosis. 8 change that WQldd limit glomerul. filtration (Oget8
etal., 1982). Hence, it is possible that the effed of this vasa.llar ocdusive disease
in potentiating renin release by restricting glomerular filtration may outweigh the
Sl.4JPf8SSive effec:ts d a high salt diet on renin nMease, resutting in a net elevation
in plasma renin and All levels.
The8efindings 8'8 consistent with the results of Enea et al., (2000) using 8
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Japal8Se style diet plus 1% NaCI cP1king solution in SHRsp. The investigators
fo.n:I tt8. hV1 salt diet induced a rise in plasma alctosterone in SHRsp'Mlereas
SHRsr plasma aldosterone was suppressed. This finding was per.1eIed by an
increase in adrenal aldosterone synthase mRNA is SHRsp whereas the same
enzyme mRNA Ievets were reduced in SHRsr. In contrast however, plasma and
adrenal renin activity as well as AU receptor mRNA were comparably reOJced in
response to the high salt intake in both strains. The authors proposed an earty
irJ1paim&1I: in h9l salt irUke induced afdosIerone synthesis as a posaib6e mediator
at pathogenesis in SHRsp.
1•• ANGIOTENSIN CONVER11NG ENZYME INHIBITORS
U.l~ Ovenriow
ACE mbitor history begins with the discovery of a bradykinin potentiating
factor from the venom of the South AmeriC8'1 pit viper. This substance was a
mixtL.nl d peplides which inhibited ACE (Ferreira et aI., 1965). Captopril, the flf'St
orally ae:tivet ngn.peptide ACE inhibitor was synthesized based on research
involving the most potent of these peptides (Ondetti et aI., 1977). There are 3
c:hemicaI cIas8es d ACE irhbita's b8secI on differences in binding to a Zinc ligand
on the converting enzyme. These chemtcal dasses differ in several
pharmacokjnetic v.-iebtes including e1inination hatf life and time to onset of action.
Aport ""'" in1llicalions on dosing fr8quoncy howeWr, ditI8nInces in IIle lI10fapeUtic
oll8diYenossolllle__or ACE irhibilonIiolikely smaJl (Gums, 1992).
20
All ACE irhibitors exert their hernodyrwnic etreds primarily via the inhibition
ctAll formation (Gl.ms, 1992). This resutts in a reduction in peripheral resistance.
Plasma AI and pfasma renin activity may inc:rease while plasma aldosterone will
decreases. The decrease in aldosterone will promote Na· and water loss in the
urine (GLMns, 1992). There is however evidence that plasma All and aJdosterone
levels can, retLm to or, exceed pre-treatment levels with chronic ACE inhibitor
exposa.re. Forexll'npkt, Mento and Wilkes (1987) treated adults Sprague-DawMty
rats with enalapil (30 mgIkg, d.w.) for 1 week and for 2 months. The animals were
fed standard rat chow and given tap water. Investigators reported a similar .-lei
siglificant decrease in mean arterial pr8SSU'8 (retative to controls) at 1 week and
2 months. PRA did not c:hange significantly during either time period whereas
plasma All was elevated significanlly at 1 week and 2 months relative to controls.
Similar investigations were conducted by Lijnen at at, (1982) in hypertensive
patients. The onset ctc:aptcpri11r8atnWll: was followed by a gradual rise in plasma
aJdosterone levels. PrHeatrnert centrol values were signiflC8l1tly exceeded at 12
months. A hypotensive 8ff8cI: was repoft8dty maintained during the course of the
study with plasma Alilevefs remaining suppressed.
ACE inhibitors can also dea'e8se the breakdown of the vasodil8tor
bradykinin. This inftuence on bradyt<inin has been impticated tn the dry cough
sometimes 8SSOCial:ed with ACE inhibitor therapy (Kartberg, 1993). There is
..-..ce thal bradyI<inin plays. r<>la in """ anIihypolIensiY aIIac:t of ACE inhillilo<s
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in some foons of hypertension (Bee et aI., 1992). ACE inhibitors have also been
reported to aneliorate cardiovascular damage via the accumulation of bradykinin
and niIric oxide (Kitikaze et aI., 2000). In paltents with a highly active RAS caused
by Na· depletion or otherfad:ors. ACE inhibition produces an especialty marked
reduction in BP.
ACE inhibitors have also been demonstrated to intertere with sympathetic
transmission, most probably by antagonizing the faciliteling action of AU on
presynaptic transmitter rektase (Zimmermam, 1981). A more tong term
artihypertensive mechanism may reside in the inhibition of the trophtc actions of All
(Gohlke and Unger, 1994).
The dinical use c:I ACE inhibitors indudes tint line therapy in hypertension
and congestive he.-t 'aill,n (The Joint National Convnittee on Detedion,
Evaluation and Treatment c:A High Blood Pressc.n, 1988). ACE inhibitors have also
been suggested as a possible treatment for ischemic heart disease (Gohlke .-ld
Unger, 1994), kil2ley diseese such esd_ nepIYopethy (Metre e/ aI., 1988) as
well as an agent to enhance cognitive function (Costall et aI., 1989). Recent
studies have indicated that ACE inhibitors such as eaptopril exhibit en antioxid....
efIed end can scevenge superoxide ,edicel. (Chopre e/ 8/., 1989). ~ i. posoibIe
thai; some cllhe therapeutic effects of captopril treatment in heart or renal disease
could be medieted Vla this mechanism.
1,4.2 Tho _ of~nCon_ng Enzyme InIlIIliIon on SHRop
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There is a vefIJ oommon view that the differences in the incidenCe of stroke
lhal .... _ in SHR ...... SHRsp .... simIlIY due 10 the fact lhalSHRsp have
hV'*' btood pressu-es Ihan SHR .-ld that the devekJpment of stroke in SHRsp is
si~ a c::or"ISIJql.* of the presence d extreme hypertension. A growing body of
evidence suggests that ACE inhibitors retard or prevent mortality assod8ted with
hemonhagic stroke in SHRsp with minilrel or no signiflC8l'll reduction in BPs. Stier
et aI. (1989) fed SHRsp a Japroesa _ stroke-prona rodent dial supple_
_ al%NaCIdrirl<ingsolutionfrom7IoS_ofaga. r.......-_theACE
inhibnor anaIapril (15mg1kg1day, ...- in dinnlOng water) bagan at 8-9-. 01
aga. Using the tailcuIf~_, weekly BPs measuraments revealad
a signific:lrOdaaaasain BPs at 10 and 12_oIaga. Although the hypOtensive
effect was mild, the moftaIity rate was dramatically altered with no stroke related
deaths in the enalapril treated group at 36 weeks of age when the study was
disoonlinJed. In contrast. rapid mortality occurred in the lrII:reated control animals
between 12 and 14 weeks of age. The asthors did not directly comment on 8
possibfe mechenilm for this proIeCtive eff8d:. However, the results did suggest the
possibility of 8 weak association between BPs reduction and mortality associated
with stroke in SHRsp.
Under virtually identical conditions as above, Stier et aI. (1991), found that
using the ACE inhibitor captopril (SOmgIkgIday) yielded very simil. results.
~I_pn>ducada small bU SVlifioant raduclion in BP _ 9 and
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11 weeks of age IWIitive to l.I'lIr8ated CXJntroI animals. There 'MW'8 no stroke related
deaIhs in the captq:lril treated group noted through 26 weeks of age at which time
the study was terminated. Untreated control animals died between 12 and 16
weeks of age. In spite of these obsefvations, lhe paper suggested that lhe
therapeutic benefit of captopril treatment was independent of a hypotensive effect
and inferred that RAS inhibition c:oufd be an important factor in the protective
effects of ACE inhibitor treatment.
Stier <It aI. (1993) treated SHRsp with tho All rocoptor antogonist _
(1Omglkglday, by gavage). Losartan treatment produced similar results to those
reported with ACE inhibitors in that the onset of death from stroke was retarded.
However, no significant differences in BPs were detected in the losartan treated
group compared to untreated SHRsp. In spite of the lack of 8 significant
hypotensive effect, the Iosartan tr88Ied rillals were able to survive until the study
wasclisc:::or1mued at 28 weeks. Untreated control SHRspachieved 1ClO% mortality
by 14 weeks of age. The authors concluded that AU may playa s;gniflC8nt role in
the development of stoke in SHRsp. This study indicates that virtually identical
results were obtained from either ACE inhibition or AU receptor btockade. This
suggests that ACe inhibitor induced bradykinin poIentiation may not be an
important mediator of the reduced mortality rate in these animals.
Further investigations into ACe inhibitors in SHRsp 'tY8f'8 conducted by
Ogiku etaI. (1993). SHRsp __ fed. No-_, low protein,"- style diet
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and were administered the ACE inhibitor imid8pri1 (5OmgIk~ by gavage)
begiming at 11 -. cI age. Tho imidapril_ SHRsp __ not found to haw
significantty differenl BP values reI.ive to LI1treated controls. The control animals
died between 13 and 23 weeks of age Yt'hereas the first death in the imtdapril
treated group did not occur until 31 weeks r:l age (2 weeks after treatment was
withdrawn).
Investigations by Wang et ai. (1995) fOU1d that perindopril treatment in
SHRsp result8d in silJ1ificar"Iy _ BPs during 9 and 10-. cI age. Tho ACE
inhibited "mals also lived rru:h Iongllrthar'l c::onb'Ols. Although these resutts were
similar to those of Stier et aI. (1991). lhe conclusion d_. Tho onoet of stroke
in SHRsp was sigl"lific81tty comtIated to the age when BPs exceeded a 240 mmHg.
It was suggested that 8 modest hypotensive effects capable of maintaining an
animat's BPs bekJw 240 nwnHg could exert a profou'ld antistroke effect. However,
close sautiny of the data indicates that there are inconsistencies with the above
hypolheoiS. Wothin1ho vaMous__ per1ormocl by Wang at aI. (1995) some
groups of c:ontrol SHRsp deve!oped stroke before reaching a systolic BP of 240
mmHg and low doses of perindopril treatment failed to produce any
antihypertensive effect but still protected the anim&ts from stroke. Finally even in
cases where perindopfit suppressed BPs during the developing phase of
hypoftension and~ stroke. sane SHRsp perindopMl developed
BPs.- _ than 240 nvnHg end yet did not _lop stroke. Thosa studies
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suggest at best a 'II'88k association between BPs and stroke related mortality in
ACE imibited SHRsp.
Stier et ai. (1988) studied the effects of inhibition d thromboxane A,.
synthesis by dazmegreI in satt loadecI SHRsp. They found that SUCh treatment
resulted in asignificanl:reci.JCtion in BPs in SHRsp8l10and 11 weeks c:iage. This
hypotensive effect was virtually identical to that reported with enalapril treatment
(Slieret •., 1989), captcpril_ (Stiefet"'.. 1991) and perindopril treatment
(W1r'lg et 81., 1995) yet no reduction in mortality rate was achieved. An additional
problem with ma"ly c:I the above studies was in the statisticallests chosen for data
W18Iysis. In several instances, a series of t-tests were used to analyze BPs values
c1 treated and contJ'tM animals over several weeks. Given the repeated measures
natu'e c:I the BPs l'118lISI..ntI', an _lysis c:I variance of the effects d treatment
Vt'ith age would have been 8 more appropriate test to use. This would eliminate the
potential source of error introduced by repeated Heats.
In view cI the above controversies we decided to undertake experiments to
more adequately assess the pouibility that ACE inhibitors exert an antistroke effect
independent 01 then' ability to Iowor blood pnlSSlKe. K this prayed to be the case,
eu intentions were to IIlt8n1lt to study the mechanisms by which the ACE inhibitor
captopril exerted it antistroke effects.
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EXPERIMENTAL RESEARCH
1.5 THE EFFECT OF BLOOD PRESSURE SUPPRESSION ON STROKE
DEVELOPIIENT IN SHRop DURING TREATMENT WITH THE ANGIOTENSIN
CONVERTING ENZYIIIE INHIBITOR CAPTOPRIL
1.5.1 THE OBJECTIVES OF THE STUDY
we aIt8rJllled to determine if treatment with the ACE inhibitor caplopril was
__m~nghemorrI1agic within our colony t:A SHRsp
with the intention r:A carrying out further studies to determine whether or not
captopril treatment requires a significant redue::tion in BPs in order to significantly
retIw'd mortality in SHRsp. To.,... the above question, an attempt was made to
e6evaIe BPs dl.J'ing capIopril treetrnenI by treating the animals cor'ICdT8fltty with the
glucocorticoid dexIwneIhasone (.... agent known to produce hypertension in normal
animals) or the mineratocorticoid deoxycorticosterone. The results of these
experiments would then be used to detennine if an efevation in BPs or a
_ t:A tITJ'{ potential antihypertensive'-' of c:optoprillr-...nt affected
tho ability mc:aptoprillo retard stroke developmonl In__monts, SHRsp
were treated with the antihypertenstve vasodilator hydralazine. The ob;ective of
these experiments was to determine if rihypertensive treatment of SHRsp via a
non ACE inhibiting drug was equally effec:tive in altering stroke devetapment in
SHRsp.
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1.1.2 HYPOTHESES
we _ bl1yll<lbsis lh8t the__ .. _ AlI_dirodly or
via the incr8lIso .. c:or<ribWllO the~ all1ernorTh8gN:
stroke in SHRsp in • I1W'I"I8l" that is not totally dependent on the t'1ypert--.ive
-.-alAlI. FlIlI1ormor8, 8Ilhoogh~I_alSHRspmay_
blood pr8SSU"8 in these animals, the potential .-.tiItToke effects of such tre8tr'nert
will not be aIledod by celnNlting the animels with dnlgs lh8t will _ the
suppression of btood presIU"8 duing captopril treatment. we also exanined the
in1>OClal~_ onon-ACE _ ..ihyportonsivo __• on BP
and I1ernorTh8gN: .. SHRsp.
1.1.3 IIATERW.S AND METHODB
1.1.3.1~_
ThoSHRsp'-"'"__--_from 0 colony housed ..
_ c.-. SoMcos, wiIhin the__ConIro ot _lJni-.ity aI
_ (SI. JaI'n"). Tho porfonnod .. conIormity_the
guidlll_ ... by Conodion Ccuncil on _ c.-. and _ the~ aI the
MemoriaIlJnivenIity Anin8I c... Committee. Animal, were kept in roorna on a 12
hour lightldork cydo .. 2G-21" C with 0 tunidity 01 """",xi_ely 50%. Tho
dlar8cteristic: of the ItnIin were pr8S8fY8d by brother a'1d sister matings. To avoid
poIoriioI~ pnxIuc:od by honnonol tIucluIIiotw _ng !he..-.. cydo.
onIy"' .-do Our _ breeding'- by pIocing
28
1 male with 1-3 females at approxinetefy 910 10 weeks of age. Animals were kept
together for approximately 1 week. At 4 weeks of age, anmals were weaned,
placed 1 rat par cage and given _ rat d:YJw(~ Inc., Syracusa, NY,
USA; _ Rat, MousaIHam_ 3000), A16 -. of ago mala SHRsp -.
_ on a slrtlI<a1'fOO8..-. diet containing 4%NaCllOld O.75%K" (Zaiglar Bros
Inc., Gcn'ler5, Pennsylvania, USA). All ctug treatments were initiated at 6 weeks
of age and water a'1d food were provided in .....limited quantities. Animals were
wo91Odtothe naarast gram every other day _ 6 lOld 12-.al_ lOld
once~-.r.
1.5.:1.2__ allllugo
All drugs and chemicals were purchased from Sigma Chemical Co. (51.
Louis, MO, USA) I....dest OIherwise stated. Captopril was dissolved in drinking water
at a <Xll'1C8t'Irati to provide an__ doSa alSO mglkglday. Tho concantraIion
d captopril in the drinlting water was based on the average 24 hour drinking rate
d the captopril treated animals as 8Y8tuaI8d once weekly. Drinking rales for these
animals averaged approximately 350 mllkgldly.
Dexamethasone was first dissotved in dimethyl sulfoxide (DMSO), at 3.0
mg\100tJ1. OWe oil was then added to thts mixture to attain 8 final voll.l1"t8 of 1OmI.
Tha _ used was O.lmg1kg1day irjedad 1lilaJIanaousIy. Tho iattar traatmenI has
been prayiously shown to anhanoa hypertansion daval_ in SHR (Nagoi<a at
8/.. 1976). Daoxyoorticosta _ was dissolved in DMSO, at 10llmg/200\11.
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Olive oil was then added to the mixture to attain a final voIlIl18 of 2.5m1. A dose of
40mgIkg was irlected subcutaneously into the rats twice weekiy. This treatment
w;lh deoxy<:orti<:oslerone corresponds to a -.:t doIa usad to produce
deoxycorticosterone hypertension in 8 normotensive rats. Hydralazine was mixed
in the drinking water at 8 c:onoentration of 20, 40, eo, 80, and 100mg11. The two
hv-t doees fA hydralazine are typically sufficient to lower BP to normal levels in
SHR(_etal.,1988b, _.ndLee, 1991).
1.$.3.3 Sya10Iic Blood _ra__
SystoUc BP's were measured in unanesthetized rats using a tail cuff
"",-ion _lOld """"""'"' purthasad from lITe Inc. (Woodland Hills, CA,
USA).. Prior to testing, animals were warmed in their cages at 350 C for
approximately 1 hour. This exposure to heat was found to be I"I8C8...-y in order
to obtain a tail pulse. When the heating period was completed, animals were
placed one at a time in a restrai1er (IITC Model 81, 82 or 83 depending on the size
of the rat). The pulse sensor and tail cuff...tlfch were contained in a single unit (lITe
Model 860-318"' or 860-1116") was p(aced over the animals tail. The rat wei then
allowed 5 minutes to settle in the restrainer. The tail cuffIputse sensor unit was
connected to an amplifier unit (lITe Model 29-SSP BP Meter with buitt in Artifac;:t
Filter) and then to 8 2 charnel chart recorder (Unear instruments Corp.• Irvine, CA;
Modet 285, M\t). The c:hart reoord8r was calibrated before eec:h sesston to 8 111098
of 0 to 300mmHg. The tail cuff was inflated to 8 pr8SSlft where the
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~icaI,-.od llliI pUoe Tho p<--..e within the aIf_
""" _ to slowl)' doc:8y until" tail pulse nltumOd. Tho ptesan_the
o.I/wllon the llliI pulse__-._the systolic BP. E8cll_ hod its
BPs taken 3 times per JeSSion an:::Ifle ......... rec:orded aslhal. week's ~ue_
The-.BPs.-...-u__ QllllIlleted during~ oIlico hc>n on the
same day each_.
1.5.... 1110 _"II '" _llovoIopoMm ond tho 8ompI1ng"'_.
The rats were monitored daily for the 0CCUT8fl0I of stroke. The symptoms
__wiIh...-~within5HRsp have boOn previously dnaibed
(5medo, 1989, 1992). Initially, SHRsp doYeIop corwuIlIive __ ,."..",
movement IoIIowed by i__ --the rot silo with its lOgo hyper
__ in a --.,., typo"_. The _ symptom _oft8n_
wiIh Iett-.gy lO1d poor~ Thoro is Iypically a 1.5 _ period~ the
onseldthefirst_oral~d .
Soma 5HRsp diad -.,ely, not allowing uo to _ blood~ or to
carry out fiJnclionalotudieo ontha_. ~,themajarilyd
animals exhibited signs d Rake that IX'OQl'esMd to the point where death 'MIl
imminent. In such insWlceI. the animal was MeSthetized with 8 mixbn of
X,lazine and __(10 mg X,lazine (Rornpun, Ila)'Of Inc.. Onto , Canada) plul
50 mg Katamino (Katalaan, MTC _call, on., e.-I per kg body
woigIO, Lm). A poIformed and--...2 mI d __
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cdIected no hel:*inized syringes via cardiac: ptMlCt....e. Blood was centrifuged at
14000 rpm for approximately 1-2 mirUes (Brinkmann Instruments Inc., westbury,
NY, USA: EppeOOOO Centrifuge 5415C). Sen.m was col_ and stored at-2<1'
C for aldosterone determinations to be described in c:hapter 2. The animals were
then 8XSWlgUW1al:ed rid the middle cerebral wteries (MCA) were collected and
used in fl..nc:tional studies to be desaibed in chapter 3. The brains r::I all animals
were removed and fixed in 84mM po. buffer containing 4% formaldehyde and 1%
glutaraldehyde at a pH of 7.4. The fixed brains were Ialer examined for the
.....,. or absence r1 tlomclnt1egic _ by goss visual inspocIior1. In the event
thai no stroke was tdentified using this method, brains were cut into .5-1.5mm
sections 8ld examined miaoscopically (Olympus America Inc., Melville NY, USA;
Model SZ40 microsoope).
1.5.3.5__ AnoIyoIa
Alterations of blood pre$SUfe with age with respect to indiv)dual treatments
were analyzed using a general Ii~ mode( of multivariant ..aJysis of variance
(suIloequenlly _ to as NlOVA). Tho effeds r1 varying treatments on blood
pressures were detem1ined wrth respect 10 age over common ages between
treatment groups. Mortality with age was assessed using a Mann-Whitney rank
order test. Results -..c::ons_ sq,ificanI at P<O.05. All results .... expressed
as the meal +1- one standard error measurement. All tests were performed using
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Minitab Statistical SdMare (State College. PA. USA)
U.4RESULTS
1.5.4.1 Tho_ofCoploprll_~T_on ___
_ 1I_11ly _
The effec:t of captopril end hydralazine treatment on the systoliC blood
pressure Md mortality of SHRsp is outlined in Fig&.n 1A and 18. Caplopril
treatment produced a small reduction in the me.-. BPs of SHRsp when compared
to controls between the ages 8 and 11 weeks. However, when the SP data was
a18lysed over theI~d the controls (ANOVA) no sign_ dillerences ......
observed. Captapil treated SHRsp SU'Vived to an older age than control rats and
at ages _ d1lV112-. d age (the age at which the ccnlrOl rats developed
a 100% mortality associated with stroke) captopril treated SHRsp exhibited BPs,
Yttlich surpassed those recorded 88l1ier in untreated control group. For example,
BPs values from control animals peaked at approximately 265mmHg at 11 weeks
of age while the BPs of captopril treated SHRsp often attained SP't greater than
275 mmHg _ 22 _ d age.
SHRsp were treated with the anlihypertensive agent hydralazine at doses
d 20, 40. 60. eo and 100 mgIL of drinking_. The antihypslt_ve eIfecIs of
this drug were variable beNteen animals. It was not uncommon for the animals to
initially exhibit a suppression d BPs only to have their SP's re-elevate to levels that
were present in oonIrOI animals. 5inoe the ob;ective of the study was to achieve an
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Figln 1. ..........in IyIIOIicl*>od pnlO1U8(A) _ rnortaliIy(8)-with hemonhagic _ in unInloIed~ 5HRIp _ SHRsp __
coptapril 0< hydnIIozine. 0- tho liIesplw1 of tho ex>rOroI SHRsp, coptopril
___ (50 rngo1q1dIy, c:noIy) did not~ _l*>od pnlO1U8 in SHRsp
_ .. SHRsp""'-upto 34_ofogo. ot
38 _ of ogo ("") with • coptopriI __ SHRsp IUViving. n- _
IlICked _I _ of _ bU 2 of • SHRsp I
_ """",",-. To study tho efIeds of _ l*>od prws<n on
_SHRsp __ ....ed _ hydnIIozine (OG-l00 mgII., d.w.).MortaIily from in SHRsp _ reopondod to hydraIazine_
by Oldlibiting _lyItolic blood prossurvs <220 mmHg from 10-.of ogo
to-. DospiIo tho~ of _ blood prossurvs in tho hydnIIozino ....ed
~... oneet c:l11'lOl'UIIity 8IIOCiated with stroke occ.rred et., eer1ier age then
_ oboeNed in coptaprillr88t8d SHRsp. Staliotico: Fig. 1A· NlOVA • ov«!he
lifespw1 of A, AvI8-NS. Av.c-p< 0.001, over the lifespen of C, BvsC - P<O.OO1;
Fig. 18 - Mann-Whitney - Ava8-P<O.OO1, AvsC· P<O.OO1, BvsC - P<O.01. (n =
val..... A=11,a-7,C=7SHRsp).
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antiI1ypertensiYe eIIed and not to study the _ of hydralazine per se, mortality
was onty studied in SHRsp thai: eJdlibited average weekly BPs values of less ttw1
220mmHg from 10 _ ofage U'lIiI the time of_. Three SHRsp treated with
«lmgIl, 1 treated with 6OmgII., 2 treated with llOmgIL and 1 treated with 10lllnWL
of drinking water met these aiteria.
The ability of hydralazine to supp<ess BP was greater during the first haW of
1he<I~ wilen~ to Itlo se<:ond haW, Irequently not ...-passing v81ues
of 20ClmmHg. The hydralazine treated SHRsp were shown to have significantly
r8du08d BPs when compared to the untreated control group when Ihe BP's were
c:cmpared over the lifespan d CClf'llrots. The hydralazine treated .,imels were also
shown to have 8 significantly _ BPs profilas~ 10 tho caplopril
treated group when analyzed over the common lifespans of both groups.
Untteated SHRsp controls bagan to dis .. 8pIlfOXimata<y 10.5 _ks of age.
A 100% mortality associated with stroke was attained before any of the rats
achieved 13 __ of age. None of the SHRsp treated with C8IllOtlriI developed
stroke or died up to 19 weeks of age. At this point in time, four captopril treated
SHRsp were randomly picked from the group and sampted while the remaining
seven captopril treated .,imals were allowed to live t..ntil the termination of the
a>q:JOriment (040_ of age). The sampled caplopriltreated SHRsp __ used in
other investigations to be desaibed later. This also allowed us to examine the
brains of the captopril treated ret_ !of eny potential physical evidenca of
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hemorrhagic stroke. No evidence of infarcts or hemorrhagic stroke was observed
in !he sampled ~llnlatedSHRsp.
The mortality pn>file of !he capt",,"l treated SHRsp indicates that !he
earliest stroke related death in this group did not occur until approximately 34
WIMlks of age. AJ. 38.5 weeks of age, only three captopril treated animals had died
with evidence of hemorrhagic stroke IVld at 40 weeks of age, the remaining feu
animals were sampled wiUl no apperent signs of stroke. Upon autopsy however,
2 fA 4 c:A these ..imals were fOlSld to have hemon1'l8gic lesions. Statistical analysis
of the mortality rates of untreaIecI control verses the captopril treated SHRsp
indicaled that captopril treatment significantly inaeased the lifespan of SHRsp.
The mortality profile of the hydralazine treated animals showed that this
goup began to die at approximately 17 \¥88ks of age and six of the seven animals
were dead by 26 'N88ks of age, about 2 months prior to the age at which the first
stroke related death occurred '" the captopril treated gfQ4). Statistie8l analysis
..-thal!he moI1IIIity in hydralazine __ SHRsp 0CCLmId at a _ age
than captopril treated animals despite the facl that the same treatment resulted in
8 more effective reduction in BP. Hydralazine treatment did produce a benefic:ial
effect in that it retarded the onset of mortality associated with stroke when
compared to the absence of treatment.
In~, captopril treatment significantly retarded !he onset of mortality
associated with stroke in the absence of a statistically significant (i.e., P>O.05)
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change in BP aver that present in untreated rats. The latter obsefvation combtned
with the observation that hydralazine treatment did significantly lower the BP cA
SHRsp llYl CXlUid"", dl4>licale the _ eIIecls of_april would sugges'lhal
captapril's antistroke effects are likely not mediated by the suppression of
hypertension.
1.5.4.2 Tho_oIoe--....__xycortl_T_on
____ltyAuoci InSHRopT....... _
CapIopril
Due to the..-e<llong _ of the proposed experiments (40-l.
the experiments studying the effects of dexamethasone and deoxycorticosterone
cotreatment on stroke development in captopril treated SHRsp were performed
concurrently with the experiments studying the individLJa' effects of eaptopril
treatment on SHRsp. This was done with the anticipation that csptopril treatment
wouJd suppress the BP d SHRsp and the realization that there may not be enough
time during the graduate studies time period to r\Kl consecutive multiple 40 week
dosetion__. The oboefvetion Ihat caplapril .._ did "'" significently
lower the BP over that present in Wltreated SHRsp diminished the need to re-
_ BP using de>anelhosone ordeoxycor1icostercne__• since
these experiments were in progr&S$ we completed the studies as outlined. The
etrec:t of dexamethasone and deoxycorticosterone cotreatment on blood pressure
a1d mortality associated with stroke in captopiI tre&ted SHRsp is outlined in Figure
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F1gun 2. __ in systcIicblood _(A)_mollaIityassccialod_
hemorrhagic _ (B) _in untnlaIod control SHRsp and SHRsp treated _
captopril in the presence Of __ ol co-treaIment _ do_ Of
deoxyccrticooterone. The _ ol C8IlIOPriI(~. Of811y) _
dooxycort_ton>ne (40 mgIkg.~. s.c.) but no! with _ (0.1
mglkglday, s.c) prevented captopil _ from reta-ding the or.- ol
_c _. None ol the captopil treolod SHRsp c:c>-lnlatod _
dexall8Ch88oll8 died or devefoped symptoms associated with_c stroke,
_whontho_SHRsp_....,1od-.24to30_olage(".
2 ol6 SHRsp showed histolcgical_ of inIracerat>rlIl hemorrtIage. Statistics
-IWOVA - in Fig. 2A - ove< tho lifespan of A, AYSC and AvsO - NS. <He< lifespan
of C, BvsC • P< 0.001, over lifespan of 0, BvsO P< 0.001; In Fig. 28 - Mam
VVhitney - AvsC - P < 0.001, AvsD - NS, BvsC .-K1 BvsO - P < 0.001 (n values A =
11. B = 7, C =6. 0=6).
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Figon 3. __ in systolic blood prosa.nl (A) and mortality _ated with
hemOfThagic: _ (B) in untreated SHR'Il and SHRsp treated with
dexamethasone Of deoxycorticosterone. Treatment aI SHR'Il with
deoxy_ (40 mgIkg. 2XfMIeI<. s.c.) lICCOl8nItod the onset aI _
deveIopnent in SHRsp wIlile treatment wilt1 dexamethasone (O.lmg.1<g1day. s.c.)
had no eIfed on the cnset d cteaIh associated with stroke. Statistics~A- Fig
3A-.,.. """",,""09 IiIe __• A VI B, A VI C - all NS: In Fig 38 - Mann Whitney-
Ava B-NS,AvsC·P <0.01 (n valuesA= 11, 8 =6, C =6).
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2Aand 2B.
SHRsp -.. lraatad with captoptil from 6 weeks of age and
_ialsterone (40 mglkg~) or dexamethasone (0.1 mglkglday) was
iflId8d into the animals. As shown in Figu'e 2A when comparecI over common life
spans neither of the latter injections significantly elevated the BP d SHRsp over
that present in untreated control animals but, both deoxycorticosterone and
dexlWnetha80ne irlectiOMS signific8ntfy eIevaIed the UP ofcaptopril treated animals.
The injection of deoxycorticosterone into caplopril treated SHRsp prevented
C8ptopril treatment from retarding mortality associated with stroke devefopmenI
whereaS, ctexamethasone did not (Figll"8 28).
None of the 6 rats treated with captopril plus dexamethasone died or
exhibited~oms related to stroke development (Figl.nt 28). The captopril plus
dexamethaSone _ SHRsp wee sampled _ 24-30 weeks of age. None
of the rats exhibited behavioral symptcJm$ of stroke, however, histological
examination revealed the presence of intracerebral hemOlTtlage in 2 of the 6
animals.
The c:andusions reached were that despite the ability of dexamethasone to
_ blood pr8SSU8 in caplopril .raatad SHRsp, tho latter glucocorticoid did not
greatly reverse the antistroke effects of captopril treatment on mortality. To our
surprise deoxycorticosterone cotreatment of captopril treated rats produced
com~. blood pressures in SHRsp to those observed in dexamethasone
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cotreated animals yet unlike the latter treatment. cotreatment with
dooxya:Jrti=-cntl~ nullifiedlhe _ eIfec:ts of caplopril treatment
in SHRsp. Untike dexamethasone, deoxycorticosterone binds to the same
mineraloc:ortic:otd receptors and mimk:s the action d akfosterone. Since the renin
angiotensin system is hyperaCtive in SHRsp we contemplated the possibility that
the potential mineralocorticOid receptor stimulation via aldosterone, secondary to
the presence of All mediated hyper-release of aldosterOne may play an important
role in promote hemorrhagic stroke deYeIopment in SHRsp.
We also tested the individual effects d dexamethasone and
d8oxycoI'ticclI on blood pre5Sln and mortality associaIed with stroke within
SHRsp not treated with captopril. The results of this experiment ant shatm in
FiglIe 3A ald 38. 1he blood pnI8SU1lS 01 SHRsp sU>jocted to deoxycorticostemne
or dexamethasone injections did not significantly differ from untreated control
SHRsp when compared over corresponding life spans (Figure 3A).
Deoxyoorticosterone injections accelerated the onset of mortality associated with
-.on _ by 2.210 2.5 weeks when compared to untreated SHRsp. The
ir1Odion of doxlonelhasono did not significanIty .her__ dovek>f>mont in SHRsp
(FiglIe 38).
1.5.5 DISCUSSION
w. have shown lI18I caplopril treatmenI of SHRsp is oapal>le of promoting
a dramatic reduction in the onset of mortality associated with hemorrhagic stroke
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without significantty attering BP. Hycnlazine treatment produced a much greater
reduction in BP than captopril treatment but was less effective than captopril
___ in retarding the or.-dhemont1agic__. The ..istroke
effects of caplopril treatment were preserved under conditions where the level of
hypertension was ertla-1C8d by CXltreatment d the rats with dexa'nethasone. In view
of these findings it seems unlikely that the nistroke effect of capl:opnl treatment
was the result of the small (statisticBlty insignificant) hypotensive effect seen
between 8 iW1d 11 weeks d age in SHRsp. k would appear that ACE inhibition and
tha suppression of All independonl of the proc>Jction d hyperlen$ioo may ploy a
role in promoting the antistroke effects of captopril in SHRsp. It is important to be
ClOSJ'1izant of the fact that the aforementioned results do not indicate that elevated
BP plays no role in the promotion of hernon1'\agic stroke in SHRsp. The
observation thai hydralazine treatment of SHRsp resulted in significantly rec1.K:ed
BP and a retarded onset of mortality acknowledges this association. It was
oonsider8d that the hydralazine mediated BP reduction could have increased RAS
ectivity lWld partieIly _ a potential antistroka effect of BP reduction. ThenrfonI,
a number of stud. were revMMed in order to gain an l..W'IdersBlding d the
influence of hydralazine treatment on the RAS.
~ et al. (1975) reported serum renin activity and serum aldosterone
values were signific:anUy elevated by a sing", intraperitoneal dose of hydralazine
(1 mglkg), peaking at 20 lWld 60 minutes respedively. The result$ derived from
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Wistar rats were not~ied by BP values. Similarly, treating SHR with
hydralazine (3 mgIkg, d.w.) for 2 weeks resufted in a 2 to 3 fold increase in PRA
and a s9lifiar'i. reduction in IT'I8al arterial pre5SlIlt relative to untreated controls.
Neither value changed signiflC8"ltly when re-examined at 3 and 6 months
(Antonaccio et al., 1979).
In a clinical study by Abraham et al. (1987), patients diagnosed with
essentia hypertension and treated with hydralazine (163 mgfday, p.o.) for 8.3
weeks, showed 8 sigr'lific::a't reduction in supine diastolic blood pressure relative to
a p6aoebo treatment phase. However, there were no significant changes in supine
systolic:,~ systolic or l4'fight _ic blood pressures. Among those patienIs
fou1d 10 be c:onIrolled on hydralazine rnonolhe<apy (supine diastolic blood pressure
< 91 mmHg and reduced at least 10 mmHg relative to placebo) no significant
changes were found in supine and upright PRA or supine and uprighl ptasme
aldosterone levels.
Additional animal studies were conducted by Morishita et al. (1995) and
found BP and plasma All levels significantly elevated in 2 kidney, 1 clip (2K1C)
Wistar rats relative to 8 sham operated~. Treating the 2K1C group with
hydralazine (2Omg/I<g, d.w.) for 4 -. ..gnif....,y decreased BP but had no
significant effect on plasma All concentration. The investigators further reported
lllatlhe """" dose cO~ne given 10 SHR reduced BP to normotensive WIf:f
Ievets and also had no significW'II: effect on p&asma AU c:oncentration. Furthermore,
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treating SHRsp with hydralazine (30 mg/I<g, d.w.) fer 28 days resulted in
signifteantly reduced SP, significantly efevated PRA but no stgniflC8f1t cIwlge in
kidney renin mRNA levels. The ""*'" grtlLll was -.ated SHRsp and all anlmals
had unrestrided access to standard rat chow' and distilled water (Keuneke et al.,
1995).
lJnforb.naIeIy, the investigations outlined above differ from those desaibed
in the thesis in several potentially important ways. For example, there is little
consistency among studies in terms of the particular component(s) of the RAS
examined, methods a bkxx:I pressa.n evaiJation, the species studied as well as the
hydralazine dose, delivery method and dtraIion of treatment. In addition, due to
tirre limitations. we were lXI8bIe to examination the RAS in our hydralazine treated
.,imals. Consequentty, the relevwa of these findings to our own is questionable
cn:IlN8 are l.I"l8bIe directly address the status d the RAS is SHRsp. Based on OU'"
results, we suggest that variables in conjunction with the presence of hypertension
can determine whether stroke develops in SHRsp.
Although the present preIimifwy study ca1 not escertain the mec::hanisms via
W'hic:h captopril exerts its antistroke effects, the obsef'vation that
deoxycorticXlsterone cotreatment of captopril treated rats reversed the antistroke
effects of captopril is a significant observation. The level of captopril given to the
rats far exceedS the levels typically required 10 compfetely inhitHt both ciraiatory
and lisa» ACE ae:tMly in _ (S- at8/., 1987). Hanca,"-lhe conditions of
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the experiment, )ocal and circulating All levels should have been suppressed in
SHRsp by captopril treatment. Studies outlined H1 the introduction of this chapter
presented evidence that All (Mento and Wilkes, 1987) and aldosterone (li"",
1982) nwy retl..m la, or eXC88cl pte-tretement levels with chronic 8xpo$U1'8 to ACE
inhibiticW'1. However. these stucfies differ from those outlined in the thesis in
potentially importa'rt factors such as the species studied and the duration of
treatment. Consequently, it is difficult to retat. these results to our 00NI'l. The
question d ptasma aldosterone leve's in SHRsp under chronic captopril treatment
however will be specifically ae:tdreSSeCI in chapter 2.
The observation that deoxycorticosterone treatment in the presence of All
suppresston permitted stroke to develop would suggest that mineralocorticoid
action independent d All dired effects can facilitate the onset of hemorrt\ag;c
stroke devek:lpment. Silce aldoSterone is comparable to deoxycorticosterone in its
StructlX8 and acts to stimJlate the same receptors (Agawat and Mirshahi, 1999;
Rogerson and Fuller, 2OCXl) and in view of the fact that activation of the renin
qiotensin system occurs in SHRsp, it is possible that elevations in aldosterone
and not the direct actions of All may play a role in promoting stroke devetopment
In SHRsp. tf this were to be the case, the antistroke effects of captopril could be
mediated via the suppression of plasma aldosterone, a hypothesis that will be
tested in Chapter 2 of this thesis.
Otxing our investigations, tour captopril treated and six caplopril plus
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dexamethasone treated SHRsp were sacrificed prior to the development of any
overt signs of stroke. Of interest, two of the feu captopril treated SHRsp and two
of the six capt",,"1 pt.a _ilothesoile _ SHRsp_fol.r1cI to hove_
a hemorrhagic stroke when the autopsies were performed. As previously
disaJSSOd, SHRsp only livo to< 1.5-. after the~ 01 stroke (S'-, 1989).
This oIlservaIion suggests the possibility__1_not only deloyo the
onset of stroke but pm60ngs life after a stroke has oc:c:urred. This is consistent with
the obsefvations made in rec:ert studies that capIopril tr88Iment not only retMjs the
onset of stroke in SHRsp, but also significantly prevents death even when the
_ is _ "" to 6 deys _ the~ ofhemorThagic stroke development
in SHRsp (Smeda et aI., 19998). The mechanism via whid'l this effed takes p'ace
is lXICIear, however MRI studies of the brains of SHRsp during the initial onset of
stroke indicate that an earty event preceding the development of cerebral
hemonhage is the OCQJrrence of intra to extravascular plasma movement across
... vasc:uI« wall caJSing the~ formation of edema (Takalhi et al., 1994;
B~z.r at aI., 1998). Treatment with an ACE inhibitor prior to the formation of
edema retards this event and treatment after edema has formed, reverses this
pathoklgy. M: is possible that the extravascular movement of flukt occurs at the first
siles of vsSOJIar ruptIxe and is foHowed by the movement c:t blood cells into the
brain tissue. ACE inhibitors could pI'Ol1Jce a physiological change altering cerebral
bkx:Jd flaw to the region in 8 I1"Ia'Yl8r that reduces local hydrostatic pressures. This,
.9
in 11m, <XlUd~ the inIegrity at the ..-.etium end -.by _ ex limit
n.¢Jre at the blood brain _.
A second~ oction at~I <XlUd be .. a ranal_ SHIUp
deWIop ranal dysfLndion priork>_(~ 1997).~....-;oo
at the~~the_atis<:homic~....... Glomerular
fittration decreases, urea and likefy other lAl'l1k: IOxins .-e not littered and ..
.-in the blood (.......). The -.. atfi are such Ihat plaama
proteins such as albumin are lost into the urine (Smeda, 1997). These atlerationa
c:oukt be promoted as a resutt m the development 01 preglOm8rular .-teriOIar
ocdusiYe disease such as the 0CCUTenC:8 of .-terial fibrinoid neaosis in the
kidneys at SHIUp (Ogata at aI., 1982). Suc:h _ <XlUd play an if11)Ortant role
in the doNeiopmor< at hemorrhagic-. in SHIUp. Tho doNeiopmor< at uramia
i~ at hypottansion is with tho doNeiopmor< at blooding
disordeB due to tho ar<ic:olIguIn _ at uramic toxins (_,1992, 1997).
Honc:e a small n.¢Jre in the blood brain _ thai~ be repaired by dotting
<XlUd, in the pr--.oo at uramia "-1d to loon a _ ir*aconlbral~.
sn::e aI:u'rWl CXlf'tritlutes to the onc:otic~ of the blood, which tends to draw
fluid from the extra into the intrav8SCUlar space, • deaUse in blood ab.min level
woold promote the oxtravascular movement at tIuida, an .......m that has been shown
to pracade hemont1agic stroka development in SHRsp (S~, 1997). Tho
po-..J importance at tho _ altanIlions in reIaIion to _ ~ il
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~by_~SHRwI1icl1typicollydonotdeYelop_.p_
nopIlr8dDmy 01 SHR whidl producas. docANlIe in gIon81J_ fi__,
arw:t__ tta__modollOdeYelop_<-. 1992).
NophOClOi'_ SHR can dewlcped_ic_...wcondilions-.
the blood pnossure 01 the ";maIs is not further oIevlll8d <_, 1992). ACE
inhibitor treatment of SHRsp prior to stroke hal been shown to irilibit the
doveIopmer"< 01~_fiIlrinoM:l nocroois, prevent the -..... In
gkmeruIa' fillration a1d inhibit the development of uremia end proteiruia (Slier et
aI.• 1989; 8m" et e/., 1998). n is possibte that some of the benefidal antistroke
eIrects d ACE inhibition c:ouId be the resun 01 the renal proted:ive effects exerted
by this class 01 drugs end the ability of thess drugs 10 W1hillit the~ 01
.-terial fibrinoid necrosis in the kidney. Recent stud_ have suggested thai
___ in plasma-....__ .. SHRsp may play. plWtiaJWly iTlportarO
_ .. promoting the typo of ronaI'-- descnbod _ (Rocha et III., 1999).
An~ finding .. ourSluly is the obs«vation that caplcpril_
did not sQ'ifiC8'1IIy aw-tho blood pnlSSU8 of our SHRsp. The _ of tta
situItion is that as discuned in the literabxe review. SHRsp develop high pIasm8
renin and A1llevets (Stier etal., 1991; Kim et aI., 1992; Hubner elal., 1995), 8M
alt8ration that should facilitate the enhancement of hypert&nston. Ironically, ACE
inhibitors ... effective in lowering the BP of 5HR to new normotensNe levels
dosPIs tho facl that plasma I8f1in and All _Is ... normal .. thess _ <Morishita
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et aI., 1995). 1heIe .... indiv_ populations of SHRsp that do not develop. high
incidence of stroke, ACE inhibitor treBtmenI does suppress the BP in these groups
of SHR",(Hadju etal.. 1991; Chillonand _,1999). The reason why 0\1'
SHR'fl.101d Olher SHR", (that dovel"". high incidence of strok.) do not _
to ACE inhibitor treatment by exhibiting 8 suppression in SP is unknown. It is
possibte th8t the struc:ILnl atterations in the renal arteriolar vasculatu'e are of such
8 massive degree in our SHRsp that kidney h.nction is permanently reset. The high
BP present could be a consequence of 8 structurally reset kidney and may be
necessary to maintain a viable level of glomerular filtration, salt and water balance
(Guylonetal., 1986). Wlhe__... in.mamer ......... given range of high
BPs were required to maintain a viable salt and water balance, a decrease in BP
which potentially oouId pertu'b this baiance (i.e., via ACE inhibitor treatment) would
be resisted by the body since the disruption in the fluid water etectrolyte balance
'MlUId cause death. The presence d the renal dysfl..nc:tion would also activate RAS
and elevate plasma All levets which could increase the risk of stroke. SHRsp
colonies that do not develop stroke could have more normal renal function and
normal plasma All levels as is the case in SHR, hence the risk of stroke may be
abart In these colonies of SHRsp 8 decrease in BP promoted by ACE inhibitor
treaIment could be sustained without compromising renal filtratiOn, salt and water
balanc:e to a point where death is immanent.
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ClW'TER2:THE_PROII01lNGTHE~EFRCTSOF
ANGIOTENSIN CONYERT1NG ENZYIIE INHI&TORS IN SHRop
UTERATURE IlE\IlEW
2.1 AN ASSESSIIENT OF THE POSSIBLE MEDIATORS INVOLVED IN
PROIIOT1NG THE AN11STROKE EFFECTS OF CAPTOPRIL
2.1.1_
., chapter 1 we provided evidence 10 support CU' condl.U)n th8I c:aptopril
_ dKyoIo W_ ...... prone~ hyporIenoive _ (SHRsp)
'otanls mottality associated '"'" _ indepondor'O d a significant nldudion in
blood pnISSl.n (BP)~, OU" foaJs progressed to ,......;gat;ons ahned
at identifying possible medMdOl"l of eaptopril's antittroke effects in theM animals.
The rnojor pharmacologic~ d angiolansin converting enzyme (ACE) ;,-,hiM""
are _ to be tha mbition d angiolansin II (All) _ and tha nldudion d
plasma aldostorono _ (Guns, 1992). 1llln are allo _ that~I
__.~-=t(Xieot•., 1994). Thesa __
lhareIont<:cns-.clas~.--.dtha~ aetionod~1
_inSHRsp
2.1.2 Tho_O#tha Nar-.S_lntha_.
E_O#~IT.._
The pooM>ilily1hal~I'._--- mediated as • .-,II
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ofa syIl1llIOhoIytiefloct .... consGrad, but _ LnIika1y. _ and iliad<
(1985), ....~ nerve actiYity from 1ha -""c:ervic:al trunk at
12 10 25 _ of ago in SHRsp, K,,"o Wi_ ..... p.-ona~
hypeI1enlive rats (stroke resistant stram) (SHR) and Wister Kyoto ratl fed a
stand8rd l1Il chow diet. Peak I)'fl'lplIIheti I"I8t"Y8 activity (ac:hieYecl via the induction
of C8f"ItnII ischerrri8) and resting sympathetic nerve activity were found to be
signifieatllJy otevated in SHR~ 10 SHRsp. _authors~ .... Iha
_~__"~_IOSHRmay.. ac:or'Olil>Wlg
_"Iha~of__. SinUrty,_aU/.(I983)
exaninodlha ofI<lds d un;laIaral eatvicaI ganglioneclOmy, performed at 7 months
c:I age, in SHRsp fed a Japanese styte 08t and a ,,, HaCI ctlnking solution. These
investigaIors found that stroke occurred only in the denervated skSe in 79% of the
_ which...-Iha proc8lU8. In sham oparaIad <:ontroI1, Iha incidonca
of stroke W8S similar in the 2 hemispheres. It was 81so reported th8t vascular
~ofp;alard~brain8l1_(axtomal __<llOIm)
was reduced in the derwv.ted hemisphere. The &lthors conduded that wall
~may_1ha_ maoc:in::uIatio from_. The .....
~ proc:odtn performed a1 3 monIhs d ago had no ofIecIlUll\lOIting
that sympathectomy altered cerebrovascular development only at • young age.
0Ihar 1'-' have ohown tile donsiIy of COf8I>royllllCUlar lympaIhatic
imorvatkln;1noI_with or-.SHR and SHRsp (S-,I990).
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_8bo¥e_"""d ex>rOnIdid tho hypothesis _ a __ in~
"""",activity<l6ing~I- _ ... _
2.1.3Tho_oI"_~S_In" _
_ oI~T_
"_unlikeIy_~1 _oxertodilsonti__ in
SHRspYiasylTl>lllholytimochanisms. ~.OUl'_fcr_"",oI
capkJpril's therapeutic actions in SHRsp towsed on the renin angiotensin system
(RAS). The justiflC8lion for taking the investigation. in this direction was derived
from experimentsl evidence indicating thBl various~ d the RAS in
SHRsp.-n" be__ cUing. high No' diet. " this may
be an inappropIiale _ .. """"""Y. tho adivity 01 tho RAS would be
~ cUing. high 10" diet(_ in Chapter 1).
Stieretal. (1991). _flallollowing5_01-.. '" the-'
prone roder< _ and 1% saline '*""<ing _. '2.5 _ old Kyoto W....
nonnotensMl (WKY) '"" reY08Iad plasma renin activity (PRA) _ 01 0.6 ng
ALiITlUhr compared with 3.5 ngAIIrnIIty in WK:f on • Uldafd died .-ld ......
SHRsp 01 ........ago~,placed on tho ...... high .... dial produced PRA
.-0129.' ngAIImllhr comparad '" 9.2 ngAl/mIIhr in SHRop on • _ dial
and water. These resub suggest that while PRA may be suppressed in response
to an increased ..It intake in \fIIt(:f, the PRA of SHRap may rise inapproprialely
..- idantic:al. high salt oonditions.
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F,"""",81CllT18lieo inlhlRAS dSHRspweereported byVolpeet •. (1993).
lhoso a.lhors fQ.nd tho! <Urg a 1 _ """"""" 10 lhllll'ol<a-prone rodanl diet,
the PRA d 6 _ old SHRsp, SHR ani WI<:( was _ approxirnalaIy
~_10__ilhod prior 10__on the special diet.
However, plasma aldosterone suppression and Lrin8ry Na· excretion was less in
SHRIp oompared with both SHR and INKY over the S8fI"I8 time period. BP among
lhl3grtlO4lOd_wasnotS9l_ d-.nt 01 any_ cklring Ole study,
Tho imest;gatcrs concluded tho! """"l SHRsp __ a d
_ani deladive Na·_during high saIt-..
In another study of the RAS in SHRsp, Volpe et aI. (1990) examined the
__in-.a raninaclivityrd-.a__sin_1O a 12
_""""",""lOahighsalt,~diol,_ingat6-'d_. Nt.
4 weeks on the diet, there was no significant ditterenoe in pIasna renin activity or
plasma aldosterone between the se/t loaded SHRsp .-'Id a group of SHRsp fed a
standa'd diet. At 8 weeks a'ld 8QlIin at 12 weeki however, the pt8smII renin activity
in lhe oBIt _ SHRsp rose IO..-adty high _ ~ with animals on
lhl_diol, """' .... 12 -1*ioc1 PIaMla
akiosterone IeYels 8110 rose chmItiCIIlly at 8 a"d 12 weeks of age in I8It Ioeded
SHRsp oornpated to baseline values. Simil.. resutts were reported by Camargo ",
• (1991) wIlo began _ing SHRsp lhe streI<e-prona d" at 6 _ d_.
F~4-.on lhl Na' _ diol, pa.na ranin acIivity_ not__
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relative to baseline values deI&mined prior to begiming the h91 sal diet.
HoweY., at 8 and 12 weeks d ltllPC*ft to the special diet. PRA incr88sed .-1d
_lJ88Iorlhan twice .
In addition 10 tho .. pIasmo nril adMIy _ -..._,
plasma AU IeYelI have -so been shown 10 be high in SHRsp using
radioirnnLrloas. For....,..,.., Hlbw.. aI. (1995), fou1d lhot -... All _.
__ oignificanlIy_inSHRop~_INKYboIh.__eftor
a 12 day exposure 10 8 1% NaCI drinking solution. In another study, plasma
atdosIen:lne levels determined by radioimrJU"108SS8y ....... fol.nd to be nearty four
times hig- in 25 _ old hypot1enoive SHRop c:ompared _ ago.<nalchod
nonnotensive INKY (Kim et 01., 1992).
The studies desalbed above irOcate that various~ of the RAS
_be~_wl1enSHRop ...__ on.h;gIlaaltdiollt>r
1J88Ior1han'-.. Tho normal_d-",-."", _ inc:reaIa
il HI· 8XCAItion in reIIpOfWe 10. "'.1oad8d diIII rMY""be~. In addition,
as discussed in c:hepter 1, deoxycorticosterone treetment was shown to inc:reaIe
the mortatity rete of SHRsp refative to II1treat8d c::cnroI enimals.
Deoxycorticosterone W8I 8110 IIbIe to &'iminate the antistrcke effects obMfved in
~I treated SHRop. Compared with untreated control., deoxycorti<:oatarone
or dexamethasone treatment produced Y8fY similar BPs effeds. However,
deoxy<;orticoItarono _ ortlancod tho onMI d .......Iity _ .. SHRop
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whereas dexamethasone did not. Hl.m8I'1 studies also report an association
between aldosteronism and hemorrhagic stroke. For example, Nishimura et al.
(1999), reported that stoke and proteinuria were particularly common in a study
group of 58 patients diagnosed with primary aktosteronism. Additionally, the
incidence of cerebral hemorrhage was signiflC8f'ltly greater in patients with primary
aldosteronism relatiVe to age and sex matched CXlI'lIrols with essential hypertension.
Diastolic blood presstnt was also signifK*ltly higher in the primary aldosteronism
group. However, diast~ie blood pressure was not significantly different between
primary aIdosteronrsm groups with and without vascular complications (Takeda et
al.,l995).
Based on these observations it was speculated that the rnol'tIMity rate in
SHRsp may be related to a rninera60cXJrti effecl ConsequenUy, we focused our
search for a possible rTI8dIator of c:aptopril's antistroke action on aldosterone. The
following sections will review the pharmacology and physiology of aldOSterone.
2.2 PHVSIOLOGICAL AND PHARIIACOl OGICAL AC110NS OF AUlOSTERONE
2.2.11_
Aldosterone is the main mineraloc:orticoid in mammals and ptays an
iTlpc:lr1an role in Ne·, K"' and H"' homeostasis regulation. This occurs primarily via
its aciions on the distal tubules cortical collecting duct of the nephron (Bartlet-Bas
and Doucet, 1995). Other aldosterone target tissues indude the urinary bladder,
colon, salivary and .- glands (Gatty, 1986). Regulation of alOOstarone
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seaetion takes p&ace via chInges in the activity of one Of more d its IJiosyntt'Wjc:
0l'lZylMS. Conditiono _ tend 10 -.ce "'"'" porluIion pr8SSln (e.g., sodium
~~__) in<:tease__indinldlyvio
the RA$. Aldosterone _ is also inlluenced by plume -.un_,
possibly via ., eIfed on N8+. K+-ATP.. activity in the adren8I gJorneruIoIa.
P1aIma akbiten:lne levels .... increased and deaeaHd by l"IIised and depreNed
plesme polessi.... a>ncentretions, .-..pectively (Seeley and Laragh, 1995).
Additionatty, aIdoIIerone reIeese Lnder conditions of acute stress appear to
be mediated by an adrenocorticotrophic hormone effed on adrenal cortical
___ F\I1tler<Xlf'llrol is mediaIlld by _ --..etic feclor wllicIl hes been
shown to SI..W"8SI both a6dosterone ....... as ....., as the 8kbIIerone response
to d8ilOCUtiu:Alopbic hormone (Guming et at., 1996).
__.... i1solleclby~..__of_pr-.
'M1ictl fLn::tion either. icr'l tr8nIpCIl"tWS or regulalcfy proteins whict\ modulate the
ecIivity of spec:ific pre-<>xisting ion _. 8Ypporting..-.:e_
prM«IIed by WoIIiomIon (1963) who ro.m1hIII-.ne _ antineIri\nIis
in adrena__ wes completely _ by" inIlibitor of lno1Icription,
eclinomycln O. ROOIfOly, __ end Doucet (1995), described 3 distind
rncHec:u1ar targets which could explain the effects of aldosterone on Na· transpOrt
in the collec:ting duel These t.-gets are the apic81 Na+ chamels. the basoIat....'
He-, ~-ATP... ond _ enzymesi_in..s~ of ATP (lIle
59
fuel required lor the Na',~-ATP ....).
2.2.2 Tho Action 01AI_ on Iho Apical No' chonnol oflho CoII_ng
Duct
Aldosterone is knOwn to increase the apical entry of Na+ into the nephron
epithelium ttvough amiloride sensitive channets. The exact mechanism via Ytt1ic:h
aldosterone increases apical N.+ entry is undear (Bartlet-Bas and Doucet, 1995).
Palmer et aI. (1982) examined the effects d aktosterone on the isolated lXinary
bladder from Na+ loaded toads. These investigators found that akiosterone
producecl an inaease in apfc81 Na+ chalYl81 area density thereby suggesting the
synthesis 01.- channels. In_. Garty and Edelman (1983) reported thet
trypsinization of the apical Na+ c:tlanne6s of isOaled toed bladder before the addition
of aldosterone reduced the aldosterone induced effects on Na+ transport. These
resutts suggested that aldosterone did not inckJce the synthesis d new proteins but
instead adivated channels whiCh pre-existed in the membrane. A possib&e
_lorltd-' <is<:nlprocy was proposed by Bartlet-Bas and Douc:et
(1995) wIlo suggo_ thelthe ap;ear No' channel may be composed of both a
pore-Iooning ("";Ioride binding) slA:Iunit and a regu~ SIb.Ml~ which may ccntrol
the activity t1 the pore fofming subunit. The pore-fonning subu"lit may pre-exist in
the membrane with a6dosterone inducing the expression d new regulatory subu1its.
eo
2.2.3__01_Oft lIlo _ No", K"·Ano- oIl1lo
~Duct
---_.-.np-~­
levels end Na·, t<+-ATPasellCtivity in the collecting c1Jd: oInwrmals (Barttet-Bas
and Doucet, 1995). Evktence in SI.4'POft of., aIdost8rClnB induced synthesis of
nffW Na+, K'"-ATPue pumps includes the results of Memitai n Doucet (1984).
Using isoleted collecting ducts from He· 108ded. ildAtn8lectomized rabbits these
authors foLn:I that aldoslerone simultaneously restored both Na+, I( -ATPase
activity (as .-..ad by qu8r'Iificalion of radi_11ed phoIphaIe li_ from
hydrolyzed ATP) lind lIlo ....- d calalytic: 1Mblnits d No', K" -ATPase las
_ by 'H...- bCInl/n'm I1bJle lengIh). Studies conclJcled by F_
atat, (1992) evidlnced..__syrolllesisdlWW
No',K"-ATPase_uUlgkidr'eyslicesfrom_. kl .... hyI>ridizaIion_
a reduction in mRNA .-lCXlding for the 0 1 -stb.m (cal8tytic c:omponert) in
_1-...edeplete) ...... _irUc:t_.
2.2A__oI_Oftlllo~_oIl1loColocllng
Duct
Tho third mechanism -.oily thought 10 be responsible tor the aclionI d
aldosterone on electrolyte transpoft in epithelia i, the induction of oxidative
enzymes important tor ATP QI<l8reIion (used as fuel by the Na" • K -ATPase).
According to Bartlet-Bas _ eo.- (1995), lIlo -..- aclionI d
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aldosterone are btunted by anolcic conditions. This issue was addressed by Law"
lO1d Edelmlol (1978) wI10 examined cWate synthese activity (Kr_ cycle enzyme)
in Na·1oeded achlnaIedomiZed rats. Renal citrate synthase activity was found to
be signtficantly elevated by ardosterone treatment compared with controls. The
enzyme adivity was determined by the rate of Coenzyme A-SH generation from
mitoc::hondrial fredions. Law and Edelman (1978) also found that aldosterone
8JQl'1"lef'lIe the incaporation of radiQabelled methionine into citrate synthase from
mitochondrial fractions comp&"8d with controts. This etred was obliterated by
actinomycin D. TogeIherltwse _ Slnlngty suggest _ e_increeses
the activity or citrate synthase and that this is due to the induction of new proteins
as opposed to ll'lOdu'ation of pre-existing ones.
2.2.5 TIle EtIec:1 ofAl_ on ~ Tronoportln the CoII_na Duel
Morel end Doucet (1992), expleined thet K' trensport begins _ K' being
actively pumped into the tubule epithe4ial cell via the basotateral Na·. t("-ATPase
followed by K' leaking passively irto the h.men of the tubule tlYough Be'" sen";live
apical K" chamets. The entry of Na1nto the epithelium promotes depolarization of
the tubule aHl increasing the driving force for K'" exit from the apical boarder.
_-Bas lO1d Doucet (1995), _ point "" thet oonIusion persists regerding
'Atlether aldosterone exerts a direct effect on K"tra1SpOrt ex if the kaliuretie changes
occur indirectly as a result of other aldosterone induced effects.
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2.2.1 1lIo EtIKl 01__on trT_" in tho CoIIocting Duct
Studies generally agree that the aldosterone induced acidification of urine
oco.n via an upregutation of the apical, efedrogenic H"-ATPase in the collecting
duet. For example, I<hadouri et aI. (1987), examined the H"-ATPase activity in
iscUled renal tubules from adrenalectomized rats. The adivity of this H"-ATPase
(which is _ by N-<llhylma_ rod assayed by the quantification of1_
~1_oftullulelenglMT)_..... tobesig_ly_
in the CCl6Iecting 0Jds of adrenaledomized rats compared with controls. Similarty,
Mujais (1987) also using isolated tlbules from rats founcIlhat the activity d N-
ethy!maleimide sensitive H"- ATPase was significantly increased in the collecting
duct by prolonged administration of aldosterone.
2.2.7 Rapid, Nongonomic _ 01A1_
HistoricaUy, the actions of alc:kmerone on epithelial transport of electrolytes
have been thought to be mediated via an intracellular mineralocorticoid receptor.
With the binding of atdosterone to its receptor, the steroid-receptor complex is
thought to translocate to the nucleus -.tIere binding to specific DNA segments
occurs resulting in subsequent production of specifIC proIeins invotved in ion
_.
Recently, aldosterone has been de$aibed as exening nondassical
rItil ...aIocorticoid effects (to be desa1bed betow) via 8 putative membrane receptor.
The primary characteristics fA these effects which renders them inconsistent with
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the classical theory of steroid action is the rapidity with which aldosterone is able
to induce the effects Md by the fact that these effects are not bkx:ked by inhibitors
of transcription. protein synthesis or the mineralocorticoid receptor antagonists
spircrxllactone and l31IW1OflO~.1995). Fur1llermo<e. the specificity at the
membrane receptor is suc:tl that aldosterone tends to be approximately 1000 times
more potent than glucocorticoids (cortisol). Aldosterone's actions on the surface
receptor tends to occur within minutes of its administration (versus hc:M.n for
traditional steroid effects) and are thought not to directty involve actions at Ihe
nucleus. These etJecls are often referred to as raptd or nongenomic effects of
aldosterone.
Most evidence for the rapid effed:s of aldosterone have been derived from
tunan rnor<ltlUClea" '"'- and _ smoolh muscle cells (VSMC) from rat
thoracic aorta (Wehling, 1995).
Christ et a/. (19958), fOU"Id that aldosterone was able to stgnificantly
increase 22Na. influx relative to pretreatment baselines in isolated VSMC's from rat
thoracic aorta. A near maximal response was achieved within 5 rnmutes. The
response was btocked by the inhibitor of the Ns·/H'" exchanger
athyli~loride (EIPA) but not by the inhibitor 01 trensaiption. ectinomycin
o or the mibi\or 01 prote;n synthesis, cyclohexemide. Compered with pretreatment
c:ontroI oonditions, intraceUular levels of inositoI1,4,5-triphosphale (IP3) were also
shown to be SO'WficanttY eMwated within 30 seconds of aldosterone administration.
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The-.no_ stimulalion of the Na·/W~_ inllibited by the
pl1oIpholipoIe C (PlC) inhibitor """"'Ydn. The'- desaibed -..__
that 1tw adrninistnIticr of aldosterone mey activat81tw Na·"'"~ in VSMC's
via a nongenomic pathway Wld may possi)Iy involve PLC (an enzyme that initiates
the Ioonliion of diacylgIyoorol (DAG) and inositol triphosphate (IP,), twoi~
signal..-...-s "VSMC's).
., '"'__SUly by cmst et 81. (1995b), uNlg the some ;n vitro VSMC
~ a~ ina'e8Ie in ir'1tra:::eMlJW D.ftG "'*'wes fould 30 sec:onds
after administration d aldosterOne. The admintItJ1Itjon 01 aIdost.-one was also
!<uld to_tho.- of IJf"OI8W1""-C (PKC) from cytosollract_
to memtnne fractions within 15 minutes. The rapid eff8ct of aldosterone on DAG
levefs wei blocked by a 30 minute preincubation with the inhibitors of PlC,
neomycin a"Id U-73122. FlA1hermor8. the etfec:ts of aldosterone on PKC
translocation by the PKC~_~. AlSOuNlg
VSMC's from rot aorta, WohIW1g et 81. (1994) !<uld lhal "- _Iu_ c.r
~aCa'1l~__the_of~
with." 30 seconds lWld peeked within 2 to 4f minutes. Similar resub regIWding
[c.rl in cult\nO ,,-lial cells from the pig llOf18.
CIYist at 11/. (1995b), speculated on a pcmtble signal transduction pathway
involved in the rapid effecIs of aldosterone in VSMC. They reported that the
signaling _ the PLC . PLC 8Cliv8tion via
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membrane aIdostenJne reoepta'S could result in the tormation of IP, and OAG with
IP3 promoting the sac:ropIasmic IlHease of Ca2+ from intracellular stores and DAG
activating PKC. They UIher reported that it remains unclear if PKC is responsible
for the rapid aldosterone effects on the Hs·"" exchanger.
AkbIterone induced rapid inaeases in Na+JK'" exchanger activity have also
'-11llpOf1edin t......"nano....dear__. Wehlingetal. (1991), used cell
swelling in ., isotonic He· solution as an indicator of N4' Itf exch8nger activity.
With this in vitro preparation the authors reported a dose dependant, aldosterone
induc:ed S91ifica't increase in eel swelling relative to control COl'ldffions d up to 30
to 50%. This effect was statistically significant as early as 1 minute after
aldosterone application and was blocked by EIPA Hydrocortisone and
dexanelhasone were effective agonists only at concentrations much greater than
aldosterone. Canrenone, K"-canrenoate (antagonists of the intracellular
minerakxxlrticiod receptor), actinomycin 0 and cyclohexamide did not antagonize
the response. The investigators proposed the possibility that this rapid effect of
aldosterone on the Na+M exchanger in human mononuclear leukocytes may be
mediated via distinct membrane receptors with high affinity for aldosterone.
The rapid effects of aldosterone have also been studied in epithelial cells.
Oberleithner et ai. (1987), reported nongenomic effects of aldosterone in a renal
tubule epithelial cell preparation after the induction of 8 transient intl'aC8llular
acidosis. These authors used the time taken for intracellular pH to recover 81 an
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indication of Na·/tr exchanger activity. The application of aldosterone allowed
recovery of intraeellulw pH significantly more quickly than control preparations
without aldoslerone. This response was noted as ea1y as 20 minutes after the
addition af the steroid.
wehling (1995) proposed a~ two step model to axplain the """"'"'"
diversity of mtneralocorticoid actions described above. Step one involves
aldosterone tHnding to membrane receptors resulting in changes to electro4yte
transport systems characterized by their rapid onset (the nongenomic effects of
aldosterone). The second step is based on a completely different response Vt'hic:h
begins to affect ion transport after a latency of 30 to 60 minutes. This is the
dassical..of steroid action involving the intracellular MR and synthesis of ion
transport related proteins (the genomic effects of aldo$terone).
2.3 THE INTRACEU.ULAR ALDOSTERONE IINERALOCORTICOID RECEPTOR
2.3.1_ ~of,,",_"""'III"""_coldRoceplor
Acx:ording to Funder (1995), receptors normally disaiminate between
polanlial signals via two basic moc:hlnsms. Fnt, the liglold with the _ aflinily
for the receptor will be more likely to binci, Secondly, the binding of some ligands
will activate the receptor (the agonist) while others will not, regardless of how well
they bind (the antagonist). Mineralocorticoid receptors (~) do not appear to
conform to these generalizations. For exampkt, Aniza et aI. (1987), found that
~-....,caticosI8tone,_~and cortisol competed
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approximaIely """,11y with a-""" binding in cy\OSOI from a monkey kidney cell
line transfeded with human MR cornpfementary DNA. This indicates that all the
steroids examined had similar affinities for the human MR. Simi. results were
reported by F..- et aI. (19730), wt10 studied tho ability of aldosterone,
deoxyc:cJtticosen:ne and ax'ticosterone to compete with akIosterone binding in rat
kidney slices incubated with the steroids in vitro. They foood that
deOxya)Iticoste was approximaIely 80% and CClfticosterone was approximately
11)% as effective as akSosterone in competing with aldosterone binding. The
authors stated that in light of the much higher plasma levels d cortieoslerone
(ctlftlIl"'8d with -...e), withc>.A lu1her discriminating factors, tho eldosterone
binding sites Yt"OUk:I be inappropriately ocx:upied by corticosterone.
Funder et aI. (19730) further reported that when tho steroids __ infused
in vivo, the ability of corticosterone to compete for aldosterone binding sites was
reduced compared with observations made in vitro. This indicated that
0Clfti00sten::I was aweaker competitor for aldosterone in vWo than in vitro. These
investigators reported that Ihe in vitro renal aldo8tetone binding sites fell into two
classes; Type I with high affinity for aldosterone and Type II with a lower affinity.
~ was shown to have higl ellinity lor tho Type II receptor but less then
2% of eldosterone's al!inity lor tho Type I receptor. Funder (1995) I_described
those sites as tho Type I high eIIiniIy lor aldosterone _ (tho minereloc:ortic<>d
receptor) and the Type II receptor having low affinity for aldosterone 8'ld high
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affinity for dexamethasone and physiological glucoc:ortic::oids (the gluc:oconicoid
r8C8pIllr). The MR _ianwill _ denote the Type I receptor lOld GR
will denote the type II receptor.
The studies described above suggest the existence of rnec:h8'lisms which
oIfer the~ sefedivity for aldosterone over glucocorticoids in renal tissue in~
which are not: functional in vitro. However, this does not appear to be the case in
nonclassical mineralocorticoid target tissue. For 8xamp6e, Sheppard and Funder
(1987) fOUld that in vitro cytosol preparations from rat pituitary, c:oIon WId parotid
tissue boLnd aldosterone and cor1fcosterone with simi!. affinity to the MR. In
contrast, in vn.o studies using rats injected with tritiated aldosterone .-.d
corticosterone, found that pituitary tissue retained both aldosterone and
cort:icosterone'Mlereas colon and parotid tissue retained only aldosterone. These
llllthonl used OXCOS$ RU 28362, e higtIy spedfic syrIhetic glUCOCOf1icoid 10 prevent
binding d the labeled akmsterone and corticosterone to the GR. These results
suggest thai: the mec:hErlism which CXlIlferI specificity in VIVo 10 the MR in epithelial
tissue may not exist for noncIassic:a1 mineralocorticoid l«get tissue such as
piIuitery.
2.3.2 Tho Spoc:Ific:ity ConIening ..- lor the II_cold
Rec_
Fu'- e1 01. (1968), proposed the enzyme '11l-hYdroJ<ysterd
dehydrogenese (11IlHSOH) os"'" specificity <:orIIening _ilm for classical
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mineralocorticoid target tissue. These investigators examined the rate of
conversion of 3t-k:ortisol to 'H-<:ortisone (as an assay of 11 PHSOH activity) in rat
hea-t, I'lippoawnPus, kidney, parotid and cokJn tissue. No activity was found in the
hippocarrpJS or heart tissue whereas the kkhJy, PEW'Otid and CClfon tissue exhibited
11PHSDH activity. Func:ter et aI. (1988), also foood that the differential ability of
classical and noncIassicat mineralocorticoid target tissues to show 11PHSDH
activity was virtually abolished by pretreatment with carbenoxolone, 8 blocker of
11PHSOH. The authors reported that the action of 11PHSDH is essential to explain
the selectivity of the MR action in dassical mineralocorticoid target tissue. It was
reported thai: Ihe l'88SOl"l that in vitro preparations do not show the selectivity of the
MR is that 11(3HSOH is amia'osomaI enzyme not present mcytosolic preparations.
Mineratocortiooid effects from glucocorticoid and mineralocorticoid receptor
ae:tivalial have been reported. There is evidence that GR activation can induce a
classical mineratocorticotd response. Fl.Mer et aI. (1990) reported that patients
with pseudohypoaldosteronism (undetectable MR levets) who were treated with
<:a'benoxOIone 8lChibitBd., antinaIrilAtic response. Similar results Vll8re observed
with the highly specific gtuc:oc::orticoid RU 28362 given to adrenalectomized rats.
This minerakx:crticoid effect became more marked with concurrent carbenoxoJone
administration a1d was not affected by the MR antagonist RU 28318. The authors
ooncIuded thai activation d the GR could be followed by mineralocorticoid effects
on uriNlry eledrolytes. They sunmerized by stating that not only is the MR
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rilenlr<ly""- bU.. nlilOOaIoc:uliooil response-.. (tile~
ofDNA~by 1110__'agonist~)_to be similarly
nondiscriminoling.
In SUTII118I'Y. the in Wto MR app88'S to MY8 the c:er:-:itY to bind both
-.... _ pI1ysiologicoI gIuax:ortiooids. .--, it> _, 1110 physiological
glucoc:orticoids _ prevented from binding 10 tile MR by 1110 enzyme 111lHSDH.
This specificity confening mechanism does not seem to operate in non-epitheliel
tissue such as pituita'y. Fld'IInnore, evidence exisII that mineratocortiooid effects
CWI result from GR activation lJI'lder certain conditions.
2.3.3~
Spin:lnoIactone antagonizes the aetionl d aldosterone n is used in the
treatment of hypertenoicn, hyperaldosteron and -...... states such as
c:cngestive "-t faiILA. SpironoCadone andIOI' its metabolites .. thought to act
as.~ lOllagonlstllll1o MIl (Los _ Colby, 1994).• Is not~
undarolood _1110 -. of this drug ... tile diracl
..... of spialolackre _ or f thay ... rnadiatad primotily by _itasof tile
parent~. Furthermore, th.e _ to be"-'- In tile1_
regarding whic::h of the spironot8ctone rnetabo'itel play an important rote in the
aldosterone antagonism. The major pathway Ie8dtng to the metabolism of
spironoladone was outlined by Los and Colby (1994) who reported that
spironolaclone is rnetabo'ized into both sufphu' CXXUining and non-suIphIx
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COIUining_. The nor>«JIpluCXlIUirircl- include c:anrwlCflO
ond its hydrolytic p<oducl ---.. while tho I<lIphur 00lUining _iIes
inc:Iude7a~.-.d 7a-thionl8thJ'IIpilOid8c:tone.
The bosic pharmooot>gy at spircnoIactcno was discussed by Sheny (1986)
who ouIlinod thai .,,;ronolaclono is quiddy __ 10 _ -V 1_ at tho
parent c:on-.m i. -..:t in biological fluidI. In tho p8Il ~__ty been
belMwed that the primary cifculeting rt'I8tatxHite d spironolactone was caY8flOI"I8.
AJIO, that because of cenrenone's antimineratocorticoid activity, it was thought to
be tne primary mediator d spW'onoIectone's eIreds. HoweYer, it was also noted that
canrenone IeYeIs may have been overestimated by the older relatjyety non-
18IectiYe tIl..Ir::QneCri -.ay and that canrenone alone ca'l ac::c::ooot for only 8 smell
part of the ..........._ actions at spir<>nolodono. The.- highly
SllIedive high--.:e liquMl ctromaIo\JrOllh (HPLC) onaIyIes later showed
_plasma aonnono _' bythofl~_
The spironoladcne _ite 7a-thiomolhyllpironolaclono has received
......,as..~.-at~'.orlimil ...aIocoo1icoidodMty.
For example, 7a-lhiomolhyllpir<>nolodono was shown 10 h8Ye _ oflinity for
the MR than canrenone using competitive binding studies with rat kidney slices
(Funder et aI., 1973b). Overdiek et aI. (1985) examined the aerun concentration
at spironolactono, canrenono, 7a-lhiomelhytllpir<>nolodono and ~ydroxy-7a­
~in~tun81.-.TheHPlC _ateighl_
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blood samples over 8 24 hou' period following one 200mg oral dose of
spircnolac:lllrolshowedlhal7a-lhiomelhylspironoladooo _nod tile higllest _.
amongtIle~ examined. They ropotted that 7a-lhiomolhylspironolac:tone
is the p'irrwy metabofite falowing one oral dose of spirono/adone. However, these
authors noted that bec8use C8IYWIOfl8 had a m..ch IongBr eliminatoo half life (11.2
hrs) compered with 7a-lhi~ly1spironoledone (1.8 hrs), 6~ydroxy-7a­
thiomethylspircnoledone (3.1 hrs) and spiron_ (1.0 hrs), further
i.-igelions with multiple dosing d spirooolaclone were_. In e later study,
Fanestil (1988), noted that the high levtHs of 7a-thiomethytspironolaetone were
higher than the other substances investigated only for approximately the fi~ 6
hours after spironotactone administration. It should be noted that the serum
metaboItte profile of spironolactone derived from the first few hours after one dose
may be very different from the profile which deYeIops CUing chronic administration.
It may be thai: due to carnnone's relatively long elimination half life, this metabolite
plays the dominant role in the antimineralocorticoid effects seen with long term
spironolactone administration.
In spite of the limitations of the study described above, results favoring an
"'-_for 7a-lhiomelhylspir by los end Colby
(1994). These investigetors found that following three days of spironoledone
treatment, 7a-thiomethyfspironolaetone was the most abu'ldant metabolite in the
steroid receptor fraction of guil188 pig kidney cytosol compared 10 7a-
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thtospif'OnOlactone and canrenone. However, the steroid receptor fraction from
renal nudei contained approximatety equal amounts of 7a-
thiomethylspironolae:tone, 7a-thiospironolaetone and canrenone. The authors
concluded that while 7a-thiomethylspironolae:tone appears to be the mafor
spironolactone metabolite that interacts with the cytosolic MR in kidney, 7a-
thiospironoladone and canrenone may play their prim.-y role contributing to
nuclear receptor binding.
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EX~ENTALRESEARCH
2.4 THE INVOLVEMENT OF PLASMA ALDOSTERONE IN PROlIIOnNG
HEIIIORRHAGlC STROKE IN CAPTOPRIL TREATED SHRop
2.4.1 THE OBJECTIVES OF THE STUDY
The rnechwlisms via which ACE inhibition alters mortality and stroke
deveIopnent in SHRsp is not wellSldersIood. To date little consideration has been
given to the possibility that elevations in plasma aldosterone may play 8 rokJ in
stroke deveklpment in SHRsp. Plasma aldosterone fnaeases in a paral~ marY'ler
to renin activity with increasing age in SHRsp(Okomoto etaJ., 1991) and during
estabHshed hypertension, the levels of plasma aldosterone a"Id All ..e both 4 to 6
times the levels present in normotensive rats (Kim et 81., 1991). ACE inhibitor
treatment should lower plasma aldosterone levels in SHRsp.
The general objective of the proposed experiments was to gain an
understanding of the rote that plasma aldosterone suppression plays in the
pnNenIion of homorTllagic _ during captopril treatment. In pursurt of this goal.
plasma aldosterone Ievefs were 8SS8)'8d in reAation to age and stroke devetopment
in SHRsp to detennine, if in fact plasma aldosterone levels do ekwate in relation
to stroke deve50pment in SHRsp and to further determine if captopril treetment
reduces pWsma aMXIsterone levels in these animals. Subsequentty, further studies
were undertaken where aldosterone was infused into captopril treated SHRsp via
the use d osmotic~ The objec:tiYe d these experiments was to re-elevate
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lIleplasma -.no_ CUing captopril_ to ll10se _ presorO in
SHRsp not .- with captopril to delennino tho efIecI _ this _
wouId_onBP.-.:IlTlOrt8IiIy_with_~lntho_
._. tislIuo .-.:I plasma All __ be honco tho
selective invotvement of etevailed plasma afdosterone couJd be assessed. Finally,
the ability dlhe"1i l8lalOOOrtiooid reosptor antagoniIt~ to alter stroke
~ was8$NSHd in SHRsp.
2.4.2 HYPOTHESES
It is ox hypothesis that plasma aldosterone levetl .. etevatecl in SHRsp
prior to _ dovolol>n*U.-.:I_ olovotions d plasma -.no_I ploy
ani~ "* in promoting stroke in these riNIIs. If this is the case, the
antistroke effects of captopril treatnwlt in SHRsp woukt be ft)q)8Cted to be
.-bylllealJililyd""*",,, ...".,.to_pIasma-.no.• 11111
proved to be lIle cooo Ihon tho ............. d plasno _lilring captopril
tteatmont should irI1il>il tho ....- oIIec:ts d tho .-. Finally. ltho
__ d captopril duo to tho d plasno
___ltho _ d _orono modiotod by tho Illimulolion d tho
aldosterone 1Th, ...........tiooid reoeptor, treetment r:I SHRIp withspi~, an
aldotterone mkler8tocorttcoid receptor antagonist should mimic the antistroke
otIocIl d captopril_nt.
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2.U MATERIALS AND METHODS
2.U.l Expori_ AnI...... SyoloIic Blood noli.... tho
_ng"'_o~_thoSompllngof""_
These aspects cI the~ proIOCO/8'8 idertieal to those used in the
experiments oUIined in Chapter 1. Specifically. desaiption d the SHRsp colony
and the breeding protocol is outlined in section 1.5.3.1. The techntques used to
measure blOOd pressure in the rals is outlined in S8dion 1.5.3.3. The monitoring
of stroke development and the sampling of the animals is outlined in section
'.5.3.4.
2.4.3.2 PlastnII Aldosterone DrltenniI'Nltlona
RadK:lirmuloassay techniques were used to measure ptasrna aldosterone
1eYefs. These were performed by the Memorial University of Newfoundland Health
Sciences Renal O;egnostic Laboratory (5t. John·s. Newfoundland. Canada) by
qualified persorreIlhal peofonn _ assays on a rootine _s. The assays-.
performed using a Coat-A-eOl.Ilt rad;oimmunoassay kit (Diagnostic Products
Co_otion. Los Angeles, CA, USA). The """""nel who peflonned the ....ys
__ blinded of the identity of the samples.
2.U.3__"'.... Drugs
All drugs and chemicals were purchased from Sigma Chemical Co. (St.
LoUs. MO. USA)..,1ess otIle<wise staled.__ fil1t dissolved in OM50.
5mg1O.4ml. 111is mixture was then _ to polyathylene gIy<:ol (3OOMW). The
n
drug irto_mi~(_Corporation,Palo Alto, CAl
and implanted subaJtaneousty in the fl.,k region under anaesthesia (10 mg
Xylozine (Rompun, Bayer Inc., ant. , Canada) plus SO mg Ketamine (KeIaIe8n,
MTC Pt1lmlaceuIicaIs, Ont., Canada) per kg body weight, i.m). Pumps having a 2
or 4 week~ capacity werei~ed into the SHRsp depending on the size
and age fA the animal. The aldosterone/polyethylene glycol conc:entration was
adjusted per pump to deliver akiosterone at 0.67~ or 16 ~day (Morris end
Kanyon, 1982). Vehiclo...- SHRsp .... _ sludied. Those SHRsp conIOinod
the i~anted pump with polyethylene glycol minus aldoslerone. The 2 week
pumps de4ivered vehicle at 0.5 fJlhw' while the 4 week pumps had a delivery rats of
2.5~1IIv.
5pironolodonewaslirst_in DMSO, 20mg1100,.l. Tho mixturowos
tI10n added 10 O.9ml of olive oil (GoraJd S. lloyto Limited, So. John's, NF). The drug
_ was injodod Slb::uIoneousIy into SHRsp 10 _ a dose of 2Omg.1cgldoy
(Brillo at oJ.. 1993). Vehicla control SHRsp __ also S1ud1od. The.. SHRsp wara
injec:ted with the above vehicle minus spironolactone.
2.4.:5.4 Expori_ Groupo
SHRsp without stroka ogod 9.510 12.5 _ woro SOIfllIod according to
the methods outlined in chapter 1. The plasma aldosterone values derived from
this QIO<4> woro plottod against age. In addition SHRsp with stroka (typically
~1hon 12 _ of age) and age _ SHRsp.-ad with coptopril (SO
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mglkglday, o.llItlm 6 -. d age -.. also ...-.pled. Tho changas in plasma
akklsterone levels in pr8Stroke verses poststroke SHRsp and captopril treated
SHRsp -.. """-"<I.
Stroke development and mortality were assessed in SHRsp treated with
captopril (50 mgIl<gIday, 0.) 0< in SHRsp concurT9IltIy -... _ ~I plus
atdosterone from 6 weeks of age. Other SHRsp were treated with aktosterone in
the absence of captopril treatment from 6 weeks of age. A group of SHRsp were
also treated with spironolactone (20 mglkgfday, s.c.) from 6 weeks d age. In
addition. OCher groups r:I SHRsp were treated with aldosterone vehic6e infusions or
spironolactone vehicMt injections.
2.4.3.5__ Anllysla
The method of statistical analysts used to describe BPs and mortality rate
changes was desaibed in Chapter 1 within section 1.5.3.5. Plasma aldosterone
levels derived from multiple groups were anatyzed using 8 one '*fit analysis of
VIWWa to determine if a sqificant difference existed. Subsequently, a student's
t_ oompansated for nUtiple~ using tho Bonlerroni method was used
to determine which groups dtffered significantly from each other. Changes in
ptasma aIdost«one IeYets with age were analyzed using lme.~on analysis
coupled with the determination of a Pearson product of correlation (r vaiue). All
-.-.. partormed using Minitall Statistical Softwara (Stata Col_, PA, USA).
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2...... RESULTS
U.ot.1 Alterations in PI_ Aldosterone in SHRap
The alterations in plasma aldosterone IeYeIs in prestroke SHRsp are outlined
in Figure 4. Plasma akmsterone levels elevated with age in prestroke SHRsp.
L__from_. SHRsp (ogod 9.5-12.5-l versus ago showed
a significant positive~ion. Using the line of best fit as a point of reference,
at the youngest age investigated (9.5 weeks), plasma a6d0sterone lewHS were
approximatety 0.25 nmelll. This value increased to approximately 3.9 nmoUl by
12.5 weeks of age. The results suggest that the pUisma levels of this hOrmone rise
with age during the prestroke time period examined.
The mean ptasma aldosterone levels in the above prestroke SHRsp was 2.0
nmoUI. This value is plotted in Fon 5 (Group 3). As shcMf'l in Figure 5, poststroke
SHRsp (10.5 to 13.5 weeks d age) had significantly higher mean plasma
aldosterone levels of 11.4 nmoIJI. Captopril treated SHRsp had plasma
aldosterone levels of about 0.50 nmovJ which were t*ow those levels observed
in both pre end pos~ nontrooIod SHRsp. ~I Iro8lmOnI equally
"-'IJIlI1lSSod piaIma aldoslon:Jno _ in SHRsp" _ -. lho animoJI did not
develop stroke (18- 20 weeks) as well as in animals that eventually did develop
stroke (35 to 40 weeks of age). As we will subsequently demonstrate, the
coinfusion d atdoslerone (16tJg 81dosteroneiday/l"8t, s.c.) into captopril treated rats
_ishod lho obility 01 copIoprillo rotord__.~I plus
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Figure 4. AJterations in plasma aldosterone with age in untreated SHRsp aged
9.5 to 12.5 weeks prior to the development cI hemorrhagic stroke. The resufts
suggest that plasma aldosterone may inappropriately rise with age in SHRsp (r =
0.62, P < 0.01. n =: 15 SHRsp).
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FigIn 5. Plasma aldosterone levels in l.Wltreated SHRsp and captopril treated
SHRsp with and without a_arona~ The rasuIts show that plasma
aldosterone values were higher in untreated poststroke vs prestroke SHRsp.
~1_(50mgIkgIday, aaJly) signifiaV1tIy reduced plasma aldostarona
-.as the suI>c:utar-.s Infusion oJ aldos1arona (0.66 IJIl/hr) into~I
trnIed SHRsp raised pfasmI aldosterone to levels between those present in pre
and__SHRsp. SllIIistics -One-way analysis 01 va-ianoo of groups 1 to 5,
P<O.OO1, 1YS3, 1"', 1vs5, 2vs4,2vs5, 3.$4 and 3.sSsllslgnificantly diffatent at
P<O.05, t-test compensated for multiple comparisons using Borlerroni correction
(n ..I.- -1.= 15, 2.= 5,3. = 15, 4.= 5, 6. = 5 SHRsp).
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aldosterone treated SHRsp (sampled between the ages cl10.5 to 13.5 weeks of
age. all with evidence of stroke) were fOUld to have significantly higher plasma
aldosterone values when compared to SHRsp treated with soIety with ceptopril (
Figure 5). The..-. -...a-..one value 016.3 rrnolII was~nad from the
captopril plus aldosterone treated group of SHRsp was between the levels
observed in untreated prestroke and poststroke SHRsp. Therefore, aldosterone
supplamenIaIion 01 c:aplq>ril_ SHRsp successfully approx_ed the plasma
aldosterone ktYels typically observed in non captopril treated SHRsp.
2.A.U'The EffectofAIdoetIrone StIllPII ._1&IIion Dwtng CIIptopriI TrNtrMnt
GIl 1Io....1ly ...._. Dovolopmonl in SHRop
The results d this experiment are outlined in Figure 6A W 68. As shown
in Figure 6A, SHRsp receiving captopril treatment plus aldosterone infusion had
BP's that did not significantly differ from those present in SHRsp receiving no
treatment 'Nhen these groups were compared over common life spans. When
compared over common life spans, captopril plus aldosterone treated SHRsp did
have h;ghar BP's than SHRsp _ GIlly with _,._. at ages past
those 't\tIere a 1CJQ% mortality occurred in SHRsp lre8ted with captopril plus
aldosterone, SHRsp treated with captopril alone achieved BP's equal to Of higher
than those of the former group and still SlKYived. As indicaled in FiQlX8 68, the
Infusion 01 al-.ona Into SHRsp treated with captophl p<avenIad captopril
.....,. from.-aing tho onoat 01_ d8YoIoprnorL I'd previously dlscussad.
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fig.... 6. _ens in sysIOlie blood pre5SLnl (A) lI'ld morllIJity associated witI1
hemorrhagic stroke (8) in untreated control and captopril treated SHRsp in the
presence or absence of aldosterone infusion. The infusion of aldosterone (0.66
1'llIIY, I.") into c:aptapil treated (SO mg/kgIday, orally) SHRsp raised plasma
_ to levell _ those......,. untreated pre lI'ld poststroke SHRsp
(seeF_ 5). The infusion oIaldosl"""", into _apil trooted SHRsp rovarsod
tho anti_ aIIacts 01 c:aptopril~ Statistics - Fig. 6A - AHrNA -0Y0f lila
lifespan of A, AvsB -HS, over lifespan dC, Avse - NS, BvsC - P< 0.01; Fig. 68-
Mann-Whitney - Avse - NS, BvsC ~ p < 0.001 (n values A = 11, B = 7, C = 9).
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FigIn 7. in syslOIic blood presan (A) rod rnortaIily _ with
hornontl8gK: _ (B) in__ SHRsp rod SHRsp __with-...e.
T..- 01 SHRsp with -..... (O.~, s.c.) acceIonIIed lI10 or.- 01
stroke in SHRsp. Statistics -IWOVA- Fig 7A- owr owrIopping life
spans, A VI B - NS; In Ftg 78 • MerYl Whitney - A vs B - P < 0.01 (n values A =
11, B-7).
A.
340 88g;
r 320 .~E
5 300
..
~ 280
.r"
"
" 260 0/"'t-t""~a..
"0 240
/'.._._ 1
0
0 220iii
.51 200~ 180 ..... B.o""o_(o.se,.gjh,)Ji' 8
160
5 6 7 8 9 10 11 12 13 14
Age (wks)
8.
a> 100 .0 T.:<[> 90
°iii o' I
:S 80
A.e-econtror !
•• 70
B. 0····0 aldon-on. f' /
"0 60 /0
.! 9
.2
°u 50 /0 p T.. 40~ l];- 30 /':s 20 /0
-e t °0 10 /~ 0~ 0
5 7 8 9 10 11 12 13 14
Age (wks)
89
an analysis of plasma aktosterone levels of the SHRsp treated with captopril plus
aldosterone infusion (Figure 5) indicated levels that were less than those of
untreated SHRsp that developed stroke and~ than those present in
comparably aged prestroke SHRsp. The data all consistent with the hypothesis
thai the ability 01 ""I*>Pri1 to'-" the onset 01_ devetopmont in SHRsp may
be produced by a lowering of plasma aldosterone Ievefs.
The effects of aldosterone treatment in the absence of captopril treatment
is outlined in Figure 7A and 78. \Nhen compared to non treated SHRsp over a
common lifespan, aldosterone treatment did not Sig1iftcantly modify the BP's of
SHRsp (Figue 7AI but did accelerate the onset 01 mortaI;ty associated with strcke
(FIg..... 7B).
204.4.3 Tho ElIoc:t '" SpIronolactone T.._ on M_11ly _ Stroke
DovoIopmont In SHRop
The results of these experiments are shown in Figure SA and 8B. Statistical
analysis perfonned on the BPs recorded over the COl'MlOI'l lifespans of the
spironolac:tone and control groups indicated that the spironolactone treatment
signifiCWllty reduced the BPs (Ftgure SA) and ret.ded the onset of IT'IClft8lity
associated with stroke relative to that~ in lX1treated SHRsp. The average
age at death of these 2 groups of SHRsp was 14.7 and 12.5 weeks respectively.
The magnitude of spirono£actone', etrecl in retarding the onset of mortality in
SHRsp wes less than IheI observed in SHRsp _ed with captopril.
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Figunt I. Alteraliono "systolic blood pressue (A) lOld mortality associated wi1h
hemorrhagic stroke (8) in untreated control and spironolactone treated SHRsp.
Spironoladone (20 mg.Iqjday. s.c.) __ d SHRsp siglilicanlIy reduced blood
pressure but produced only 8 small ina'88se in the lifespan d the animals.
Spironotactone treatment did not duplicate the effects of C8ptopril treatment.
Statistics -ANOVA- in Fig SA - over lifespan of, A, A vs B· P < 0.()01: in Fig 88-
Mann Whitney -A vs 8 - P < 0.05 (n values A = 11, B =5).
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2.4.UThoElloc:lofV_T_ on_lty__Develop_
InSHRop
Tho poteroIial eIfeds of \flo inIusionIinjoction _ on'-' development
within SHRsp were also studied. The injed:ion vehicle for the administr8l:ion d
spironolactone, dexamethasone or deoxycorticosterone was ~ive oil which was
administered at a vollme of 0.1 mV100 g body weight. SHRsp ir1eded daily with
the abo't'e vehicle died at an average age of 12.2 :i; 0.3 weeks (range 11.2 to 13.0
weeks, n =4). SHR!p infused with poIyeIhyIene gly<:ol (aldosterone vehicle) at 0.5
or 2.5 ~lIhr by implanted osmotic puTlpS from 6 weeks of age dted at an average
age of 13.6 .0.5 weeks (range 13.0 - 15.0 weeks). WIlen mortelity profiles MrS
~ to thOse oIlA'1Ireeted SHRsp (everage age of death, 12.4. 0.36 weeks,
IlV'lg8 10.3 to 13.7 weeks, n =11), no significant differences were obsefved (Mann
Whitney rank order test). In other experiments, captopril treated SHRsp (50
mglkglday) were injected with olive oil (the deoxycorticosterone vehicle, n = 4) or
infused with polyethylene glycol (the aldosterone vehicle) by osmotic pumps (n =
4). None of these animals developed stroke. The latter experiments were
_when SHRsp_an_ageol17weekswhidl surpessed \flo
age at which e 100% mortelity ocx:urred wi1hin ceptopril traated SHRsp raceiving
ei\tler.-.erone inIusion (O.66IJll'11r) Of deoxya>rtic:oslerone injections (40 mgIkg
2XIweek). When the alterations in blood presstI8 with age were statistically
a18/yZed over comperabIe life spans, no significa'1t differences were obs8t'ved
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-.~ SHRsp, SHRsp treaIed with caplOpril aJone and SHRsp injected
with olive oil or infused with poIyethytene glyall vehicle in the presence or absence
of cap!"I'ri1 (Group eII8d oIlrealmenIs, P • 0.436). It was coocIudod that
the ace:eleration in stroke dltvelopment observed in SHRsp treated with
deoxycorticosterone or ak:tosterone, the inhibition of the antistroke effects of
captopril treatment obsefved during cotreatment with cMdosterone or
deoxycorticosterone and the antihypeftensive effec:ts observed during
spironoladone treatment could not be attributed to the vehides used.
U.lllISCUSSION
The key finding of the present study was the Observation that the
reconstitution of plasma aldosterone levels to values observed prior to the
Sl.flP!'8ssion of this hormone by captopril treatment negated the antistroke effects
d c:aptopril treatment. PCasma aldosterone levels elevated with age in SHRsp after
10 weeks of age and were about 5 times higher in SHRsp that devek)ped stroke
when compared to similar aged SHRsp that had not yet developed stroke. This is
a remark8bIe elevation in _me aldosterone levels. Normotensive Kyoto Wister
rats (WKY, the normotensive strain used to develop SHR strains) typtcally exhibit
1 nmaUI levels of plasma aldosterone between 5 to 25 weeks of age (Kim et 8/.,
1991). ,., 12.5 weeks of age prestroke SHRsp hod three times and poststroke
SHRsp had ten times the plasma aldosterone levels typically observed whhin the
llCltll-.Ml_in.~I trNbTlent 01 SHRsp plasma aldosterone
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to levels comparable to those previously reported in WKY (Kim etal., 1991) and
prevented monality aBSOCiated with stroke up to 34 weeks of age. The reintusion
c:J aldosterone into capIopfil treated SHRsp to achieve levefs present between pre
lO1d poststroke nonb'88led SHRsp "'Ily negated the efleds of_, treatment
and caused mortality to be comp.wabIe to that observed in l.ntreated SHRsp.
These ......1ts suggosl_ ...-condffions -"Alllevels should be ___
by captopOI, elevations in p&asma aldosterone represent a signiflC8l'lt risk factor for
stroke devetopment within SHRsp.
U.5.1 Roduced L..... 1Isy Account tor tile AntIs_.
E_of Csplopril
Untreated control SHRsp had much higher levels of plasma aldosterone
levels once hemonhagk; stroke occurred when compared with prestroke control
Mimals. When combined with the observation that plasma aldosterone increased
with age prior to stroke, these data suggest that as the SHRsp grow older and
approach the age at which they are lik~y to develop a cerebral hemorTtlage,
plasma aldosterone levels rise. Once the animals have sustained stroke, the
plasma aldosterone IeYeIs may l6ldergo., even greater increase. These findings
suggest that the high plasma aldosterone levels may have contributed to the
devetopment of hemorrhagic stroke. Excessively elevated plasma 8tdosterone
levels may also have played 8 "* in promoting death after stroke developed.
Consistent with this possibility, in the studies OUIlined in Chapter 1, we observed
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II11II sane SHRsp older ltal30 _ ~age II11II-"" _omatie in tenno
of pI1ySicaIsigns of Slroko ._eel <Mdence of. pest <:enlbreI~. N
previously disaJssed, typic:oIy non __ SHRIp live (on __I lor. perioc:I of
1.5__tho first signs of Slroko In obsetved. k is ,_ thel some SHRsp
mey heve __ Slroko dlrng _,__ ...... nonInNltOd
SHRlpsuvivedtho SIrCke. Inlhis~ Srr.-otol. (1999olheveobsetved_
captopril treabnent started at the first sign of stroke Of up to 6 days after stroke in
SHRsp prolongs theI~ of tho SHRsp (from 1.5_1 to between 4 to 15
__SIrCke hIIs__-.r.osupplemontelion, SUCh .. _ used
in the present experiments, nullifted the effed of captopril treatment in the above
ooonerios.
A cxn:::em in the presert study re$ided in the fad that a contiru:us infusion
~_ (0.67 UfJ/hrl-_toSHRsptreeleel _ ~ from 6
weeks 01 age end continued Lrltil approximalety 11 to 13 weeks of age when the
animals died. Over this 8Q8 range, the anim8II grew I.-ger whtch may have
resuI8d in the)'CU'lOll', IlTlIIer IrIimID receMng more aldc:*erone per kg 01 body
""'9"" "'""""_tho older, _ SHRsp. This .-ty over priming ~ tho SHRill
at a young age could have promoted the Il.bIequent devetopmenl of stroke in
SHRsp via a mechlnlsm independent of 8 subsequent endogenous rise in
aldosterone that I"I8tI.J'Wty OCCUfl just prior to stroke devetopment. .., 8 series of
mote recer< investigetions from our IabonItory (_ ot 01.,19990), copt",,"'
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Ire8tmeft was begun in a group of SHRsp at 10 weeks of age. This corresponds
to an age at Wlich plasma aldosterone was shown to increase with time in studies
OlAlined earfier. tt was determined that 'Ittlen captopril treatment was begun at 10
weeks of age, there was no mortality associated with stroke through 24 weeks of
age when the study was disexlntinued. SimiI8rly, _ 01. group 01 SHR"fl
with captopril plus aldosterone beginning at 10 weeks of age showed that the
aldosterone negated the antistroke effeds of captopril treatment (captopril
+aldosterone treated SHRsp mean age at death 16.5%0.8 weeks of age. n=6;
I.X1tre8I8d SHRsp mea'l age at death 14.O:t: 1 weeks of age, n=8; captopril treated
SHRsp, no death up to 24 weeks of age, n=7). In other experiments Smeda et aI.
(19998) observed that atthough the initiation c:I aldosterone c:otreatment with
captapril treatment in 10 week old SHRsp reversed the antistroke effects of
captopril cotreatment, the nti8tion of aldosterone coinfusion in at 23 weeks of age
in SHRsp treated with captopril from 10 weeks of age did not signiflC8rttly alter the
lifospon 01 the SHR"fl when a>rnplnCl to SHR"fl soI8ly _ad with ""'"0Ilfi1. Both
groups lived on average to about 28 weeks of age. This would suggest that
elevations in plasma aldosterone in prestroke SHRsp from 10 weeks on, exert a
significant impact in enhancing stroke development during captopril treatment,
_.r vory likoly long'8fIIl coptopril trootmont (up to at _ 23-. of age)
may promote a resistance to stroke development in Vtttich the antistroke effects of
captopril .. perpetuated in the presence or absence fA high plasma aldosterone
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Ievets. It is also possIMe that Ihere is an age related wirIdcNI in SHRsp during which
elevatk:Jns in plasma aldosterone may be particularty lethal with respect to stroke
development.
TrUing SHRsp with aldost8rono aIona did not significantly chango the BPs
profile yet it stgnificantly accelerated the mortality rate compared with untreated
control SHRsp. The effect on mortality was not dramatic, on average, the
aldosterone treated SHRsp died 2.5 weeks earlier than control SHRsp. One mtght
exped: akIost8I'On8 treated SHRsp to have extreme hyperaldosteronemia, which in
tum would be associated with a dramatic inaease in mortality rete relative to
controls. A possib6e.~ion for the modest impact of aldosterone infusion (in
the absence of captopril treatment) on mortality COUkt be due to the fact that
...nreated control SHRsp died on average at 12.5 weeks of age. This represents a
relativefy young animal. h is reasonable to speculate that the devetopment of
hemorrhagic stroke and subsequent death requires a minimal period of lime.
Hence it might be difJiaJlt to accelerate stroke onset despite the presence of
sev«eIy high aldosterone Iavels.
2..1.5.2 The MecMnI-. of Aldosterone'. Strvke Effecta in SHRap
2.4.1.2.1 The _Illy Strok. In SHRop by
StImulating tho Mlnoroloco<tk:okl Receptor
After observing the relationstlip between the onset of stroke devetopment
and e~v8tions in plasma 81dosterone in SHRsp we asSl.m8d that aldosterone's
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actions woukt be mediated soIety via the stimulation of renal mineralocortico+d
receptors. If this were the case, it would present a p1ausibte hypothetic:al
mechanism explaining a)dosterone's action. It is clear that 8 htgh salt diet
accelerateo in 5HRsp (5moda. 1989). W. had the concepIioo
that efevattor'ls in plasma aldosterone in SHRsp may act to promote sodium and
water reterU:ln by stimUating renal mineralocorticoid rec::eptors. Hence, aldosterone
might act in a manner equivalent 10 feeding the rats excessive salt and thus
promoIe stroke. If this were the case then treating the SHRsp with spironolactone,
a mineralocorticoid receptor antagonist should dupticate the effects of captopril
treatment. Spironolactone treatment was suc:cessful in stgnificantly reducing both
BPs and the mortality rate associated with stroke in SHRsp. The intracellular
mineralocorticotd receptor is a possible mediator of these effects. However, the
effect that spironolactone treatment had on the mortatity rate was considerably less
robust than that which was observed in the captopril treated SHRsp. Since the BPs
and mottalily _ of 5HRsp were significantly altered by spironolactone traatmenl
compared with controls, we concluded that the drug was active. Art explanation
CXlflSidered to 8lXOl.I'1l for spironolactone's modest effects on mortality rate was the
possibility that the once daily dosing of spironolactone (20 mgIkgIday) was too
infrequent 10 allow the drug to exert its full effects. However, this seems unlikely
as ananone. the spironolactone _ita and primary mineralocorticoid receptor
antagonist has a plasma hatflife of 16 hou's in humans (Range and Dale, 1991).
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Tho possitliIily was -.cllhlOlho 20 rngIkg/dlIy ..-..noous dose ol
spironolactone was insufficient in c::onoenIr8tion to bIoc:k the miI_aIoc::ot tK::oid
reoepkn. In this rega-d. it was nc:Md Ih8l: the dose used in these investig8tions
was--'Y4_lho per kg oral dose used 10 .... humans _ primary
hypol_.. isolilYoung-.:lKJoo,1988). Thonliu.idoncolhal__
associated with high plasma aldosterone in rats we not reversed by COt'Tlp8l'8bte
doses of ~one. For exampte, using • I'8t ITlOdel at primary
hypenIldosIeronism, Mia et aI. (1993), demonstrated hypertension, left ventricu....
hypertrcJphy 8'1d myocardtlil fibrosis. A 20 mgIkgIday, subcutaneous dole d
spirlJnotacttln W8I abte to reduce but not l"IOl'TMlize blood presIlS8. It prevented
myocardial _. bU did not chango loft__ hypertrophy. Alternatively,
these ..... investigators found that increasing lho dose ol spif<lnoIaclcne 10 200
mglkglday (subcutonoously) normalized blood pressure -.:I prevented left
_hypertrophy-.:l~iaI_.
Apilot study was..-....en 10 _no_efIecl, ~ any, _larger dose
would have on mortality _ in SHRap. A dole ol150 rngIkg/dlIy, --.s,
was used 10 .... SHRap -.:I no significant cI1ango in mortality _ was noted. In
mo«l r8C8R studies (s.- 01. 8/.,19998) involving lho ...-ol CIU' SHRsp
_ a daily dose ol spinlnoIacIone at 120 mglkglday from 10-. ol age did not
greatly _lho..- ol-.-..opmon in SHRap (on lho other hand~I
treatment sa.ted .. the ..ne age did retard stroke 8nd aldosterone coinfusion
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reversed these effects}. Consequentty, it was concluded that spironolaclone's
modest effed on mortality rate in SHRsp in the present study was likely not the
result d an insutricienUy large dose of the mineralocorticoid antagonist.
Aside from the above arguments there is other indirect evidence Ihat is
consistent with the liketihood that spin::lmIactone would be ., ineffective antistroke
agenl A wide variety of other dilX8tic's (fu'osemide, amiloride, c:nlorothiazide.
acetazolamide) that promote urinary sodkJm and water loss (in the presence or
absence of potassium loss) have been tested in SHRsp and none of these have
been able to alter the onset of stroke devek)pment in these Mimals (Smeda and
Trachenko, 1991). lronicaHy, in the latter study fu"osemtde. 8 duetic Ihat can
enhance All~ acoeIerat8d stroke~ in SHRsp. Wspin::lmIactone
was acting at renal mineralocontooid receptors, promoted salt and water loss into
the 1.Iine, and if this mechanism was important in altering the onset of stroke, then
one might expect that other diuretics could mimic this response. As it stands the
general nonetrectiveness of djuretics in altering stroke development in SHRsp
supports Ihe notion that spironolactone induced diuresis and natriuresis (via
mineralocorticiod receptor blockade) is not a mec::hanism involved in altering the
..- 01 stroke in SHRsp.
2.4.5.2.2 _ PoooIblHty _ Al__ Mod__• in SHRIp by
SlImuloling~ RKoptoofs)
There is., additional possibiNty that would explain spironolectone's modest
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eIf8cts Q'1 mortality rate of SHRsp. Aldosterone's proposed pathological role may
not be medi8t8d via the stimufation of intraceUular mineralocorticoid receptors. If
this were the c:ase the system would be spironolactone-insensitive.
There is a possfbility that aldosterone may activate surface (nongenomic)
membrane receptor(s) in addition to the intracelhJlar mineralocorticoid receptors.
One rapid, nongenomic effecl: of this mineralocortic:otd appears to be activation of
the phospt'lofipase C (PLC) second messenger cascade in the vascular smooth
muscle cells (VSMC's) (Christ et aI., 1995b). The significance of these actions
within the conIext of the present investigations is lXlCIear. A speculative eIJect of an
aldosterone mediated PlC system activation is offered below.
An important mechanism in the autoregulation of cerebral blood flow
(desaibed in more detail in Chapter 3) is the occurrence of cerebrovascular
constriction in response to elevations in blood pressure. It has been proposed Ihat
blood row <XlUId be regulated distally by the a>nsllidion of the cerebral vasculature
l6lder conditions of elevated pressure. The loss of such a function could promote
overperfusion of the distal vasculature under hypertensive conditions thereby
promoting the formation of cerebral~ (Smeda, 1992). This
auklr8guIata<y medlanism, _ to as p<essUre dependan1 conSlric:tion (POC)
is thought to be medtated in part by activation of protein kinase C (PKC) (Osof et
aI., 1991) whic:h can also be adivated by PLC activation. If in fact aldosterone
acIivaIed the PLC ""'- in VSMC's, ~ ClOUd have__ tone and POC.
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Furthennore, such an effect would not be mediated via the intracellular
mineralooofticoid receptor ald therefore would not be blocked by spironolactone.
Under prolonged conditions of hyperaldosteronism with or without spironolactone
treaIm8nt, the PlC pathway may have been chronically hyperactivated, eventually
becoming functionally compromised. Under continued severe hypertensive
conditions, the poe response c:ou'd have failed due to a compromised PLC/PKC
system. This may in tlln, have promoted overperfusion in the distal vasculeture
and subsequent hemorrtlagc stroke formation.
In addition to PKC ac:tiYatiOn, VSMC d8pOIarizal:iOn haS also been proposed
as a possible meciaklr of PDC (Nelson and auayte, 1995). Aktosterone has also
been reported to tncrease the Na· IK: exd1anger adivity in VSMC's (Christ sf aI.,
19958). The elevated plasma aldosterone levels documented in SHRsp may bind
to the putative membrane SlXface receptor. In b.m, this may activate the Na·/H·
exchanger producing altered ionic fluxes within the VSMC's, a process that could
alter poe by modifying the voltage activating mee:::hanisms that contribute to the
initiation of POCo Such an alteration could also modify cerebral blood flow
autoregulation in a manner conduc:ive to the initiation of stroke.
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CHAPTER 3: THE EFFECTS OF STROKE AND CAPTOPRIL TREATMENT DN
CEREBROVASCULAR FUNCTION IN SHRap
UTERAlURE REVIEW
3.1 THE ROlE OF PRESSURE DEPENDENT CONSTRICTION IN
PROIIOllNG CEREBRAL BLOOD FLOW AUTOREGULATION
Johnson (19fl6) described autoregulation of blood _ as tho tendency of
blood flow to remain constant in an organ or tissue despite c:hMges in 8'terial
pressure. One important rnecha'1ism that contribuIes to the maintenance of
cerebral bfood flow autoregulation is the ability of cerebral btood vessels to
respectively consIrid or enlarge their IlMT'I8O diameters in response to increases or
dec:re8ses in pt'eISl.I'8. The blood flow (BF) through a vascular bed is governed by
the bbod pr8SSU'8 <*'op acrosa the vasaJlar bed (t.P, the infusiOn pressure forcing
bklod into the orgaVIissue [primarily the mean systemic btood pr8SSlX8, near
1COnmHg in tunans) minus the back pressure [the postcapillary venule plltSSU'e
near 15 mmHg] preventing tho bl_ from leaving tho organ/Iissue) and by tho
VllSl>lW resistllnco (VR) to blood _ (i.e., SF= APNR). AP is prirn&ily governed
by the systemic blood pr8ISU"8 and a major deterrntnant of VR is the ItJ'nen
__ofthoartoriolos. Wtho__ ofatube was _ by 1/2
(increasing VR), flow through the hA:le would deaease to 1/16 at 8 constant MI.
m an organ such as the brain, elevations in blood pressure that might produce an
increase in fiatt are counterected by an appropriate degree 01 ...rial vascular
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constriction which rstses vSSOJlar resistance to blood flow and hetps to maintain
constart blood flow through the system despite the presence of efevated bfood
pr8SSl.ft. The ability of some dasses of arteries 10 constrid 10 eJevations in
pr8SSU"8 C8'1 be demonstrated in isolated arteri81 segnwtts lXlder in vitro
conditions, hence it is a characteristic, that is not mediated by the release of
SI.bItances from extravasa.ia' tissues or nerves and appeal'S to occur in response
to v8SQJ1ar stretch produced by elevations in pressure. In isolated arteries, this
........... hosboen_ ...Bayliss~or........... (Bayliss. 1902)....
myogenic response (Smeda, 1993) or pressure dependent constriction (POe)
(5meda, 1992,1993). The ability d ... isobJted vessel 10 reduCe its k.men diameter
in response to eIeYated irir'av8SClJla' pressl.I'8 is referred to as POC throughout this
thesis.
3.1.1 Tho ChoroclertolIc: _ 0CCun0nc:0 d/ ........ Dopondont eon._
InVascuIan
poe woo f... desctibed by Bayliss (1902) who can""loted 000 end ""
canine carotid artery and lied oft' the other end in a ITI8Mer theI pennitted the
manipuIaIion '" inlravosc:uIlI' pnlSSln. k woo roportod that wilen lt1e pressure woo
raised, the artery initialty began to swell then it immedialety constrided. If the
pressure was reduced, relaxation of the artery was noted. More recentty, similar
obseMItions have been made in 8 variety of vascua. beds. For example, Kuo et
./. (1990) examined iSOlated pon:ino lUbopicordial ortorioleo cannuIotad ot both
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ends for the manipulation and evaluation of intraluminal pressures. The vessels
were visuatized usrg a microscope and video system (video microscopy) providing
continuous measurement of the Ilnlen diameter. Dilation was observed when
pr8SSlX'8S were decreased from 60 to 20 anH20 whereas constriction was noted
when pressures where increased from 60 to 140~O. The authors concluded
that POC may play an important role in the regulation of coronary blood flow.
OsoIn Halpem, (1985) used videO microscopy to study PDC in posterior
cerebral arteries (peA) isolated from Kyoto Wistar stroke prone Spontaneously
hypertensive rats (stroke resistant strain) (SHR) 8ld Wistar Kyoto normotensive
rats (WKY). These authors reported constriction in response to elevations in
pres8lI'8 and dilation in response to reductions in arteries taken from both strains
of rats. However, the PDC in the vessels sampfed from SHR was limited 10
maintaining a oonstant diameter over a range of pressures wtlefeas WKY~s
showed a reduction in vessel diameter.
Evidence of PCC in human arteriolesWBS reponed by Miller et a/. (1997)
using coronary _from patients..-go;ng C81diac ""llO'Y. The coronaoy
IWterioIes were cannulated, equilibnJted81 100 mmHg for 45 minutes and visualized
using mtcrosoope and video equipment. The investigators reported their results
relative to the passive diameter attained in the presence of vasorelaxation with
sodium nitroprusside. AI 60 mmHg. the arterioles constrided to 55% of their
passive lumen diameter. Wallis et aI. (1996) dissected .-tensl segments from
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cerebral biopsy specimens cI patients Lrldergoing resection procedures for
neoplasmS. The auIhors explained that vessels were taken from an area as far as
possitlte from the diseased area. All patients were normotensive with no evidence
cI c:ardiovascular disease. Arteries were cannulated and mounted in a myograph
such that pressure could be manipulated and vessels were allowed to equilibrate
at 60 mmHg for 90 mil'lJtes. The arterial diameter was foood to eithef decrease or
remain c:onstl!W1t during a series of pressure steps. The response was lost Tn Ca2"
4ree Krebs with EGTA The investigators concluded that the poe response may
c:onb'ibU8 to 8lJklr8guaation cI cerebral blood flow in tunans in the face of varying
arterial blood pressures.
3.2 THE SIGNAL TRANSDUCTION MECHANISMS PROMOTING PRESSURE
DEPENDENT CONSTRICTION
McCarron et aI. (1997) proposed two mechanisms to explain the signal
tr3lsduction pathways responsible for the prodJction of POCo poe was reported
to rely on a streIctWnduced activation of protein kinase C (PKC); causing an
Messed <;a2+ sensitivity of the myofilaments within the vascular smooth musde
cells (VSMC). In addition, vascular stretch produced by "'vated pr8SSU"8S was
thought to promote an increase in intracellular [Ca211eve1s by depolarizing the
VSMC, thereby augmenting tha opening _lily of~_ C...
channels.
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3.2.1 Phoept cllLC 1.1 C. the in0sitoi Phoaphate lind Prot*! KJnaM CSecond
A common stgnaI transduction mechanism that promotes constriction of
VSMC's in response to a variety of vasoconstridors such as vasopressin,
norepinepYinoand~ invol_ the activation 01 pholphoHpnes.
Phospholipase C (Ple) is an important activator of vasooonstriction (Horowitz et
a/., 1996; TakuwB, 1996). PlC activation ptimarily promot.. the b<8aI<OOwn of
membrana phosphotidyl inositol, whim through a n<Jmbef of intarmediate _
forms inositol_(IPJ and diBcylglyalrol (OAG). IP, rele8lIBs intracellular
sac:ropIasmK: stores at cr--, elevating intracellularC~ which activates actin and
myosin interaction and promotes vasoconstriction. DAG activates PKC which
through a siglllli cascade can promote the phosphorylation of cakiesmon and or
calponin. These latter intermediates act on actin filaments in the VSMC's and
inhibit actin to myosin interaction. When phosphorylated, calponin and caldesmon
lose their ability to inhibit aNlStridion. Under conditions of PKC activation. low
Ievets d intraeetkJlar Ca2"can promote constnction (Nishimura and van Breeman,
1989). In addition. PKC activation can directly open voltage gated C~cttannels in
a voltage independent manner (Fish et aI., 1988). The activation d other
phosphotipBIBI (phospholipasa D and phosphalidyl choIiM~ PlC) can
promote the breakdown of phosphatidyl d"Iotine which leads to the fomI8tion of
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DAG (and PKC aclivaIion) in the -.ce of IP, IcrmaIion(_, 1994; Zannetti
et aI., 1997; Liu et aJ., 1999).
Evidonco has been _ which"'- of. role""various_
of the PKC second messenger system in the generation of POCo For example,
using video microscopy, 0s0I etaI. (1993) investigated the rote of PKC in pr8SSlRI
induc8d tone in a brwlch of the raI posterior oerebraI.wy.-let mesenteric vessels.
The investigators found that indolact8m (PKC activator) augmented the degree of
tone in cerebral Meries pressuized to 125 nmHg. Conversety, COI1'1'8rably sized
mesenteric 8I1eIies which do noI generate presst.n induced tone, were lXI8l'fected
by indoladam at 125 mmHg. StalXOsporin (inhibitor of PKC) produced a crose
dependant vasodilation of pressurized cerebral arteries. S18lxOSpOJin was also
found to be a more potent inhibitor of tone in cerebral arteries at 125 mmHg
0Clf11)8red with tone induced by K"" depoAlwization. The authors concluded that their
findings support a rofe for PKC in the regulation of pressure dependent vascular
tona.
The rote of PKC in the maintenance of tone in pressuized human coronary
arterioles was examined by Miller et aI. (1997). Addition of the PKC inhibitor
caIphostin C resutted in a dose dependent reduction in tone. In arterioles treated
with the vasoconstrictor endothelin (to produce a similar degree of constriction)
calphosti1 C produced no ctwlge in diamet8f'. Next, these investigators examined
arteriotes th8t dilated instead of constriding in response to .. acute elevation in
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transrrual pressutI (Le.• lacked poe). The addition of the PKC activator phorbol
12-myristate 13-acetate permitted PDC to occur in the arterioles in response to
elevations in transmural pressure.
In other studies, 0501 et aI (1993) examtned the possibility that PLC was
invofved in the generation cI pressure dependent tone in posterior cerebral arteries
from normotensive rats. The inhibition of PLC by U-73122 produced a concentration
d8p8ndent vasodilation. The action of the inhibitor was confirmed by showing that
the PLC mediated constriction to serotonin could be signifICantly attenuated or
abolished by U-73122. The authors concluded that their results supported 8 role
for PLC in the maintenance c:I pressure dependent tone. They explained that the
ptOViousIy reported moc1JlaIion 01 oorebnlI..-. pressure~ tone by PKC
may 0CClI' through the activation of PLe which could form DAG, 8 potent activator
ofPKC.
It has been reported that stretch of the vascular wall produced 'It'hen arterial
pressure rises may be the stimulus that leads to POCo Kulik et a1. {1991}
investigated the effects of stretching VSMC's. Smooth musde caUs from the main
and proximal branches of the pulmonary artery from adult Sprague-08WIey rats
WW8 iso&ated and cuttured on thin silicone sheets. Prelimirwy studies reportedly
shOwed that eatls could remain attached to the sheets with a 20% stretch for at
least 1 hour. 1P3 levets in the VSMC's were found to be significantly elevated
following a 20% stretch for 25 seconds. The authors concluded the VSMC'. can
1'0
respond to mechanical stretdl with an increase in IP). Studies pertormed by
Narayanan et aI., 1994, have indk:ated that OAG and IPs elevated in the VSMC's
of pressurized C8l'1me renal arteries
Vascular smooth nuscIe cefl Ca2'" levels were measured during both agonist
and pressure induced constriction in .-terioles from the rat cremaster muscle
(Meninger et aI., 1991). These isolated arterioles were cannulated and C~ levels
were determined using the C~ sensitive dye tur.2, imaged vta a fluorescence
miaoscope. poe was induced by 8 transmlS81 presswe step from 90 to 130
cmH,O. The vessel diameter was reported to shOw' a transient increase followed
by 8 retun to beseline 0( slightly smaller value. This response was associated with
a COOCU'TElC'lf. 8% increase in vessel wall Ca2'".
3.2.2 Pnlsouro~M_ Depolo_on .. 0 M_ 01
Constriction
Changes in the resting membrane potential (Em) of VSMC's has also been
proposed as a possible mediator d pres,u9 incllced contraction tn several arterial
preparations (Smedl and Daniel. 1988). Roman and Harder <'993) showed that
incnlasing lhe lrlInsmual PfllSSl.'8 from 20 to'20 mmHg produced smooth muscle
cetl membrane depolarization from -57 mV to -38 mV in isolated perfused canine
renal arcuate arteries. The relationship between tr.-ul~pressure and resting
membrane potential was also investigated using caYluhlted canine inter10bular
.-<_et w. o 1987). Tllese ........ doc:urolnIed membrane depolarization
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from a conlrOI value of -57 mV at 20 mmHg to -37 mV at 120 nwnHg. It was
___ thai Em dopoIorizaIion may allow ca'" 10 .... via~
c:hannoIs. k was interesting 10 .-_. thai _ tho _ poter<ial
wassh:MnlD be~dIpolIoized.-'~ """'_10. a>nb'tlI
vakJe at 2OTmHg, the ability to maRain near c:onstn. dianeter with inc::reasing
tranSlTUaI pressure did not begin llltil pressures greater then 60 mmHg .......
8flPliod. This ouggests !hat VSMC depalloizaIion alone i• ..-. 10 account lor tho
ability ctcanine intet1obu~ arteries 10 maintain their dJameter under conditions of
aleY_ praasure.
~ofVSMC-..... pclentiaI during~ has alao
been "'-igated in tho oonlOral circulaIicn 1_. 1984). e.t _ oonlOral
__ (MCA) __ inYestigatad using g\asIm_lWld vi$ualized with
tri<:n>a<xlI>iclWld~_V and_"'-Em
__ """""*,,ad during rnanipuIationa of transnu"aI praasure. When tho
tnnnuaI~ was~ from 20lD 90 mmHg, tho _ c::onatric;Iad and
tho rnentJrano pot....., ._ from 062 mV. Increuing tranomuraI pnoaaure
further to 1«) nmHg also resulted in vesset constridton as well as fu1her VSMC
~ lD. value of -44 mV.~T.-.uaI praasure from 140 lD 60
mmHg caused the membrane potential to return to • more negative value of~
mV.
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was made using cannulated middle cerebral arteries from SHR and WKY
normotensive rats by Harder et 8/. (1985). N. 0 mmHg the membrane potentials
recorded in the vessels from SHR and WKY were not significantly different from
each 0Iher. However, at transrnu'al pr8SSln values greater than 40 mmHg and up
to 100 ITInHg, the VSMC from SHR 08l'8I::lf8I vessels were more d8poIaized relative
to those from WKY rats. These mvestigators also reported that MCA's from SHR
~ a geater degree of active tone relative to WKY. It was suggested that
the VSMC Il"I8fI'lbrale from SHR's may respond to eMvations in trwlsmural pressure
in an exaggerated fashion. Also, that this greater degree of membrane
__may"low mono ca" ontry in _lrcm SHR CXlfllIO'8d wi1h WIf:f.
Similar findings were reported by Miller et 81. (1997) using human c:oronaty
arterio6es. Pressuized vessels from hypertensive patients were shown to possess
greater pressure induCed vasoconstriction relative to vessels from normotensive
patients.
Recently, the ion responoible for c:anying the depolarizing c:unlInl has been
investigated using cannulated rat PCA's. Using mic:toelectrodes, two CI·channel
blockers were found to produce VSMC hyperpolarization and dilation of arteries
presSl.Iized to eo rmttg. These same agents had no efred on membrane potential
'Nhen pressure dependant tone was absent. These investigators reported that
activation of cr channels in VSMC's may produce an outward Ct current leading
to depotaization which inaeases the entry r:A Ca2+ into VSMC's through voltage
113
dependant Co'" channels (Nelson BI ai., 1997).
3.2.3 The _ 01 YoI_ Goled (D;hydropyYtdIllO Sonoitivel Ca'"
Channel. in .....ng Pntu&n Dependent Constriction
Karibe et aI. (1997) examined the role of cytosolic Ca2"" and PKC in
pr9S$lJ1'8 induced contraction. Branc:hes of the femoral wtery isolated from
Wistar rats were cannulated and visualized with a video digitizing system.
Cytosolic~ levets were assayed using the~ sensitive dye, fura-2. The
small skekttal muscle arteries were shown to dilate and immediately retl.lT1 to
~inediameter va4ues when the transmural preS$Uf'8 was increased from 40
to 100 mm Hg. A CXlr'lCl.MT8r'I 33% increased in cytosolic CIJi+ relative to baS&line
was also reported. Next, these authors treated the vessels with the inhibitors of
PKC, H7 and staurosporin which abolished the pressure induced oontraction but
did not bfock the rise in cytosolic C~. When the skeletal muscle arteries \YeN
treated with the dihydropyridine Cs:k channel blocker nifedipine, both the
myogenic contraction and the increase in cytosohc Cr-- was abolished. The
investigators in this study concluded that an increase in cytosolic~ alone
may not be enough to cause myogenic contraction in small skeletal muscle
arteries. Also, that an adequ8te PKC activity may be necessary to couple the
increase in cytosolic Ca2+ to smooth musc:le contraction.
FlIther studies of the effects of dihydropyridineC~ channel blockers on
PDC were conducted using nirnodipine (Haws and Heisted. 1984). Cat pial
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arteries were vtewed via aaniotomy and diameter changes were documented
with a microscope and video equipment. A transient rise in mean arterial
pnISSlA cf 20 and 40rmlHg was """""'I'lished by partial ligation cf tho thoracic
aorta. Pressure changes were measured proximal to the ligation. Under control
conditions, ~I.rteries respectively showed a 6.6 and 12.1% reduction in
diameter in response to a 20 and 40mmHg mean arterial presstX8 step.
Intravenous nimodipine caused the pial vessels to dilate (Haws Ir'Id Heisted,
1964).
The actions ~ a dihydropyridine Cr-- channel antagonist on PDC were
also investigated in the cerebral circulation by McCarron et aI. (1997). These
investigators studied cannulated PeA's from WKY rats using a microscope and
video equipment. Using a 30 to 70 mmHg pressure step, vessel diameter
returned to resting ...~ues fotlowing an initial distension, under control
c::ondItions. This ability to maintain diameter in the face of increasing pressure
was abolished by the two dihydropyridn <;a2+ channel blockers (nimodipine and
(-) 202 791) as wetl as by the removal of extracellular cr--. These results were
offered as confirmation that PDC requires Ca2'" entry ttvough, dihydropyridine
sensitive voltage-clependent C'" channels.
3.2.4 Tho InvoIvomInl of _ ActIv_Dlhydropyrldlne ............cr-
Ctwtntt. In MedIatIng VucuI. ConstrIctIon
A number of studies primarily (but not exdusivefy) involving venous tissue
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have demonstrated the presence of Ca;r. channels that are adivated by
mechantc:al stretch wnich are distinct from the dihydropyridine-sensitive, vottage-
dependent co>' chamol.
laher et aI. (1988) found that the generation of mechanical stretch of
rabbit facial vein rings by wires induced constrid:ion that was accompanied by an
increase in ac.r. influx into the VSMC's and was not affected by a concentration
of tl1e dillydr_ne Co>' chamol blod<er (PN 200(110) that signifocantly
reduced tone and "Co>' influx in _s contraelod by ~ depolarization. The
auIho<s proposed that tl1e influx 0/ "Ca>' 0<X:l.<T0d 1hrough non """- gated
C~ ch8nneIs. tn other studies from the same laboratory invdving strips rabbit
basi. arteries, diltiazem (8 voltage gated Clf+ channel blocker) was found to
effectively block agonist induced contraction (norepinephrine, 5-
hyaoxytryptamine and .co), however it was not effective in altering streich
induced tone (Bevan, 1982). Hwa and Bevan (1986) examined the effects of
several different Cs2'" blocking agents on K" and stretch induced tone in a rabbit
... artery ring preparation. The investigators reported that both K" and stretch
induced lone were similar1y suppressed by reducing the extracellular Ca2+
concentrations, by the inorganic Ca2+ antagonists.~ and Mg2'" as well as by
the non-dihydropyridine Ca2"' blockers verapamil and diltiazem. In contrast
however, the dihydropyridine Ca2+ channet btockers nimodipine and nifedipine
were not successful in blocking the stretch induced tone. The authors
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suggested that a dihydropyridine resistant W pathway operated by stnltch may
be involved in promoting stretch induced tone.
Harder (1984) noted that when cerebral artelial rings are stretched
between two wires, the Em rec:orded from VSMC's is not depofarized compared
to the resting state, whereas VSMC's from cerebral arteries were sho'M1 the
depolarize in response to pressurization. It was suggested that dihydropyridine-
sensitive vottage-dependa Cr" channels p6ay a roJe in constridion d
pressurized but not in mechanically stretched arterla' vessets. Harder (1984),
speculated that threading wires through smaH arterial rings may cause cellular
damage resutting in a situation where VSMC's do not depolarize. McCarron et
aJ. (1997) also suggested that the djfferent~1 effeds of dlhyctopyridine-C~
Ch8mel blockers on stretch and pressure induced vascular tone could be
partially explained by different VSMC membrane potentials under different
technical conditions at the time of dihydropyridine- ca2<- channel blocker
administration.
3.3 STROKE RELATED ALTERATIONS IN CEREBROVASCULAR PRESSURE
DEPENDENT CONSTRICTION IN SHRap
Smada (1992, 1994) soggested that the cerebral hemorTt1agas obseMld
in the brains of SHRsp may result from the loss of the cerebrovasculature's
ability to constrict in response 10 elevations in blood Pf'8SS'.". The loss of this
fu1d:ion could promote conditions of elevated preSSU'8 and overperfusion of the
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down stream vasculature, causing the blood vessels to bl.nt and cerebral
hernor'Tt1age to form. In studies, MeA's were sampled from stroke resistant SHR
(c::haracteristics discussed in sec:tion 1.2.1) as wetl as pre and poststroke
SHRsp. Using video microscopy, the ability of the MCA'sto constrict to a 100
mmHg prUSSlX8 step was used as 8 me8SU'8 of poe. PresslXisation fA MCA's
revealed that vessels isolated from SHR poss8$SEId the greatest degree of poe
while those sampled from poststroke SHRsp lacked the ability to ~icit POCo The
loss of poe preceded stroke development in SHRsp (Smeda, 1992). More
recent studies (Smeda and King, 2(00) have indicated that there is an age
related decline in the ability of the MeA's of prestroke SHRsp to tHicit PDC after
about 11weeks of age, 1 to 2 weet<s prior to stroke.
laser Doppler studies (Smeda et aI. 1999b) indicated that under in Wvo
anesthetized conditions, the brain of SHRsp loses its ability to autoregulate
cerebral blood flow in animals that devetop stroke. Young 10 week old prestroke
SHRsp were capable of maintaining near constant cerebral blood flow up to
mean arterial blood prel8I.KeS of 200 mmHg while older (13 week old) poststroke
SHRsp exhibited a linear increase in cerebral tMood flow when blood preS$l,Q
was increased from 120 to 260 mmHg in a slow continuous 1TI8l"W'I8f'. This
suggested the presence of extremety high cerebral blood flows in poslstroke
SHRsp. Of particular importance, the inability to autoreguJate cerebnd blood flow
p<ecedod stroke development in SHRsp. Age matched presIrCke SHRsp
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littermates to the po5t$trOke SHRsp also exhibited an inability to autoregulate
c:erebl'W blood tkM. On the basis ~ these experiments it was suggested that if
PDC was important in maintaining cerebral blood flow autoregulaoon, a loss of
PDC could contribute to the Joss of autoregulation in postStroke SHRsp. Since
both defeds preceded stroke devefopment in SHRsp, it was fIsther suggested
that a loss of such functions under hypertensive conditions, could promote very
high cerebral blood flows in older prestroke SHRsp. It was hypothesized that the
high pressures and flows in the cerebral mio'ovasc:ulature couki predispose the
vasculature to ruptu"e, which in tum could create intraeerebraJ hemorThages.
Smeda and King (1999) studied the mechanisms promoting the loss of
POC in the MCA's of SHRsp. POC in the MCA's of young prestroke SHRsp was
inhibited by PKC inhibitors such as staurosporin. chelerythrine and
bisinolylmaleimide. 11lese inhibitors not only blocked the ability of the MeA's to
constrict to pr&SSlX8 but also inhibited the ability of PKC activators (phorbol
dibulyrate) to e4icil vasoconstridion in the same MCA's (suggesting that the
inhibitors were in fact acting as PKC inhibitors). 'v'Vhen the MCA's of YOI6l9
prestroke SHRsp with robust POC responses, older prestroke SHRsp with
attenuated POC, and poststroke SHRsp with no poe were compared, a direct
correlation was observed between the ability of the MeA's to elicit POC and their
subsequent ability to constrict in response to dtrect phannacoIogical PKC
acliYltion by phorboI esters. These experiments suggested that PKC activation
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may be partially responsibMi for the produdion d POC and that defects in the
PKC system could contribute to the stroke related loss of PDC in the MeA's of
SHRsp.
In other studies, the e6ectromechanical properties of the MeA's were
assessed (Smeda and King, 2(00). When compared to younger pres1rOke
SHRsp Iwrth MCA's that exhibi1ed POC), the MCA's of poststroke SHRsp lacked
the ability to alter their VSMC Em in response to 8 100 mmHg pressure step.
These &'tenes maintained a constant depofarized VSMC Em at all pr8SSU"8S.
This feature was further investigated. Patch c18rT1J studies of isolated VSMC's
from poststroke SHRsp indicated that the depolarized state of the VSMC's was
produced by • very high CI' conductonco in the colis (Dr. John Smedo, po<sonol
communication). Other investigations indicated that an inability to alter VSMC
Em in response to pressure shifts was not the only defect obs8rV8d in the
VSMC's of the MCA's. The MeA's VSMC's of poststroke SHRspa~ exhibited
_iva voltago gated C'" chonnols ISmoda and King, 2(00). The channal
behaved in a manner consistent wfth the possibility that it was locked in a semi
open state but was incapable of reacting to changes in Em. The chanr1ei could
be bkx::ked by low levets of dihydropyridine antagonists (nifedipine) but acted 8S
if the voltage sensor of the channel was defective. A symptom of this defect was
the observation that an elevation in extracellul. t<+ which promote VSMC
d~, -' vo~ gated co" chonnols, and promoto oonstriction
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could not produce consttidion in the MCA's r:t poststroke SHRsp while
phar'TnaccNogicl agonists such as vasopressin that were capable of releasing .,
internal $8'CClpIasmic store (likely via an IP, mediated rMase) of~
(NemenolI, 1998) did ccnstricI the MCA's.
In summary, the above experirnentaJ evidence would suggest that poe in
the MeA's of SHRsp likely involves pressure induced VSMC activation of the
PKC system. Activation of the latter system coulcl promote constriction by
sensitizing the contractile apparatus to tr" and or by the direct voltage
independent opening 01 voltage gated W _Is (see section 3.2.1). poe
may also involve the opening of VSMC voltage gated Cfjl+ channels via
pressure dependent VSMC depolarization (see sections 3.2.2. 3.2.3). Defects in
the PKC system. and an inability to promote constridion in response to VSMC
depolarization possibly because of a defect in the VSMC vottage gated Cr-
channels may acccx.nt for the klss of PCC in the MCA's of poststroke SHRsp.
Of importance to the subsequent experimental aecttons is that the
symptomatology of the above defects is manifested .., isolated MeA segments
by the observation that the MCA's are I.IlIbIe to constrid in response to PKC
activation by~ esters at in response to htgh K'" inctuc:ecl VSMC
depolarization.
121
EXPE_ENTAL RESEARCH
:1.4 THE EFFECTS STROKE AND CAPTOPRIL TREATMENT ON MIDDLE
CEREBRAL ARTERY FUNCTION IN SHRop
:1.4.1 THE OBJECTIVES OF THE STUDY
Presslse dependent constriction (POC) within MeA's becomes
compromised in SHRsp a few weeks prior to the development of stroke (Smeda
1992, Smeda and King 2000) and is abHnt in animals following the
development of cerebral hemonhage. The purpose of this series of in vitro
experiments was to determine if captopril treatment of SHRsp from weaning
preserved the ability of the MeA's to constrid: to pressure. If captopril treatment
was fOlXld to preserve poe in the MCA's, experiments were designed to
determine if functional aspects of the stgnal transduction mechanisms thought to
be involved in promoting poe were also preserved following treatment. In this
regard, the presence of poe in the presence of a dysfunction within a particular
si~ transdJclion mechanism woukt suggest that the signal transduction
mechanism may not be involved in promoting PDC and might be attered .s a
~ of hypertension. Because of the evidence implicating both VSMC
depolarization induced opening of dihydropyridine-sensitive voltage dependent
Ca2+ channels and protein kinase C (PKC) activation in the generation of POC,
experiments were destgned to test the ability of the MCA's of SHRsp to constrict
to both depolarization (via an e5eYation in extemlIl potassium concentration
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([K"J.)) and PKC activation (via phorboI dibutyrate in the presence fA nifedipine)
in relation to captopril treatment. Finally, vessels were exposed to vasopressin
to ensure that a1y alterations in POC or responses to phorboI dit:uyrate or (K1o
'N8r8 not the resuft of a generalised failure of vascular smooth muscle (VSMC)
contractility in the MCA's.
3A.2 HYPOTHESES
We tested the hypothesis that captopril treatment of SHRsp from weaning
will preserve the ability of the MCA's to constrict to pressure for a du"at•...." long
after the MeA'. of SHRsp not treated with captopril (that have developed stroke)
have lost their abiHty to exhibit POCo The maintenance of POC in the MCA's d
captopril treated SHRsp will be associated with an ability of the MeA's to
constrid in response to PKC activation by phorbol dibutyrate and VSMC
depolarization produced by efevated lK1o.
3.4.3 MATERIALS AND METHODS
3.4.3.1 Expori_ Ani.... Groupo
FLI'ldional studies on the MCA's were performed using arteries sampled
from 4 experimental groups <I SHRsp. These consisted of untreated control
SHRsp between the age. <110 to 14 _ks 01 age thai developed hemont1agk:
stroke and SHRsp treated with an oral dose of capt",,"1 0150 mgo1<glday from 6
weeks of age that were sampled at 11 to 14 or 18 to 20 weeks of age. None of
the later groups of Clptopril treated SHRsp exhibited behavioural or histological
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..-.ceol_~. Finally,a~ ol7 capIOp<il_ SHRsp
-.. _ on tho oral_ ol capIOp<il and 3 oltho 7__eel_
S9'IS ol__physicoI..-.ceol_~-.34 to 040
_ ol_. The other _ did not show '"'Y _ ov-.:eol_
up 10 the lime the operiment was terminated lifter 410 weeks c:A age.
Unfoc1unate1y,lIXp8I'imenI8I dif'f"K:U1ties only allowed UI to catty out f\.nctional
studies on the MeA's of the 3 postatroke captopril treated SHRsp sampled
between 34 10 40 weeki of age. The captopril treatment protocol was identical to
th8t previously described in detail in section 1.5.3.2 of Chapter 1. The monitoring
ol__, tho _ and physicoI S9'ISol_ in SHRsp
8l'8 diswssed in detaI in sec:tion 1.5.3.... of Ch8pter 1.
3,4.3.2 Tho _ of ......... llopor-.t<:onoutc-. In Iho_
COrwbroI_ ofSHRsp
The 8PI*8tUS used for in vitro studies d POC (Figlse 9) was based on •
~ by HaIpom lK Ill.• (1984). Tho 20 ml ti.... blIlIl cor<ainod in and oulflow
porlSwIllcII aJlowodconotant_ftow ol~sal"_
(COfllIlOSition in ITM, Na'l39, K' 4.6, Mg'" 1.2, Crr 2.5, Ct 120, HCo,' 22.1,
80...... 1.2, PO..-31.2, a1d glucose 11.1 at a pH of 7."') bL.tJbIed with 95% 015%
CO2 and maintained 8t 37-C. The temperature in the bath wes measured dired:ly
withal~ prOOe (CoIe-Parmor InstnJment C""llO"Y, _ 8402·10;
a.-c.~). The flow ci~ solution _ pt<ldoX*l by a combination
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Figu.. I. A schematic diagram of the press.... my",""",. The pressure
myograph apparatus allowed visualization and quootification ~ alterations in
middle cerebral artery (MeA) diameter in response to vasoactive stimuli. The
isolated MCA was mounted onto a miaopipette located in the tissue bath
oontaining Krebs satine soIlAion. The lumen of the miaopipetle and the artery
were continuous, filled with Krebs and connected to 8 gas cylinder ~ sud'la way
as to allow manipulalion d intravasaJlar pressure. Changes ;n &1eriallumen
diameter in response to pressure or vasoactive stimuli were rec:orded on VCR
tape and viewed via the television monitor.
125
RECOAOE:R
126
of gravity due to an elevated main reservoir and a faucet molI'lted aspirator.
Helic3 coils of plastic tubing carried the Krebs saline through a warming jacket
containing ciroJtating water at 37G C. The water was warmed with a heater
(Haake, model DI;Berlin) and circulated with a peristaltic pump (Watson -
Marlow Limited, H.R. Flow Inducer, England).
SHRsp were anesthetised with a combination of 10 mg Xylazine
(Rclrrlpoo, Bayer Inc., Ontario, Canada) plus 50 mg Katamina (Katalaan, MTC
Pharmaceuticals, Onl., Canada) per kg body weight (i.rn). Brains were removed
and quickly placed in Krebs saline solution, bubbled with 95% O~5" CO2 and
cooled on ice to approximat~y4°C. MeA's were carefully dissected away from
the surounding brain tissue and pulled onto the end of a small glass pipette
within the chamber such that the artery and pipette lumens were continuous. The
glass pipettes (World Precision Instruments Inc., Florida, USA) were pulled
using a mk:ropipetle puller (Sutter Instrument Co., California, USA). The end on
whid'l the artery was mounted had a diameter of approximately 90~. The
artery was then secured with 8 stra1d otfine suture (10.0 nylon, Ak:on Surgical;
TalCllS, USA) lied around tha anary and tha pi_. Tho lTae and altha anary
was tied to form a bfind sac as Krebs lX'Ider low pressure (spproximatety
16mmHg) passed Ihrough tha lumen 10 pAl"" collapaa. IloIh tha 8f1ary.,d
pipette contained Krebs SOlution and were connected in 8 manner that permrtted
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the manipulation of intravascular pressure.
Manipulation of intrav8SOJ1ar preSSlK8 was accomplished using a
pr8Sswised gas cylinder. preSSl.llt adjustment valve and a small pre$SlS8
reservoir colurm of Krebs (15m1 capacity) connected in series with the IlXn8I'l of
the pipette and the artery under investigation. A sphygmomanometer used for
documenting pressure arterations was connected to the system with a 'Y"
junction between the pressure adjustment valve and the pressure reservoir of
Krebs solution.
MCA rumen diameter ehanges in response to intravascular pressure
manipulation and the addition of vasoactive Sl.bstances were viewed tIYough a
microscope at a magnification of 322x (Wild Heerbrugg, M3C; Swttzerla'ld)
connected to a television camera (Hitachi, CClV camera, Japan), and VCR
(MitSLbishi, HS-2120; Ontario). The specimen was illuminated from below with a
fibre optic illuminator (Cole-Parmer Instrument Company, Model 9745-00;
Quebec). Changes in lumen diameter were recorded on video tape aong with
the c:aresponding time data using a video timer (GYYR, model G88; California).
The videO images were replayed and quantified at 8 later time. The scale of
image size to actual size was determined using 8 standardarized 100 j..m length
grid l6Ider the miaosc:ope. The relationship was 100 IJrT'l = 3.22 em on the
tefevision monitor. Great care was taken to ensure that the Il..Wt'I8n diameter
ITI88Sl..I'8m8fs were taken from en identical locatton akng the length of anery at
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eectl experimental step. AItwlItions in vessel di8meter were reported as 8
_ c:h8nge on k.mond_aocctding 10 thelollowing formula:
"d'lange in Il.WT'I8l"I diamet-= [(final diar'neler+ initial~.) -1) x
'00%
The final dial!*-_the steady .... krnoo~ in response to
either 8 100mmHg pressure step or the introduction oIa vasoec:tive substance
.....ile the initial diameter represents the steady state internal diameter prior to
this manipulation.
3A.3.3~_
One MCA _from 0lICh animal was uposed to • p<8SSlX8 step and
the phorl>oI <fibuIyrot. protocol (protoool A) and the _ was e.posed 10 the
{K1,and vasoprHSi" protocol (protoool B). The protocol portonnod first (i.•.• A
YS B) was _10 ....... _rry potential _ proc1JC8d .. the result d.
differential in time between the removal d the MCA'. from bnIin .-.cI the initiation
d the~ did net bios • porticul8" protocol.
U.U _ k I............ PIlorbollllbulynlo_
Conolrt<lion)
1. The MeA was mouried and allowed to equilibrate while pressurised to 100
mmHg for 30 minutes at a bath temperature of 37°C. This time 'NOuld alkJw
nom,.U)' functioning venels to develop presIU"8 dependent tone.
2. The arterial presIl.X8 wn reduced to ...... 0 IT'ITIHg tor 6 minutes to .iminate
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POC. It is believed that the artSfy perceives this situation as being analogous to
condittons of minimal blood flow Yt1lic:h causes the artery to nMax.
3. The pressure within the MeA was quiddy elevated to 100 mmHg for 4
minutes. Measuing the lumen diameter at 1 second post presslSisation is
considered to be a representation of the lumen diameter prior to any appreciable
POCo Once the vessel had been pressurised for 4 minutes, a steady state had
been reached and the internal diameter was meaaured again. The values
recorded at 4 mi'lutes WId 1 second after pressurisation were considered to be
the lumen diameters that existed with and without POC, respedively. These
vakles were used to calculate the percent change in internal diameter in
response to the 100mmHg pressure step for the purpose of quantifying the
ability of that artery to undergO POC.
4. The flow of Krebs solution was stopped and nifedipine was added to the
bathing solution to attain a final concentration of 3 IJM while the artery was
maintained at a pressure of 100 mmHg. This dihydropyridine (DHP)-vott.age..
dependent Ca20- ch81ne1 antagonist was used to block Ca2· influx in the smooth
muscle cells via voItage-dependent Ca2" channels, one of the proposed
Ill8<Htof's of poe. Steady state was reached within 3 minutes 8"Id the internal
diameter was recorded at that time. Previous sWes (Smeda and King, 2000)
have indicated thai this level of nifedipine maximaUy vasodilates the MCA's.
5. The PKC activator~ dibutyrate was added to the bathing solution in the
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presencoof3IMnilediproolO"-afinal"""""'*"liof1IM This_
dono10"-the otHJ;ty of the artery..-~ 10 a>nstrid 10
pI1ortlol .... _ PKC adiv..ion. u.- theM conditions. 1
1M -.ofpl1ortlol_ pt<Wce _ possible _ofconslriction
<_inod bypl1ortlol_Iwhidl ......lymbMdbyPKC irnl>itors
ouch .. staLn>oporin, bisinol~and~<s.- and King
1999). This indiceted thet COflItriction was being medillted by PKC activation.
The internel diameter measured et the end of the nifediplne step (Step 4).-.c:I
the di8'neler recorded following phorboI dibutyrate eci'ninistr.Uon was used to
calculate the peroent change in internal diameter as • resutt of phorboI
dibulynIIe induced PKC activation.
3.4.3.5_ B: (KCl _V e-IcticInl
1. The MCA _ """,,"eel lWld 81_ to oquil_ while IASSUrised 10
1lXlrm1Hg fer 15 mint.<es at alemporabJre of 23 ·C. The MCA has been_
10 _ the ability to c:onstrict to alevations in pressure when__ 811M
_<__King20(0).
2. ,.,. in step 2of __ A<_I the pressura__to 0 mmHg fer 6
minutes and the MeA was preasurised to 100 rrmHg for 4 minutes at 23 ·C to
assure that the.-tery was incapabfe of eliciting POCo
3. The flow of Krebs IOkItion was stopped and KCI wa. added to the tissue bath
10 __ a finallK"J. of M.6 rnM. This _ dono to-.. the ability of the
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MCA to constrict to K" induced depOlarization. The internal diameter was
measured betont and after this step and the percent change in lumen diameter
was ca~lated. Approximately 1.5 minutes was required for a K" induced
diameter c::hange to reach steady state.
5. The Krebs solution bathing the MeA was flushed 8'ld vasopressin was added
to a final concentration of 1.2 x 10-1 M. This was done to ensure that any
impairment in the MeA's ability to constrict to the vasoactive stimulus l.f\der
investigation was not simpty due to an generalised inability to constrict. In this
regard, 8 significant portion of vasopressin oonstric:tion within the MCA's d
SHRsp is mediated via the intracellular release of ~.1roma sarcoplasmic
store of Cr+, independent of PKC activation or Ca2<- entry through vottage gated
channels (Dr John 5meda, per$Of"I8l communication). Under these concIitions.
MCA's unable to constrict in response to PKC activation CK depOlariZation can
still constrict to vasopressin (Srneda and King, 1999,2000) demonstrating the
presence of a co~ent contractile apparatus. Vasopressin constriction
produced steady state diameter within 4 minutes. The internal vessel diameter
was recorded before and after the addition of vasopressin .-ld used to calculate
the percent change in II.fTI8O diameter.
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U.3.8~_e-
All drugs and chemicals were plXc:hased from Sigma Chemical Company
(51. Louis, Missouri, USA). Kel (used for VSMC depolarization) was dissotved in
distilled water and added to the tissue bath (20 ml) to achieve a final
concentration of 84.6mM. Phorbol dibutyrBte (8 protein kil"'.ase C adivator) was
dissolved first in OMSO (1mg11.98 ml) and then in distilled water. The solution
was Ihen added to the tissue bath to achtew a final concentration of 1 IJM.
Vasopressin (8 vasoconstrictor) was put:hased in aqueous solution and was
added to the tissue bath to achieve a final concentration of 1.2 x 1a7 M.
Nifed;pine (8 dihydropyridine type voltage-dependent Cr" chamel blocker) was
dissolved in absotute ethanol (at 1.73 mM) and was added to the tissue bath to
attain a final concentretm of 3 ~.
U.3.7 yolo
The rtriationship between percent change in lumen diameter in the 4
experimental groups was investigated using one way analysis of variance
(ANOVA) to determine whether or not a significant difference existed among
these groups. This was done for each of the studies outlined in protocoh A and
B. An unpaired student's .-test compensated for repeated measures using the
Bonferroni method was then used to detennine which groups differed from each
oCher.
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3.4.4 RESULTS
3.4.4.1 Tho ElIoc1o of CaploprllT_ on ........... Dope-...
conotriclIon of the 11_CenlbnI_ of SHRop
Figure 10 outlines the aherations in lumen diameter oc:wrring in response to a
100 mmHg pr8SSln step in MCA's sampled frcm SHRsp in the presence and
absence of stroke and or captopril treatment. MCA's sampled from 11-14 week
old LW1tr8at8d control SHRsp with stroke dilated when exposed to a 100mmHg
pressure step with an average change in lumen diameter of 15.516.5%. MCA's
Isolated from age matched P""""". SHRsp treated with caplopril exhibited
significant constriction in response to the same pressure step with an average
value -29.4±2.0%. A comparabfe degree of constriction was also observed by
pressurising the MeA's from the older (18--20 weekS of age) group of prestroke
captopril treated SHRsp. Vessels from this group exhibited a deaease in lumen
diameter of -22.7:i:2.7%. in response to the pressure step. The degree of
constriction produced was not significantty different from that Observed in MCA's
sempled from u..~ prestrok._I .....ed group. The constriction to
pressure observed in the MeA's of the two prestroke captopil treated groups
was significantty different from the dilation noted in the poststrcke control
SHRsp. The oldest group of animals from Vttli<:h MCA's were sampled were
treated with captopril up to ages of 35-40 weeks at which time they sustained 8
strcke. MCA's from this group were shown to constrict only modestly to the
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Flgun 10. The eIfed of captcp;11nlaImBnI and on pressure dopendenI
conslriction (POC) in the middle c:e<ebrlIl 811_ (MCA's) sampled from SHRsp.
poe was evaluated in response to a 4 minute expoIU'8 to a 100 mmHg
presstJ'9 step. The MCA's isolated from poststrcke control animals dilated in
response to the pressure step 'It'hile vessels isolated from age matd'18d
preotnlke COplopril treated SHRsp elChibited POC. The degree of POC noted in
the 11-14 week old prestroke captopril treated lJ"OUP was not significantty
d_lrom lhet documented in the 18-20 _ old preotnlke capt",,"1 treeted
animals indicating no significant change in this function 00CUT8d over the age
range examined. The 3440 _ old capIopril treated SHRsp lhet developed
stroke had MeA's which exhibited a small degree of PDC whic:h was not
significently different from that observed in the MCA's of younger .nreated
poststroke SHRsp. Captopril treatment may retard the age related impeirment in
POC typically observed in untreated SHRsp. However, this v8SO.JJar fuldion
may eventueIly fail in spite of the captopril treatment eft... stroke...-.elly
cteveJop$ in theSe animals. Statistics: One way~OVA plus Student's t test
~ed for muhipl8 cornp.-isons using Bonferroni correction, A VI. B
P<O.05, B vs. C. A vs. 0 are NS. (n= values A=7, 8=8, C=12, 0=3 SHRap).
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MIDDLE CEREBRAL ARTERY
CONSTRICTION/DILATION TO 100mmHg PRESSURE STEP
A. CJ control SHRop (11-14 .koo); poot8trokoo
B. _ coptoprll treoted SHRlp (11-14 .koo); prootrokl
C. IllllI coptoprll treoted SHRlp (IB-20 _); prntroko
O. IZZiI coptoprlllnlalod SHRop (34-40 .koo); poototroke
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100mmHg pressu-e step. The average change in lumen diameter was-
3.3t4.4%, not statistically ditrerent from the resp0n$8 seen in the poststroke
lI1treated control gro..p, which had died 20 weeks earlier.
3.4.4.2 The -..of~1T_onVoooc:onolriclIonM_by
Protein Kinaae C Activation in the MkkIe c..bnll MerI.. of SHRap
The ability of phorbol dtbulyrate to mediate constriction in the presence of
nifedipine within the MeA's of SHRsp in the presence and absence of stroke and
or c:aptopril treatment are outlined in Figure 11. The MCA's from 11-14 week old
lIItreated poststroke control SHRsp exhibited a minor degree of constridion in
response to 1'" phorbol dibutyrate induoed PKC activatm. The average
change in lumen diameter value derived from this groupwal -2.7t1.1%. MeA's
isolated from the age matched captot>il treated prastroke SHRsp group exposed
to the same concentration of phorbol dibutyrate exhibited a significantly greater-
71.4±8.0% constriction than that observed in untreated poststroke SHRsp Ol'
olde, (16-20-l_eSHRsp lIUbjocled to coptopriltrom1Of1t (-
32.3>5.6% constridion). MCA's isolated from the 35-40 _ old poststroko
captopril treated animals showed 8 variable and low ability to constrict to phorboI
dibulyrate induced PKC activation, exhibiting an average change in ILmen
diameter of -18.6±17.0%. This response was weaker than that observed in the
two prestroke captopril treated SHRsp groups but was not significantly different
from the constriction docunented in the MCA's of the untreated poststroke
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FigIn 11. The etfed of eaptcpril trealment on protein kinese C (PKC) mediated
phortJol dibulyrate induced constriction ~ the middle cerebral arteries (MCA's)
sampled from SHRsp. Phofllol dibutyrete (111M) W8S introduced into the beth in
the presence of nifedipine (31JM). Previous stud.. in au' laboratory have shown
th8t under the latter cond~ions the c:onstridion produced by pIlorl>ol dibutyrete
(in MeA's from SHRsp, Dehl end Sp<ague Dewtey rots) is inhibited by the PKC
inhibitors chele,y',,"ne (121JM) or bisinckJlylmeleimide (SlIM) suggesting th8t
the response is mediated by PKC activation. Phorbol dibulyrate administration
resutted in a marked degree of vasoconstriction in the MCA's of 11-14 week old
prestroke captopril tnN1ted animals whereas the MCA's of age matched
cntreeted poststroke SHRsp lost the ebility '0 oonstrict to pIlorbold~.
There was 8 signifi<a'd decline in the abiltly of the MCA'. from ceptopril truted
SHRsp to oonstrid '0 the pholboI ...... _ 11·14 end 18-20-.of ego
suggesUng an impainnenl in this function with age cUing captopril treatment.
The MCA's of~ _ old eaptcpril treeted SHRsp!hat _'-<I_e
ext\ibited some ability to constriCt to~ dlbutyrate hOwever this was
__not stalistically ditlenlntfrom the responses observed inuntreeted
poststroke controls. Statistics: One way ANOVA ptus Student's t test
compensaIed for multipfe~sons using BonferToni COfT8dion. A VI. B and
B VI. C P<Q.05and A VI. 0 is NS. (n= valuesA=7. 8=8, C=12, 0=3 SHRsp).
138
MIDDLE CEREBRAL ARTERY
CONSTRICTION TO 1pM PHORBOL DIBUTYRATE IN THE
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SHRsp.
U.4.3 Tho Eff....ol~1Tratmenton KCl_Co_of
tho _ ce olSHRop
The ability of high (1('')" induced depolarization to mediate constriction
within the MCA's of SHRsp tn the presence and absence of stroke and or
captopril treatment are outline in FiglXe 12. MCA's isolated from poststroke
control SHRsp were unresponsive to 84.6mM (I<"). exhibiting an average change
in lumen diameter of 1.94:t3.9%. In contrast, the MCA'strom the yClUlgand o6d
prestroke c:aptopril treated WOUPS as 'MHI as the poststroke captopril treated
a_constricted within a signifocant diffarance 01 each other 10 high [1<1, with
average decreases in lumen diameter of -8.4:i:1.10%, -9.at: 2.9% and-
8.91t5.1% respec:tivety. There were no rTl8l'Xed diffetences in the ability of the
MCA isolated from the three captopril treated~ to constrict to high (1<1,.
Although the mean coostlidion to high [Kio observed in the MCA's of captopril
treated SHRsp was greater than that observed in lXItreatecl poststroke SHRsp,
'Nhen compensated for mJltipe comparisons the responses observed between
l.I'Itr88t8d and eaptopril treated SHRsp did not S9'lificantfy differ from each
other.
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Figure 12. The efIed of captopril tream- on elevated 1K"~ induced
constriction of the middle c:erebrel erterios (MCA's) sempled from SHRsp. No
statistical differences in the ability of the MeA's to constrict to elevated (1<10 was
observed when the MCA's of 11-14 week old ootrvated poststroke controls, 11-
14 end 18-20 _ old _ ceptopril treeled lll' 34-40 _ old poststroke
ceptopril treated SHRsp __ compered. These mulls suggest Ihet the ebjlity of
the MeA'. to constrid to eleveled 1K"~mey not be significenlly efleded by
captopril treatment. Statistics: One way ANOVA-NS. (os vatues A=7, 8=5,
C=11, 0=4 SHRsp).
10
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3.4.4.4 Tho Effect. '" COploprilT_ on V--.." Indueod
Conolriction "' ......ldeI.~ _ ..of SHRop
The ability of vasopressin to mediate constriction within the MeA's of
SHRsp in the presence .-lCI absence d stroke and or captopril treatment are
outlined in Figure 13. MCA's isolated from the four groups c:A SHRsp investigated
all exhibited a significant ability to constrict to 1.2 X 10-7 M vasopressin. The 11·
14 week old prestroke caplopril treated SHRsp showed an average change in
lumen diameter in response to vasopressin of -59.5± 2.5%. This was
sign~rcantly greater thon the value of -43.9> 4.1% derived from the 18-20_
old prestroke caplopril treated animals. The poststroke untreated control SHRsp
exhibited a vasopressin rnduced average change in lumen diameter of-
35.6%3.7% significantly less tIwl the 11-14 vteek old prestroke captopril treated
SHRsp but not signiflC8l"ltly different from the 18-20 week old prestroke or the
34-40 week old poststroke captopril treated groups.
3.4.1 DISCUSSION
The following key observations were made in the study. SHRsp (that were
not treated with captopril) dovelcped stroke between the ages of 11 to 14-.
n had MCA's that <8> lost their ability to constrid to a 100mmHg pressure step,
(b) were unable to constrict to PKC activation by phorbol dibutyrate in the
presence of nifedipine and were unable to constrict in response to high
potassium ([K"~= 84.6mM). The loss of the ,..... oonstrictor functions in
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Figure 13. The effect of captopril treatment on vasopressin induced constriction
of middle cerebral aneries (MeA's) sampled from SHRsp. The retUlts indtcate
that all vessel groups exhibited a substantial ability to constrid: to vasopressin.
There were however signiflC8f'lt differences between groups. The MCA's of the
11-14 _ old '-'lIr8818d~ control SHRsp constrie:tlld significantly loss
than the age matched prestroke captopril treated rats. A signifiarlt decline in
vasopressin inc:luced MCA oonstridion was noted in the 18-20 week okt
pr_c:apt",,"I_groupwhon~wi"Ihe_~
captopril treated SHRsp. There was no stgr'lificant difference in the response to
vasopressin between the lMltreated control poststroke SHRsp and 35-40 week
old captoprillreated SHRsp Ihat ".eloped stroke. The MCA response to
vasopressin was studied to ensure that IJI'IY Mnpatrments in the response to
pressure or the aforementioned vasoactive Slbstancea 'N8f'8 not simply the
result of a ~ized inability to constrict. Slatistics: One way AHOVA plus
Student's t test compensated for multipkt comparisons using Bonferroni
correctiOI1: A VI. Band B VI. C P<.O.05 and A VI. 0 is NS. (n= values A=7, 8=5,
C=11. 0=4 SHRsp).
MIDDLE CEREBRAL ARTERY
CONSTRICTION TO 1.2.,0-7M VASOPRESSIN 0 l00mmHg
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poststroke SHRsp was not due to a general inability c:J the arteries to consbict
since MCA's sampled from the poststroke SHRsp readily constricted to 1.2 x 10-7
M vasopres$in (-35% change in 1l.A'T18n diameter). Vasopressin mediates
constridion. in part, via the release of 8 sarcoplasmic store of ea+2(Jackson
1996; Nemenoff 1998), a mechanism that is not utilized to promote constriction
in response to pressure, PKC activation or VSMC depolarization (discussed
later). Captopril treatment 01 SHRsp pnlvented stroke up to 30
weeks of age and attenuated the loss of vasoconstridion in response to
pressure, PKC activation and high potassiLm induced depofarization in SHRsp
sampktd between 11 to 20 weeks of age.
The present study was limited by the fact that we did nOl sample a
prestrok8 group of SHRsp at an age prior to stroke d8vek)pment. Therefore, the
ability of captClprillreatment to preserve Y8SOJ1ar function could not be directly
related to the degree of vascular function present prior to stroke development in
untreated SHRsp. However, shortty after completion d this Pl'oiect. young 9-10
_ old prestroke SHRsp __ sampled by other memI>ors of lhe laboratory
using an identical protOCOl used to study the MCA's in the present thesis (Dr.
Jam Smeda. personal communication). Tho MeA'. of 9-10 _ old SHRsp
exhibited a pr8SSlSe dependent constriction to a 100rnmHg pressure step d 26
:t2 " (n=5), produced 67 t10" reduction in kJmen dtameter in response to 1
~ p/lorI>ol dibutyrate in the presence of 3~ n_ipine (11=6) and -.cod
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thW lumend_by" til '" in response to 84.6rilIK'J. <_I. The MCA',
of these animals constricted to 1.2 X 10-1 M vaopressin at a IeYeI of 50:t4% (n=
6). In the case of constrictor responses to presIUI1l, PKC activation or
vasopressin, the magnitude of the responses observed in the MeA's of the latter
group c:l9 to 10 week okt prestroke SHRsp were simil.. (not signifICantly
ditfwenl) to corresponding reaponses in the captopril treated SHRsp aampted
between 11 to 14 weeks of age shown in Figures 10,11 and 13. Therefore in
the case at u.se responses, at 11 to 14 weeks of age, captopriI treatment of
SHRsp__.. ability of lhe MCA', to constrict to__ PKC
activation 8r'Id maintained vasopressin rn.ponsiveness at IeYeIs presert in
SHRsp two weeks prior to stroke development. On the OCher h8'ld the MeA's of
9 to 10 week old SHRsp constricted to depolarization in response to htgh
potassium to a nu::h greater degree than the MCA's of ofder SHRsp treated with
caplopril. This woukt suggest that constric::tion in response to potassiLm
-"'"dodinos with ago in lhe MCA', of SHRsp~ lhe Ilf1I-.c8 of
_1-
MCA from SHRsp _ foiled to dewlap__aged ..- conditions
of captopril treatment showed a small decline in their ebility to elicit POe to a
100 mmHg pressure step and a more substantial decline in their CXIIlStridor
responl8l to PKC activation by phorboI dibutyrate. These fulctiona were further
atl8nulIled in SHRsp ... .-.uaIly developed__ 34-. of ago.
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_, the__10 press<n or pI1oIbol ditluIyrlIle -.._
.. 34 1040_oId SHRsp Ih8l~ _ during_1_
lNnin_.......ed111014_oIdSHRspIh8l~_inthe
-.:001_1 tnoatmonl In the case 01 t,;gn IK1. _ constriction, the
MCA'solthe__I__ oISHRsp<_11 1040_)
exhibited~__loss 01 the prosonco or obsonoo 01
stroke. The above results would indicate that captopril treatment delays the loss
of pressure dependent, 8I"Id PKC mediated consttidion in the MCA's of SHRsp
as well as stroke development in the animals. In addition, captopril treatment is
of some benefit in preserving this fu1ction even in 8flimatI that eventually
~__ng coptcpril tnoatmonl
3....5.1 The~ IetwMn ... Loa of CelebiOV••C1'"~
~ <:onotrtc:-. .... _llevoklpr-w In SHIIop
Studios(_1992,__King, 1999, _0/01.19991>,
Smodo and King, 2000) hove indicotod thot the loss 01 PDC .. the MCA's 01
5HRsp p<ocodos _ ~ _ is _ .. SHRsp Ih8l have
deYefoped stroke. The decline in this Y8SQJ'" fmdion starts to ocos in
_e5HRsp _ eboul11.5 _ 01 ago _ rogtOSsion ...lysis of the
change in this function with age predicl:s that POC would be totally lost in MCA
of prestroke SHRap at about 16 week$ of age, II tkne wtIic::h coincides with the
ago _ 100% """"'lily ouocioIed with _ oc:an (5"- _ King,
'48
2000). "was suggested lIlIIltho loss cI POC could promote • loss cI cer-.I
blood _<CBFj~ in tho MCA peofusion_, promoting
ovwperfusion in tho reg;on, leading to _ ~ _ .• is
-'I~to suggosttl1llt by .........ing POC and CBF~
fl..nction, ca.ptopril trNtment prevents stroke .-ld duIh in SHRIP. Such a
conclusion is premattn and in view of recent experiments, not fully o:lfT'eCl
Studies (8mede et aI. 1999b) involving Iuer Doppler techniques have indiceted
that CBF regulation is IoIt within the perfusion domain of the MCA in SHRsp a1d
that this ion does precede stroke devefopment in SHRip. However, it was
also __tI1llt tho pertullion _ serviced by tho poeterior_Iarte<y
(PCA) also Iost;os ability to Ill.COnlgulate_I blood flow;". rnamer parallel
to the MeA perfusion domain whikl PDC was not abolished in the iso&ated PCA
.-teries studied in W10 using • myoglIph. The condusions reac:hed were that
the loss or pr8S8nC:8 of PDC in the Larger .::: 200 j.m diameter cerebral vessets
-.ng tho miauYaaculat1n do not oIways perfec:lly lAdid tho loss cI CBF
aJIoregulaIion 1whK:l1 ;. primarily goyemed by tho~ <40 I'M in
d_er). "was suggested lIlIIltho loss cI PDC m,ely extendll_ ...,........
from the microvasculature towards the larger arteries in the c:ase of the MCA
verses the PCA vascular tree in SHRsp that have developed stroke. It is
possible that if the extent d POC loss was more extensive in the MCA vascul8r
tree, 0't'WJ)erfusi0n might f8YOIS this area over Ihe PCA perfusion domain. In
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this regard hemorrhagic lesions do preferentially oc:eur at higher frequencies in
the MCA versus the PCA perfusion domains (Smeda, 1992)
In ooncIusion, atthough the loss of PDC in the MCA and the other
associated aspects of vascular ftn:tion demonstrated in this section may
represent, the type of alterations present in the cerebral microvascuLature. this
has not been proven. In view of this, one can not conclude with certainty that the
preservation of POC in the MeA's of SHRsp during ceptopril treatment is the
mechanism that is responsible for retarding the onset of stroke development in
SHRsp. Despite thiS, we would expect thai the preservation of POC, even rr only
in the MeA vasaJtar tree, would signifICantly reduce overperfusion R retard
the onset of cerebral hemorrhage in the region.
3.4.5.2 Tho Effect of Coploprtl Trutmont on tho ng
ee..brovooc.................... Dopondent COnstriction
As discussed in the introduction. two general possible inter-related
mechanism have been suggested to promote PCC in cerebral and other
vascutar beds. Elevations in pressure have been suggested to promote PKC
activation. In this regard PKC inhibitors inhibit POC in cerebral~s from
SHRsp and normotensive rats (Oso! et el.,1991; 5mede and King, 1999).
Likew;se, the levels of the PKC activator OAG have been shown to elevate in the
VSMC's drenalarteries (Naraya1a'1 etal.. 1994). Other studies have shown
that elevations in pressure promote VSMC depol.-izatton d cerebral bloocl
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vessels, including those 01 SHRsp (Harder, 1984; Smeda and King, 2000). Such
a response will open voltage gated ca2"' channets admitting Csz..-let promoting
constridion Ca2" channe4 antagonists totally inhibit POC in cerebrat blood
vessels. Theories have emerged suggesting It18t PKC activation in combination
with C~ innux into VSMC's is responsible for the production of POC (Hill et aI.,
1990; Gokina et aI., 1999). Differing versions of these theories have suggested
that the combined individual effects of Ca2"" entry and PKC activation are
required to promote poe and that the inhibition of either of the two individual
mechanisms is sufficient to inhibit POC (Hill at aI., 1990). Other resean:::hers have
suggested that the influx of <;a2+ may in fact promote the activation of PKC which
in t..." activates constriction (laher and Bevan, 1989). In this scenario the
blockage of PKC with inhibitors or C~ entry via Ca2+ c:hann&I bfockers would
also inhibit POC.
In the present study, stroke development in SHRsp was associated with a
10$$ of POC and a defect in the ability of the MCA's to constrict in response to
PKC activation (by phort>ol dibutyrata) and depolarization (by high (~L). lhasa
mechanisms have been previously studied in SHRsp. The ability to constric:l in
response to Hriated pressure was very strongly related to the ability of the
MCAs to constrict in response 10 PKC activation and is inhibited by PKC
inhibitors (Smeda and King, 1999). In the present study we were able to study
poe in a 100 mmHg pr8SSU"8 step and responsiveness to 1~ phorboI
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dibutyrale with." the same MCAs. Consistent with the observations of Smeda
and King (1999), regression analysis indicated a significal'll oorrelation between
the two funclions when the data for aU the anim" groups were combined.
poe r,"""""", (Ii) = 6.14 + 0.535 _ dibulyme ,"-nse (Ii).
Pearson coefficient d correlation (r value) = 0.764. P<O.OO1
Since high [K1. induced constridion was measured under conditions where poe
was inhibited by low temperatures (23"C), the~shipof high [K1., induced
constriction to POC response COlJId not be studied in the same 8I"leries.
However, Vt'hen the left vs the right MeAs from each animal were compared, the
observation that a) the MCAs of YOU'lQ. untreated ~'Oweek old prestroke
SHRsp (S8lTf>ledafter project) and 11·14 and 1S-2O_old captopril treated
SHRsp exhibited comparable PDC responses (- 23 to 28%) and quite varying
contractile responses to high [K"lo (44 to 8%) and b) the further observation that
poststroke 30-34 _ old capt"",il treated SHRsp lost their abHity to elicit PDC
but were still ab+e to constrid to high (K"1. at levels comparable to those present
in prestroke~I treated SHRsp (11-2O) ....ks of age (Figure 13) would
suggest that a direct relationship between the ability of the MeA to constrict 10
pressure and respond to high [K1. induced depolarization does not exist.
The electrophysiologiesl atterations associated with the inability d MCAs
to constrid to~jonhave been studied in poststroke SHRsp (Smeda
and King, 2000). \MIether these defect... e mechanism _ibIe for \he
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loss of poe in poststroke SHRsp remains unresofved. The MCAs of 9-1 0 week
Old prestroke SHRsp exhibit press... dependent depolarization but ... change
in membrane potential is small in response to a a to 100 nvnHg pre5SlX8 step
(from -46 t 2 to 38 :i: 1 mV). This degree d cIepolaization can not account for
the substantial degree of constridion producecI in the same .-teries (42 ± 3%)
simply through the opening of vottage galed Ca2" channels. There was also no
evidence that etr entry through ve>'tage gated chameCs triggered an alternative
contractile mechanism such 8S PKC activation, since PKC inhibitors had no
etreeI on depolarization induced constriction in these arteries. After stroke
devefopment, the VSMCs of MCAs from SHRsp ~arized and maintained a
constant membrane potential with varying pressure (-34 ± 5 VI -35 ± 2 mY, 0 vs
100 mmHg). Patch damp studies indicate that the depolarization obSeMtd in the
VSMCs of the MeAs of poststroke SHRsp was mediated by a very 1.-ge
increase in chloride conductance in the VSMCs which could be bkx:ked by
chloride channe' blockers (niflumic acid or 1AA-94). When the MCAs were
treated with chloride channel inhibitors, the membrane potentials were
normalized; however poe still was not recovered in the MCAs of SHRsp by such
treatment (Or. Jotv1 Smeda, personal COfT1fTU'lication) suggest that this
electrophysiologiesl alteration was not sofefy responsible for the loss of poe in
the arteries. Other studies indicated that high [1<"10 levels depolarized the
VSMCs of ... MCAs of poststroke SHRsp, _. the VSMCs _ es W
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the """- sensor on the """- gated , cte8ling.
__dopoIarizaIicn COUld nol oMance the opening prct>ob;lity althe
~W_(_-.lI<ing,2000). _
_ Ihat dopoIarization in__ 10 pnlSS<n may OCCU' _ canotridion
has Iakon place in the MCAs alSpraguo~ _ -.I~ SHRsp
1__ King, ,""",*"ilhod .......).
3....5.3 V.......n IIedWrted Con8triction of .... Middle c..bnIl AI'terte.
The purpose of exposing the experimental groups of MCA's to
vasopressin was to enItX8 thai .-ly differences in vasoreec:tivity founcl in the
afot 8lTl8l1tiol18d studies were not simply due to a oenera1lzed il"'l8bility to respond
to vasoactive stimJli. It was inIeresting to note th8I statistically, the MCA
response to vasopressin mirrored the phc:lrt)oI dibutyr8l:e c:onsbictor responses.
That is, the 11-14 _ old__caplopril trollied SHRsp__MCA's
_ c:onsIrided slgniticantly more 10 pI1ort>ol dbJIyrale -.I vasopressin
_10 _ rnatct-ed -...~ arteries. Thenl_. siglificant
dedine in phcwboI dibutyrMe lind vasopressin induced MCA oonstriction
_the 2~ c:aptopril treated groups. Also, the pI1ort>ol dibulynlte
and vasopressin responses in bOth poststroke groups were not significantly
different from eacI1_, but __ reduced~ with __groups.
Generally however, the magnitude of the vasopreAin tnduced consbiction was
'-II« IIwlIhat documonted in__ to pI1ort>ol dibJtynIle. fe<.-nple, the
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average vasopressin induced constridion including the 4 experimental groups,
was 40.9% whereas the average~ dibutyrate induced response was
31.1%.
The reason that the phort:loI dibutyrate and vasopressin induced
responses are simil.. may be related to the similar medlanisms via which these
two vasoactive stimuli exert their constrictive effects. According to Jackson
(1996) and Nemenotr (1998), vasopressin receptor activation in the VSMC is
thoughI to activate PlC via a Gi>Jotein and thereby generate 1P3 and OAG via
the degradation of phosphatidylinositol-4.5 bisphosphate. The IP) is tI'loc..Vi: to
cause the release of ~from internal stores. The DAG is thoul;;1l: to activate
PKC which in tum, lowers the cr"' requirements I'l8C8S$8I'}' for VSMC
contrael:ion. Consequently, the two arms of this second messenger s)'$tem
seem to participate in VSMC activation in response to va5Opf8SSi"t.
Alternatively. phorbol dibutyrate is thought to lead to vasoconstliclion soktty via
the PKC arm of this second messenger pathway which may acoount for the
greater vasopressin induced MCA constriction relative to the phorbol dibutyrate
induced response.
3.4.5.4 concluding Romorb_to.... Studios In~3
Collectively, the observations of MCA function suggest pressure induced
depolarization may not be Ihe primary mechanism of action in POC. The
reasons are 8S follOW; a) the magnitude of VSMC depotarization is iMlUfficient to
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promote the IeYef of constriction seen; b) the absence of 8 depolarization
induced triggering 01 PKC, and 0) preliminary evidence that pressure induced
depolarization may follow constriction in the .-teries. This is further reinforced
by the obs«vetion that the MCAs from 30 to 34 _ old captoptil treeted
SHRsp Ihot develop stroke exhibit some constriction to eleveted IK"~ (Figl.<e 12)
but show very little ability to constrid to pressure and the observation that the
MCA's from 9-10 week okJ prestroke SHRsp (sampled l!Ifter the project) exhibit
comparable POC raponse 10 10 to 14 week old captopril treated SHRsp but
.....ntially higher constrictor responsiveness to &Ievated [1<'1. .
On the other hand, the ability d MCAs to constrict to PKC activation in
response to phorbol dibutyrate is well correlated to the ability fA the arteries to
constrid to pressure in all the animals tested. This would suggest that PKC
activation may be an important signal transdudion mechanism involved in
mediating POCo The preservation of this mechanism by captopril treatment may
be instrumental in preserving poe in the arteries. The obseNation that PKC
activation can open voltage gated ca2+ channels in VSMCs in a voltage
independent manner LI'lder conditions where membrane potentials are clamped
(Fish, et 8/.. 1988) could provide an explanation as to why both PKC inhibitors
and voltage geted C'" chamel _isis cen inhibtt PDC in the MCAs of
SHRsp. tf suc:fl a medwlism existed in the MCAs of SHRsp, the voltage gated
cr- channel could promote PDC solely v;a PKC activation independent of
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pressan~~.
2O-hydro><yeicoollt_ acid (:zo.HETE), an aracI1idonic (M)
.-ite produood by tho cytodYomop~~~, has also boon
~ ... possible~ofPOCinrat__(~a1
at, 2(01). This suggestion was based on the -..oors' in vivo findings including
II1e obsarvaticn that inhjt>1ion of:zo.HETE lomIalion _ ~-..nyI-12,
12-dibromododec-11«l8mide (DOMS) or its .,8IOCXlMtridor actions using
1!HlETE or2O-hydr~Z),15(Z)-<tianoic acid (2Q-HEDE), impaifad II1e
autoregulation of CBF to elev8tions in arterial pressure. Support for 2O-HETE',
aforementioned role .'-0 included the in vitro observation that PDC in the rat
MCA was eliminated by administration d DDMS, 15-HETE Of 2O-HEDE.
A possible IllIationIhip-.thosa lindings and those OUlIinad in lhi>
Ihesis is higN;gtotad by rapo<1S of an ACE inhibilor mediated inaeasa in
2O-HETE formation in renIIl miaosomes. The microlomel W8I"8 derived from
~ I (25 mgIkd) oranalapil (10mglkg)for
one 'IIII'88k.. 'Nhile the invettigetors noted thet the reIevalce of these firldtng to
the .mhypertensive actions of ACE irltlbtorI have yet 10 be detennined, it is
reuonabIe to consider that 8 captopril treatment mediated increase in~ETE
levels could play a role in the preS8f'V8lion of poe noted in our captopril treated
SHRsp.
Racant..-. indic:alo__1_in~_ at tho fitst sign of
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stroka and '"" to 6 days following, can p<olong theI~ of SHRsp by
approximately 16 weeks (Smeda et aI., 1999a). Aldosterone co-infusion with
_1_ nullified the effect ofceplopril_ suggesting lI1elthe
ability of~Ilop<otong life .. poststroke SHRsp could be mediated by the
suppression of aldosterone retease secondary to the inhibition of All production.
Of interest, the treatment of poststroke SHRsp with captopril alkMed the MeAs
of Ihe animats to regain their ability to constrict to PDC and PKC activation via
phorbol dibutyrate in the presence of nifedipine. This would indicate that
ceptopril _ not only reterds the loss of PDC along wid> the onset of
stroke in SHRsp but can repair the loss of poe after stroke has developed in the
animals.
The systemic effects of poslstroke captopril treatment tmportant in
preventing death in SHRsp are not fully understood. In recent years the brains
of SHRsp have been studied using magnetic resonance imaging (MRI), 8
tedYlique that can detect brain edema, hemon1lage and ischemia under in viw
concIitions. The ea1iest brain defect 0CCUTing in SHRsp was the onset of
cerebral edema(BIezer etaJ., 1998). This _wrth alTlOl1<ed loss of
proteins into the twine in the animals (> 40 mglday). MRI studtes indicated that
edematous sites often became hernorrtIagic (Takahashi et al., 1994). ACE
inhibitor treatment started after the first MRI signs d edema stopped the
davelopnent of ptOleinuia and raversed the onsat of brain edame (Blazar et 01.,
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1998). Edema formation in the brain in hypertensive patients can promote a
condition termed hypertensive encephalopathy wtlich is associated with a loss in
cerebral blood flow autoregulalion. It is possibte that the sites of edema
formation may also lose blood flow autoregulatory ability. If this were the case,
they may become overperfused. This would not only increase edema formation
but it might also place these sites at risk for hemorrhage formation. Hence, by
either preventing or reversing edem8 ACE inhibitors coufd help prevent the
or.- 0( further spread of he""",,"-,
4. A SUMMARY OF THE ANDINGS AND THE GENERAL CONCLUSIONS OF
THE ENTIRE STUDY
The results of investigations outlined in Chapter 1 showed that captopril
treatment is capable of markedly retarding hemorrhagic stroke re4ated mortality
in SHRsp independent of 8 significanl reduction in blood pressure. This in
combination with the observation that a non ACE inhibitor antihypertenstve
agent produced a~ial hypotensive effect with onty 8 very mild effect on
mortality rate suggested that caplopril's antistroke effects may be refated to this
drug'S specific mechanisms of action. In investigating this possibility, we found
that plasma aldosterone levels increased as Ultreated SHRsp approached the
age at v.t1ich the developmenl: of hemorrh8g;c stroke is likely. We also found
that plasma aldosterone levels were reduced in captopril treated SHRsp
compared with untreated controls and that supplementing plasma aldosterone in
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captopril treated SHRsp via an exogenous source reversed the antistroke effects
of this drug. These findings led to the suggestion thai 8 component d the
paIhogenesi. In SHRsp may be mediated by IIl8PPfOIlri8tely elevated level. 0/
plasma aldosterone. AA attempt 10 simulate the etreds of captopr;l treatment
with the aldosterone a1tagonist spironolactone was initiated. Unlike caplopril,
spironolactone treatment produced 8 small but significant hypotensive effect as
well as 8 significant, but modest, reduction in the mortality rate. The mild effects
of spironolactone treatment on mortality rate were not .-rticipated and one
posstble explanation is that aldost.-one may not exert 8 pathoIogtcal ef'fed in
SHRsp via 8 spironotactone sensitive intracellular mmeralocorticoid receptor but
instead, may act via the relatively newly described nongenomic pathway. This
suggestion however is spec:ulative and the role that such 8 nongenomic:
mechanism may play in SHRsp is l.f'Idear.
Next, investigations tLrned to the rekltionship between MeA function,
captopril treatment and mortality associated with hemorfhagic: stroke. Recall
that untreated SHRsp typically develop homorrllagic _ over the age range
of 11·14 weeks. This is closely preceded by., impaired ability of the MeA to
exhibit poe, thought in tum, to result from a reduced ability to constrict to PKC
activation. We fOlI'ld that MCA's isolated from 11-14 week old prestroke
captopril treated SHRsp had retained the ability to constrict to prassOOzation and
PKC activation. In contrast, vessels isolated from age matched poststroke
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controls exhibited a markedly reduced ability to constrict to the same vasoactive
stimuli. Based on these findings we proposed that captopril treatment may
retard the development of hemon'h8gic stroke via the preservation of the MCA's
ability to constrict to pressurization. Also, this preservation of POC may be
mediated by a captopril induced protection of the PKC signalling cascade. The
ability of the MCA to oonstrict to high [K1. induced depolarization was not
related to the loss of POC.
Once the ceptoplil tnlated SHRsp reached the age 0/1&-20 weeks, the
ability of the MeA to constrid to PKC activation was significantly reduced
relative to yoooger c:aptopril treated animals. This preceded the development of
hemorrhagic stroke in a manner which paraflelled observations typic:ally noted in
untreated SHRsp. While speculative and in need of further investigation, we
further suggest that this impaired second messenger system may subsequently
lead to a significant impairment in poe between 18-20 and 34-40 weeks of age.
The end result of this could be that the ability of the MeA to regulate bkxxt flow
is compromised. This, in tum, leads to the foonation of hemorTtlagic stroke in
captop,i1 tnlated SHRsp, porallelling the pethogenesis wIlich """'" in untreeted
SHRsp, yet et e much older age.
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